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Abstract 
    
ABSTRACT 
Pseudomonas aeruginosa is an opportunistic pathogen of animals and humans causing medical 
complications in burns, wounds, and cystic fibrosis.  P. aeruginosa is efficient at adapting its 
virulence phenotype depending on the site of infection.  Emerging multi-drug resistant strains 
and a limited number of effective anti-pseudomonal antibiotics renders P. aeruginosa 
infections increasingly difficult to treat.  
 
To address this need, this thesis considers targeting bacterial quorum sensing, which regulates 
the production of virulence factors, as an alternative prophylactic strategy.  The P. aeruginosa 
quorum sensing system is compromised of three interlinked but independent systems, Las, Rhl 
and Pqs, which produce and utilise quorum sensing system molecules, 3OC12-HSL, C4-HSL 
and PQS respectively.  Immunological targeting of the quorum sensing system molecule 
3OC12-HSL, through active immunisation (vaccines), inhibits the Las system, resulting in a 
longer life expectancy in mice infected with P. aeruginosa in vivo. 
 
However, P. aeruginosa has the capacity to develop resistance, through compensatory 
mechanisms, towards quorum sensing inhibition that targets the Las system only.  This 
emphasises the need to target all three quorum sensing systems, Las, Rhl, and the Pqs, in order 
to inhibit quorum sensing.  The present study focuses particularly on the development of a 
multi-component anti-quorum sensing system vaccine that would target the three main quorum 
sensing system molecules, effectively compromising the quorum sensing system and 
minimising compensatory mechanisms.   
 
This involved the synthesis of haptens based on the quorum sensing system molecules, which 
were used to haptenise the immunogenic carrier keyhole limpet haemocyanin.  Syntheses of 
the haptens, AP1 (derivative of 3OC8-HSL) and AP2 (derivative of PQS), were conducted 
using adapted published methods.  The resulting conjugates, AP1-keyhole limpet haemocyanin 
and AP2-keyhole limpet haemocyanin were immunogenic in mice and rabbits.  The specific 
anti-hapten polyclonal antibodies that were generated demonstrated cross-reactivity with the 
natural quorum sensing system molecules of P. aeruginosa that translated in significant and 
specific anti-quorum sensing system molecule activity in bioluminescence reporter assays.  
Anti-AP1 polyclonal antibodies were able to reduce biofilm formation at high concentrations, 
however, significant reduction of biofilm formation was seen when the anti-hapten antibodies 
were used in combination.    
 
In this study, it has been demonstrated that the inhibition of the quorum sensing system should 
include the three systems, Las, Rhl and PQS, and that this can be done by a multi-component 
anti-quorum sensing system vaccine.  These data suggest that a multi-component anti-quorum 
sensing system vaccine takes us a step forward to a viable prophylaxis against P. aeruginosa 
for susceptible patients.  
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M Molar (moles per litre) 
m/z Mass to charge ratio 
Mab Monoclonal antibody 
MALDI-TOF Matrix assisted laser desorption ionisation-time of flight spectrometry 
m-CPBA meta-Chloroperoxybenzoic acid 
MDR Multi-drug resistant 
Me Methyl 
Me2CuLi Dimethylcopper lithium 
MeCN Acetonitrile 
MeLi Methyl lithium 
MeOH Methanol 
mg Milligram(s) 
Mg Magnesium 
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MgSO4 Magnesium sulfate 
MHC Major histocompatibility complex 
MHz Megahertz 
Min Minute(s) 
mL Millilitre(s) 
mM Millimolar 
mmol Millimole(s) 
MoA Mode of action 
mol Mole(s) 
Mp Melting point 
Mr Relative molecular mass 
MRSA Methicillin-resistant Staphylococcus aureus 
MS Mass spectrometry 
MW Microwave irradiation 
MWCO Molecular weight cut-off 
N2 Nitrogen 
Na2HPO4.7H2O Dibasic sodium phosphate heptahydrate 
NaCl Sodium chloride 
NaHCO3 Sodium hydrogen carbonate 
NaOH Sodium hydroxide 
NH4Cl Ammonium chloride 
NH4HCO3 Ammonium formate 
NHS N-hydroxysuccinimide 
NK Natural killer cells 
nM Nanomolar 
NMP N-methyl-2-pyrrolidone 
NMR Nuclear magnetic resonance spectroscopy 
NO Nitric oxide 
NuH Nucleophile 
O2 Oxygen 
OD Optical density 
Opr Outer membrane protein 
OVA Ovalbumin 
pAb Polyclonal antibodies 
PAMP Pathogen associated molecular pattern 
PBS Phosphate buffer saline 
PBST Phosphate buffer saline-tween 
PBST-M Phosphate buffer saline-tween-milk powder 
Pd-C Palladium on carbon 
PE Petroleum ether 
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PGE2 Prostaglandin E2 
Ph2O Diphenyl ether 
pI Isoelectric point 
pIgG Polyclonal immunoglobulin G 
pM Picomolar 
PMN Polymorphonuclear cell(s) 
pmol Picomole(s) 
PPA Polyphosphoric acid  
PPK Polyphosphate kinase 
PQS Pseudomonas quinolone signal; 2-Heptyl-3-hydroxy-4(1H)-quinolone 
PRR Pattern recognition receptor 
PS Polysaccharide(s) 
pTsOH para-Toluenesulfonic acid  
QS Quorum sensing 
QscR Quorum sensing control regulator 
QSS Quorum sensing system 
QSSi Quorum sensing system inhibitor(s) 
QSSM Quorum sensing system molecule(s) 
RBF Round bottom flask 
Rf Retention factor 
rpm Rates per minute 
Rsm Regulator of secondary metabolites 
rt Room temperature 
s Singlet 
s/c Sub-cutaneous 
SAM (S)-adenosylmethionine 
scAb Single chain antibody 
SD Standard deviation 
SDS Sodium dodecyl sodium 
SDS-PAGE Sodium dodecyl sodium-polyacrylamide gel electrophoresis 
SO2Cl2 Sulfuryl chloride 
spp. Species 
t Triplet 
t-BuOH Tertiary butanol 
t-BuOK Potassium tertiary butoxide 
TC Cytotoxic T-lymphocytes 
td Triplet of doublets 
TFA Trifluoroacetic acid 
TH T-helper lymphocytes 
THF Tetrahydrofuran 
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TIPSOTf Triisopropylsilyl trifluoromethane sulfonate 
TLC Thin layer chromatography 
TLR Toll-like receptor 
TMB 3,3!, 5,5!-Tetramethylbenzidine 
TMSCl Trimethylsilyl chloride 
TNBS 2,4,6-Trinitrobenzenesulfonic acid 
TNF-! Tumour necrosis factor-alpha 
US-FDA United States - Food and drug administration 
UTI Urinary tract infection 
VfR Virulence factor regulator 
VqsM Virulence and quorum sensing modulator 
VqsR Virulence and quorum sensing regulator 
w Watt  
WT Wild-type 
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1 INTRODUCTION 
1.1 COLONISATION, INFECTION AND DISEASE 
Pseudomonas aeruginosa, a Gram-negative bacterium, can survive in many different 
environments, such as soil, marshes or water, including harsh conditions such as high 
temperatures (42 ¡C) or in low O2 (1).  P. aeruginosa is an opportunistic pathogen of animals 
and humans; it is considered to be one of the major causes of nosocomial infections, 
presumably as the pathogen can survive on dry surfaces for up to 16 months (2) and can 
colonise on sinks, floors, toilet surfaces and dialysis machines and the other Ôin-dwellingÕ 
appliances (3).  If allowed, P. aeruginosa can infect any site of the immunocompromised host 
to cause various clinical conditions (Table 1-1), such as pneumonia, urinary tract infections, 
and complications in clinical burns, wounds, and cystic fibrosis (CF) (4). 
 
 
Respiratory tract infections 
Bacteraemia and septicaemia 
Otitis externa 
Skin conditions: ecthyma gangrenosum, pyoderma, folliculitis, acne vulgaris 
Eyes: ulcerative keratitis, endophthalmitis, neonatal opthalmia 
Rare conditions: meningitis; endocarditis; peri-rectal infections and specific forms of 
osteomyelitis 
Table 1-1: Diseases caused by P. aeruginosa.   
Adapted from (4).   
 
The pathogenicity of P. aeruginosa, once it has adhered and colonised, is due to the diverse 
virulence factors that contribute to disease aetiology.  Table 1-2 lists some of the virulence 
factors produced and used by P. aeruginosa, however, the virulence phenotype of P. 
aeruginosa is subject to change depending on the site of infection, the primary disease 
condition and progression. 
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Table 1-2: Virulence factors produced and used by P. aeruginosa.   
Adapted from (5-7).   
Virulence factor Action 
Colonisation 
Flagella Involved in motility, adherence, and invasiveness.   
Pili Adhesin and involved in transfer of type III secretions.   
Exopolysaccharides,  Alginates are involved in adherence and pathogen persistence 
(biofilms, antibiotic and immune system effector resistance).   
Lipopolysaccharide 
(LPS) 
Endotoxin and an inflammatory agent, also involved in adherence and 
biofilms.   
Invasion 
Alkaline protease Degrades immune system components such as complement factors.   
Elastase  Las B and Las A.  Degrade elastin; disrupt membranes; impair 
monocyte chemotaxis and degrade complement proteins.  Las B also 
destroys collagen, IgA and IgG and impairs wound repair.   
Lipase A and C  Unknown role - possibly involved in degradation.   
Phospholipase C Haemolytic and disrupts lung surfactant.   
Protease Degrades complement factors, plasmin, IgG, and fibrinogen.   
Pyocyanin Inhibits lymphocyte proliferation; causes apoptosis of neutrophils; 
impairs mucocilliary motility by stimulating production of H2O2 by 
polymorphonuclear (PMN) cells. 
Siderophores  Pyoverdine and pyochelin are iron scavengers.  Pyoverdine regulates 
secretion of exotoxin A and proteases. 
Pathogenesis 
Exotoxin A Unknown role - possibly causes apoptosis of eukaryotic cells. 
Biofilm Confers protection against biocides and immune system effectors as 
impenetrable to antibodies (Ab), antibiotics, and biocides.   
Hydrogen cyanide Unclear role Ð toxic agent.   
Rhamnolipids Dissolve phospholipids; cause apoptosis of leukocytes; impair 
mucocilliary motility and are solublising agents. 
Type III secretion 
system 
Exoenzyme (Exo) S, T and Y, and exotoxin U.  Exoenzyme S inhibits 
phagocytic motility; induces death of macrophages and PMNs and 
disrupts tight junctions of epithelial cells.  Exotoxin U is cytotoxic to 
eukaryotic cells.   
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1.1.1 BURNS AND WOUNDS 
Skin and mucosa are part of the non-specific innate immune system, providing physical 
barriers against invading pathogens (8).  However, wounds or burns disrupt the barrier and 
weaken the immune system, allowing opportunistic pathogens such as P. aeruginosa to take 
advantage.  The hospital environment tends to cultivate the multi-drug resistant (MDR) P. 
aeruginosa strains, increasing the risk of complications caused by MDR pathogens.  In burns, 
it is believed that alginate, pili, flagella, lipopolysaccharide (LPS), exotoxins of the type III 
system, elastase, siderophores and biofilms, which can be formed within 8 hours of infection 
(in vitro) (9), are key virulence factors produced by P. aeruginosa (7).   
 
1.1.2 ULCERATIVE KERATITIS 
Tears and blinking are further examples of non-specific innate defence mechanisms; tears 
contain lysozymes, amylase, and immunoglobulin (Ig) A, which can form antibody (Ab) and 
antigen (Ag) complexes stimulating the effectors of the innate immune response such as 
phagocytes (macrophages and PMNs).  Pathogen associated molecular patterns (PAMPs) allow 
the immune system to recognise pathogenic antigens through the stimulation of appropriate 
pattern recognition receptors (PRRs) such as the toll-like receptors (TLR) (8, 10).  P. 
aeruginosa protects itself from phagocytosis by releasing the adherent glycocalyx whilst the 
immunogenic LPS and flagella, typical PAMPs, bind to TLR-4 and TLR-5 respectively (6, 11), 
stimulate PMN activation and chemotaxis, exacerbating tissue damage in ulcerative keratitis 
(7).   
 
1.1.3 CYSTIC FIBROSIS 
Cystic fibrosis is a recessive genetic disorder; a mutation in the cystic fibrosis transmembrane 
conductance regulator (CFTR) causing impaired chloride ion transport.  Development and 
function of certain organs (pancreas, intestines and the immune system) are affected and the 
condition is associated with a low life expectancy.  Complications are usually caused by 
infections, acute or chronic, which promote tissue damage by continuous stimulation of the 
immune system effectors.  P. aeruginosa is a leading pathogen in CF, often colonising young 
CF patients, and remaining throughout adulthood.  
 
The CF lung is an extreme environment with nutrient and oxygen gradients.  Oxygen gradients 
develop due to mucus plugs and increased consumption of epithelial cells, unique to CF (12).  
P. aeruginosa adapts and presents many phenotypes in this environment; it was found that the 
bacterial genome from one isolate from a single patient had acquired 68 mutations over 90 
months (13).  In acute P. aeruginosa infections, proteases, flagella, LPS with O-side chains 
(smooth LPS), elastase, and pyocyanin, contribute to the pathology in the lung (7, 11).   
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Chronic P. aeruginosa infections exist in biofilms, overproduce alginate, have no flagella, and 
produce rough LPS (no O-side chains) with decreased production of elastase, pyocyanin, and 
pyoverdine, typical of the mucoid phenotype.  However, P. aeruginosa can revert to the non-
mucoid state in the absence of selective pressure imposed by antibiotic therapy.  Small colony 
variants, selected after prolonged antibiotic treatment, produce glucose- (pel) or mannose-rich 
(psl) polysaccharides and are hyper-piliated, which contribute to the persistent characteristic of 
this phenotype (13).  Epidemic P. aeruginosa strains such as the Liverpool epidemic strain 
(LES) over-produce pyocyanin (14).   
 
1.1.4 URINARY TRACT INFECTIONS 
P. aeruginosa causes 35% of catheter-associated urinary tract infections (CAUTIs) (15).  The 
genotype and phenotype of 30 CAUTI P. aeruginosa isolates were studied, a mixture of 
phenotypes were discovered; isolates from the CAUTI displayed biofilm formation, low 
motility, and were haemolysin and exoenzyme (Exo) S positive, in contrast, other isolates had 
decreased elastase, pyocyanin, and alginate production.  It was noted that a specific phenotype, 
different from the isolates of the CF lung, was needed for P. aeruginosa to survive in catheters 
and urinary tracts (15).   
 
1.1.4.1 INNATE IMMUNE EFFECTORS 
The immune system is the natural defence against invading pathogens.  The non-specific innate 
system will immediately respond upon stimulation of PRRs, initiating innate effector responses 
such as (a) phagocytosis by macrophages and PMN such as neutrophils, and dendritic cells 
(DC) (b) cell death (i) by natural killer (NK) cells that target infected or malignant cells or (ii) 
by the complement system via the membrane attack complex formed from complement 
proteins.  The inflammatory response induced by various chemokines recruits the effectors to 
the site of infection.  Continuous stimulation of the effectors by PAMPs and virulence factors 
result in tissue damage that can be irreversible (8, 10).   
 
1.2 THERAPY AND ANTIBIOTIC RESISTANCE  
Antibiotics are the traditional treatment for bacterial infections that the immune system is 
unable to contain and eradicate.  The bactericidal mode of action (MoA) is different for each 
class of antibiotics; for example, !-lactams (penicillin and amoxicillin), and cephalosporins 
(cefalexin or cefradine) inhibit bacterial cell wall synthesis.  Aminoglycosides (gentamicin, 
tobramycin) target bacterial ribosomes and inhibit protein synthesis, whilst fluoroquinolones 
(ciprofloxacin) prevent DNA repair and replication (16).   
 
The anti-pseudomonal drugs include aminoglycosides, !-lactams (imipenam but not 
penicillins), 3
rd
 and 4
th
 generation cephalosporins, and fluoroquinolones.  In addition, colistin, a 
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drug that has a poor side-effect profile, is now used against MDR P. aeruginosa strains.  
Prudent prescribing methods and early but aggressive antibiotic treatment have improved 
treatment outcomes of certain diseases such as CF.  Strict hygiene protocols, separation of 
infected and susceptible but non-infected patients have also reduced transmission (17).   
 
The consequence of the bactericidal MoA is survival of the fittest through selective pressure.  
Bacteria that are tolerant to an antibiotic are selected and establish in the absence of 
competition for environmental resources such as nutrients.  An alternative class of antibiotic 
can circumvent specific antibiotic resistance.  However, bacteria have developed some 
effective defence mechanisms leading to MDR species such as methicillin-resistant 
Staphylococcus aureus (MRSA), Acinetobacter baumannii, or Escherichia coli.  P. aeruginosa 
has been promoted to Ôsuper bugÕ status, as MDR strains have made eradication of these 
opportunistic pathogens difficult (18).   
 
1.2.1  P. AERUGINOSA AND MECHANISMS OF RESISTANCE 
Table 1-3 (p 23) summarises the mechanisms of resistance used by P. aeruginosa against 
antibiotics, which can be intrinsic, adaptive, or acquired.  P. aeruginosa is innately resistant to 
many antibiotics; the intrinsic almost impermeable cell wall, outer membrane protein (Opr) 
channels (restrict substrate entry by size and hydrophobicity), and multi-drug efflux pumps 
additively give the bacteria a basal level of resistance to certain antibiotics.  Higher therapeutic 
doses and extended treatment programmes will eventually result in complete resistance through 
continued exposure (18-24).   
 
1.2.1.1 BIOFILMS 
Once the pathogen has colonised as planktonic bacteria, the cells convert to the sessile state 
and form biofilms.  These are hydrated structured matrices of exopolysaccharides and proteins, 
with a characteristic ÔslimyÕ layer and can form on most surfaces from catheters to eukaryotic 
and prokaryotic cells.  Biofilms are the real cause of persistent chronic infections; essentially 
impenetrable, the bacterial inhabitants are protected from biocides, thus physical removal of 
the biofilm through surgery is usually the only remaining treatment option (25, 26).   
 
Biofilms often have heterogeneous bacterial populations owing to intra-species (genotype, 
phenotype and growth) and inter-species diversity; P. aeruginosa can comfortably exist as the 
dominant pathogen or in synergy with other pathogens such as Gram-positive S. aureus or 
Gram-negative Burkholderia cenocepacia respectively.   
 
Biofilms have distinct microenvironments due to the heterogeneous bacterial population.  
Peripheral cells are metabolically active and consume most of the available oxygen, often 
causing oxygen gradients within the biofilm; deeper layers of the biofilm are usually hypoxic, 
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and bacteria are less metabolically active.  Metabolic, actively growing bacterial cells, at the 
periphery of biofilms may be susceptible to antibiotics, provided the drug can penetrate the 
biofilm slime layer.  Susceptibility to antibiotics varies with the phenotype and the progression 
of the infection (25, 27, 28).   
 
P. aeruginosa acquires antibiotic resistance through inter- and intra-transfer of resistance 
genes.  Biofilms are ideal environments for genetic transfer, during biofilm formation alone, 
numerous mutations occur, which can also result in antibiotic target modifications.  The origin 
of fluoroquinolone-resistant strains has been linked to aquatic bacteria (22), whilst extended 
spectrum !-lactamase (ESBL) strains resistant to cephalosporins and carboxypenicillins (20) 
were the result of genetic transfer between P. aeruginosa and Enterobacteriaceae spp. (24).   
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Mechanism Antibiotic Notes 
Intrinsic 
Low permeable membrane 
 - OprF, OprB, OprD 
 - Constitutive expression of efflux pumps 
Constitutive antibiotic degrading enzymes  
Trimethoprim; ampicillin; amoxicillin; 1
st
 and 2
nd
 
generation cephalosporin. 
Constitutive enzymes include basal levels of !-
lactamase.   
Adaptive 
AmpC depression Penicillins. Increase of !-lactamase above basal levels.   
Loss of OprD Carbapenam.  
Up regulation of:  
 - Multi-efflux pumps 
     - MexA-MexB-OprM !-Lactams; cephalosporins; aztreonam.  
 
Ciprofloxacin is affected by the increased expression of 
the MexA-MexB-OprM.   
     - MexE-MexF-OprN 
     - MexX-MexY-OprM 
!-Lactams including imipenam; fluoroquinolones 
Cefoperazone; meropenam; aminoglycosides; 
fluoroquinolones.   
 
Gyr/parE/parC Fluoroquinolones. Expression of gyrase and topoisomerase IV respectively 
are affected.  This leads to the reduced binding affinity 
of fluoroquinolones.   
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Membrane changes Polymyxin; aminoglycosides.   Mutations causing phenotypical changes to LPS results 
in colistin resistance.   
Acquired 
!-Lactamases 
 - ESBLs  Carboxypenicillins; cephalosporins; aztreonam.   Strains isolated in France; Greece; Poland; Turkey; 
Korea; China; Belgium, and South Asia.   
 - Metallo-!-lactamases Carbapenam.   Isolated in Japan/Asia; South America; Greece and Italy.   
Aminoglycoside-modifying enzymes Gentamicin; tobramycin.    
Table 1-3: Resistance mechanisms of P. aeruginosa.   
Adapted from (4, 18-24, 27).   
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1.2.1.2 THE PROBLEM OF RESISTANCE  
In 2009, the European Centre for Disease Prevention and Control (ECDC) reported that P. 
aeruginosa resistance was stable in Europe.  However, it was also reported that 23% (n = 
8,376) of tested isolates were resistant to three or more of the five classes of antibiotics 
(fluoroquinolones, cefatazidine, aminoglycosides, carbapenams, piperacilin:tazobactam) (29).  
This is a concern, especially as the problem of MDR is not counter-balanced by new classes of 
anti-pseudomonal antibiotics.  
 
The pharmaceutical industry is focussing on the improvement of antibiotic delivery to the 
respiratory tract, specifically in CF, examples include amikacin (inhaled or liposomal delivery) 
aztreonam with lysine (Cayston
¨ 
US-FDA approved) and inhaled ciprofloxacin (30).  New 
antibiotic drugs are being added to the existing classes of antibiotics (31), however, this does 
not equate to better anti-pseudomonal activity.  Doripenam, a relatively new antibiotic, has 
only marginal increased anti-pseudomonal activity (18).  Research and development of new 
classes of antibiotics is no longer a priority.   
 
Antibiotic resistance is the consequence of the MoA, therefore introducing new antibiotic 
drugs even with improved delivery may not solve the issue of resistance but simply slow the 
rate at which the bacteria develop resistance.  The development of novel therapies that can 
enhance the natural or chemical eradication of bacteria without selective pressure may be the 
way forward.  
 
1.3 ALTERNATIVE THERAPEUTICS 
1.3.1  VACCINES AND ANTIBODIES 
Vaccines are biological preparations that introduce the modified antigen to the nave immune 
system in order to establish immune memory.  An antigen is an umbrella term describing 
agents that are immunogenic, in other words, are able to stimulate an immune system response.  
This can include the whole pathogen or components of the pathogen, such as virulence factors 
- LPS is an example.  Vaccines effectively provide the immune system with the capacity to 
recognise, contain, and eradicate the pathogen before the bacterium has the opportunity to 
colonise.  Long-lived immunity against the pathogen is possible using a suitable native antigen, 
on the proviso that the pathogen does not significantly modify the native antigen so that it is no 
longer recognised by the primed immune system.   
 
Specific antibodies generated against the antigen can be given to the host through passive 
immunisation.  This therapy confers immediate and specific protection against the antigen 
provided the antibodies enhance innate effector responses or neutralise the antigen.  However, 
the specific protection is dependent on the half-life of the exogenous antibody and does not 
provide long-term immunity.  Antibodies can be polyclonal (pAbs), a mixture of antibodies 
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with diverse avidity to the various epitopes of the antigen, or monoclonal antibodies (Mabs), 
with specific affinity for an epitope of the antigen.   
 
1.3.1.1 IMMUNE SYSTEM AND ANTIGENS 
The immune system is divided into the innate immune system that provides immediate but 
non-specific defence against antigens, and the adaptive immune system, which on appropriate 
stimulation, will initiate a slower but specific response that acts to enhance the non-specific 
innate immune effectors and has memory.  The dendritic cells, which are professional antigen 
presenting cells (APC), link the innate immune system to the adaptive immune system (Figure 
1-1) (8, 32, 33).   
 
 
 
Figure 1-1: Innate and adaptive immune responses.   
Image was taken with permission from ÔRecognition of microorganisms and activation of the immune 
responseÕ by Ruslan Medzhitov, (2007).  Nature 449 (7164):819-826 (33).  The diagram illustrates how 
the innate and adaptive systems are interconnected.  Innate immune responses are activated by PAMPs, 
which activate innate immune effectors (referred to in this diagram and subsequent article (33) as 
modules) such phagocytes, PMNs, NK cells, and complement system proteins.  These are enhanced by 
the adaptive immune system effectors, controlled by T- and B-lymphocytes.   
 
The specific adaptive immune system has two responses, the cellular response, which is carried 
out by cytotoxic (TC-, CD8
+
) lymphocytes and the humoral response, which is the production 
of antibodies by B-lymphocytes.  The peptide antigen is internalised by resident dendritic cells 
Introduction 
 - 26 - 
- the mechanism of internalisation depends on whether the antigen is exogenous or endogenous 
in relation to the host cell.  This dictates the method of processing and presentation, as well as 
the adaptive response (8, 32, 33).  The next section refers only to exogenous antigens.   
 
Dendritic cells process the exogenous antigens into short peptides revealing numerous 
epitopes.  These are combined with major histocompatibility complex-II peptides (MHC) and 
are presented to nave CD4
+
 T-lymphocytes termed T-helper (TH) lymphocytes in co-ordination 
with specific T-lymphocyte receptors and co-stimulatory signals.  Depending on the cytokines 
released by the dendritic cells, the uncommitted TH-lymphocytes will differentiate to TH1-, or 
TH2-lymphocyes, (nave TH-lymphocytes can also differentiate to TH17-lymphocytes, which 
are involved in protection against fungi and extracellular bacteria), each with different 
functions.  TH1-lymphocytes release specific interleukins (IL) and cytokines that (a) activate 
the CD8
+
 TC-lymphocytes, initiating the cytotoxic cellular response causing cell death; (b) 
enhance phagocytosis by macrophages, which are also APCs; and (c) stimulate B-lymphocyte 
production of antibodies, specifically immunoglobulin (Ig) G2.  These enhance innate immune 
effector responses against intracellular pathogens.  TH2-lymphocytes, via cytokines and ILs, 
activate B-lymphocyte production of IgE, and innate effector cells including mast cells, 
basophils and eosinophils, to mediate protection against parasites (8, 32, 33).    
 
B-lymphocytes are professional APCs, and will present the processed antigen as a MHC-II 
complex to nave TH-lymphocytes, or become activated in a TH-lymphocyte dependent manner.  
Activation is supported by specific co-stimulatory signals and the cytokines released by the TH-
lymphocytes, which determines the class of Ig produced.  Cytokines are important for B-
lymphocyte differentiation to antibody-producing plasma with isotype switching and affinity 
maturation, and memory cells.  This is absent in independent TH-lymphocyte activation of B-
lymphocytes, by antigens such as LPS that bind to the TLR-4 expressed by B-lymphocytes (8, 
32, 33).   
 
1.3.1.2 ANTIBODIES 
An immunoglobulin (Ig) is a Y-shaped protein, with two identical heavy chains and two 
identical light chains held together by disulfide bridges.  Ig have an antigen binding domain, 
termed the Fab region, and the effector domain, FC, which binds to complement proteins and 
receptors of effector cells (8).  Depending on the isotype, antibodies enhance the innate 
effector responses by (a) stimulation of phagocytosis through opsonisation of antigen; (b) 
activation of the membrane attack complex by stimulating the classic complement pathway; (c) 
stimulation of NK cells via the antibody-dependent cell cytotoxicity response (ADCC) or (d) 
neutralisation of the antigen.   
 
Human Ig is divided into five isotypes depending on the heavy chain, IgG, IgM, IgA, IgE, and 
IgD.  IgG is divided into four subclasses that vary in biological effect, collectively IgG is 
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involved in opsonisation and activation of the complement system.  IgG is expressed in 
secondary immune response after isotype switching from IgM.  IgM is the first Ig produced in 
primary immune response and is a strong activator of the complement system.  IgA prevents 
bacterial colonisation, IgE is involved in hypersensitivity responses and IgD are membrane 
receptors although their biological effector role is unknown (8, 32).   
 
1.3.1.3 VACCINE INDUCED IMMUNITY  
Upon appropriate stimulation, TH-, TC-, and/or B-lymphocytes will differentiate into effector 
and memory lymphocytes.  These memory lymphocytes can circulate or remain in the lymph 
node, but are easier to activate and depending on the half-life, are present in greater numbers 
than the nave uncommitted counter-parts.  A vaccine antigen is processed as described above 
and induces the primary response.   
 
Figure 1-2 (34) depicts the processes involved in the primary response, whilst Figure 1-3 (p 29) 
illustrates the difference between the primary and secondary response.  Primary response is 
muted in regards to the speed of response, which can take days to weeks (Figure 1-1, p 25), and 
protective IgG concentration.  IgM is produced in a relatively higher concentration in the 
primary response and the isotype switch to IgG is slow resulting in relatively low titres of the 
protective IgG.  In contrast, due to the easily activated memory lymphocytes, when the 
immune system encounters the antigen in the native form or on re-exposure through secondary 
infection, the protective specific response of the adaptive immune system is strong, quick and 
persists for longer periods.  The protective immunity depends on the half-lives of the memory 
lymphocytes, but can be maintained with boosters.   
 
Introduction 
 - 28 - 
 
Figure 1-2: The adaptive immune response.   
Image taken with permission from ÔThe contribution of immunology to the rational design of novel 
antibacterial vaccines.Õ, by Stefan Kaufmann, (2007).  Nature Reviews Microbiology 5 (7):491-504 (34).  
(a) The effector T-lymphocytes (TEFF) refers, in this context, to activated T-lymphocytes.  TCM refers to 
central memory T-lymphocytes that reside in the lymph nodes while the TEM refer to migrating memory 
T-lymphocytes.  (b) Bact refers to activated B-lymphocytes, which differentiate according to cytokine 
environment.  DC (dendritic cell); IFN, (interferon), which is a cytokine; IL (interleukin); PNG, 
(polymorphonuclear granulocyte), in this context, refers to PMNs.  The image depicts the immune system 
processes and the differentiation to memory cells.  Memory cells can have half-lives of months to years.  
The secondary response upon re-exposure to the antigen is quicker and stronger as the memory cells are 
in greater numbers and are easily activated.   
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Figure 1-3: Immune system response to secondary exposure to antigen.   
Adapted from (8, 32).  The primary response to the antigen is slow and muted in terms of protective 
antibody concentration and the half-life of the response.  IgM (not indicated) is the abundant antibody and 
IgG (indicated, black solid line) is produced subsequent to isotype switching in lower concentrations.  
However, upon re-exposure to the antigen, the immune response is rapid, with a high concentration of 
protective IgG.  This response can persist for longer periods in comparison to the primary response.  IgM 
(not indicated) is produced in low amounts as isotype switching occurs more rapidly.   
 
1.4 ANTI-PSEUDOMONAL VACCINES AND THERAPEUTIC ANTIBODIES 
The potential of anti-pseudomonal vaccines, as a prophylaxis for susceptible patients pre-
empting P. aeruginosa infections, or therapeutic antibodies, is viable.  Susceptible patients 
refer to persons with a compromised immune system resulting from conditions such as CF, 
acquired immune deficiency syndrome (AIDs), diabetes mellitus, or treatment such as 
chemotherapy or immune suppression (7).  Bacterial vaccines have successfully been used to 
eradicate smallpox and for efficient immunisation programs against diphtheria, tetanus and 
pertussis to name a few (8).  However, despite the considerable research into anti-pseudomonal 
vaccines, there is still no successful anti-pseudomonal vaccine on the market (35, 36).   
 
Live or attenuated vaccines introduce the antigen, which can be the inactivated whole cell, to 
the immune system.  The antigen retains the native epitopes, and growth capacity, thus the 
immune system is exposed to the antigen for longer periods without the bacteria causing 
disease, although, there is a risk that the bacteria can revert to the native virulent form (8).  In 
regards to P. aeruginosa, attenuated vaccines increased survival in animal models, however as 
discovered with the heptavalent LPS vaccine, Pseudogen
¨
, the immunogenicity of the lipid 
moiety of LPS proved too toxic, resulting in a poor safety profile; this vaccine has not been 
developed further (35).  Various experimental vaccines and therapeutic antibodies have been 
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designed against certain virulence factors of P. aeruginosa.  Table 1-4 (p 33) lists some of the 
vaccines and antibodies against P. aeruginosa that have been investigated (35, 36).   
 
Conjugate vaccines refer to antigens that are conjugated to an immunogenic carrier in order to 
stimulate the T- and B-lymphocytes dependent responses.  For efficient vaccine programmes, 
the T- and B-lymphocytes need to be activated.  Aerugen
¨
, an O-polysaccharide octavalent 
conjugate vaccine, showed promising results in phase II trials but failed to show any benefit in 
phase III trials (36).  Based on these results, the development and use of anti-pseudomonal 
vaccines in CF, were not recommended (37).  
 
Unfortunately, P. aeruginosa can tailor the virulence factor phenotype to suit the site of 
infection and disease state.  Therefore, vaccines based on single virulence factors such as 
alginate or exotoxin A may not be appropriate for all pathologies, as the virulence phenotype 
differs according to site of infection (as described in 1.1.1 - 1.1.4, p 16-19).  Some of the 
investigated vaccines (Table 1-4, p 33) are strain specific, which is due to the targeted 
virulence factors.  P. aeruginosa infections are heterogeneous in regards to isolates, thus the 
vaccine must confer protection against P. aeruginosa rather than specific isolates; for example, 
in the case of conjugate vaccine, outer membrane protein (Opr) F-OprI-flagellin A and B was 
protective against non-mucoid strains but less protective against mucoid strains, which did not 
express flagella .  Mucoid strains are common in chronic P. aeruginosa CF infections.   
 
Vaccines based on the conserved OprF show potential strain cross-reactivity.  OprF, an outer 
membrane porin, allows non-specific diffusion of small molecules (below 1519 Da) such as 
polysaccharides (38).  OprF is involved in modulating virulence of P. aeruginosa; Fito-
Boncompte observed reduced toxicity of an oprF mutant (P. aeruginosa H636), which the 
authors attributed to poor eukaryotic cell adhesion and considerably decreased production of 
virulence factors pyocyanin, exotoxin A and lectin PA-1L, and delayed elastase production 
(38).  DNA vaccines are plasmids that contain the genetic information for the antigen.  On 
immunisation (intra-muscular) the DNA is incorporated into the host muscle cell and dendritic 
cells and the antigen is expressed, inducing a cell and humoral immune response resulting in 
immune memory (8).  OprF-OprI DNA vaccines are protective however the method of 
immunisation, either by gene gun or by intramuscular electroporation (imEPT), impacts on the 
efficacy of the vaccine (39).   
 
Passive immunisation has also been investigated, antibodies against exotoxin A, flagella and 
OprF increased the incidents of survival in infected mice (35, 36); a human IgM Mab against 
P. aeruginosa serotype O11 has shown clinical benefit with 100% survival of patients with 
hospital-acquired pneumonia (40).  Passive immunisation as adjunct treatment with antibiotics 
such as piperacillin provided strain specific protection (41).   
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Vaccine Results 
Live/attenuated/purified vaccines 
Exotoxoid A 93.8% (n = 48) pre-immunised mice survived after inoculation with P. aeruginosa.   
OprF-OprI ((Al(OH)3) (systemic) or OprF-OprI with 
attenuated Salmonella typhi (oral) or OprF-OprI (nasal) 
 
Met-Ala-(His)6OprF190-342-OprI21-83 
Mucosal vaccines (oral and nasal) with systemic immunisations, produced long lasting Ig (6 months) when nasal 
and systemic vaccination was used in COPD.  Healthy volunteers Ð nasal and oral vaccination resulted in OprF-
OprI specific IgA at bronchial surface.  Nasal vaccination induced serum Ab response.  Well tolerated and 
resulted in increase in IgG and IgA in burn patients.   
Peptide immunogen of receptor binding domain of type 
IV pilus 
pAb produced against peptide immunogen (carrying key amino acids from two strains PAK and PAO) were cross-
reactive for two strains of P. aeruginosa.   
Attenuated  P. aeruginosa PAO1!aroA Protective against certain O2/O5 serogroups but not all LPS-serogroups.   
Alginate Poorly opsonic Ab.  Not considered protective.   
Elastase-alkaline phosphatase-exotoxin A toxoids Used in combination increases survival in immunocompromised gut sepsis mouse model.   
OprI Protective as an oral vaccine.   
No Abs produced in mice.   
Flagella or Flagellin type A and B Anti-serum against flagella was opsonic, 83.3% mice survived against infection with PAK strain of P. aeruginosa, 
whilst anti-serum against flagellin was not significantly opsonic.   
DNA vaccines 
OprF-OprI Protective.   
OprF No further development.   
Mutated/modified gene of exotoxin A No further development.   
  
Introduction 
 - 32 - 
Conjugate vaccines 
OprF-OprI-Flagellin A and B Protective (mouse model) against non-mucoid strains ( P. aeruginosa PAO1, PAK and 1286) less protective 
against mucoid strains.   
PcrV Type III system effector translocation protein.  50% mice survived to day 10 vs. 20% mice (placebo).  Survival 
was increased to 60% with anti-toxin.   
High molecular weight polysaccharides (HMWPS) N-acetyl-fucosamine and glucose PS components .  Protective Abs produced with possible weak serotype cross-
reactivity.   
Pseudogen
¨ 
Heptavalent vaccine prepared from 7 LPS O-
polysaccharide serotypes  
Poor safety profile.  No clinical benefit in CF patients.  Exacerbated certain disease conditions.   
Aerugen
¨  
Octavalent vaccine based on 8 O-polysaccharide 
serotypes conjugated to exotoxin A  
Failed to show any protection in randomised trial (phase III). 
Non-integral outer membrane proteins Enhanced clearance of P. aeruginosa from lungs.   
AdC70-OprF Prolonged survival in mice (7-12 days) vs. placebo (0-3 days).   
Pilin-exotoxoid A  
Pilin-tetanus  
Alginate-PS Poor immunogen; antagonistic immune response.   
D-Alginate-exotoxin A Opsonic antibody response to 2 strains of P. aeruginosa.  Abandoned.   
Mucoid exopolysacharide (MEP) -alginate-KLH Pre-clinical trials.  Protective specific IgG, which showed cross-reactivity to 6 CF clinical mucoid isolates.   
Alginate-tetanoid Protective against alginate producing strain.   
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Table 1-4: Examples of vaccines and antibodies developed against P. aeruginosa.  
Adapted from (35, 36, 41-61).   
Polymannuronic acid-Flagellin Anti-sera (intra-nasal) enhanced pulmonary clearance by reducing the colony forming units of mucoid strains by 
71.5 -85.5% after 4 hours.  Protective in acute pneumonia model infected with non-mucoid strains.   
Passive immunisation 
Mab F429 Human IgG1 monoclonal antibody against alginate.  Therapeutic protection in ulcerative keratitis against mucoid 
producing strains.  Prophylactic protection due to reduced internalisation of specific mucoid strains.   
Fab 1A8 Engineered human Fab specific for PcrV.  Protective in PA13 pneumonia/sepsis mouse model.  Comparable to 
MA166, the murine Mab against PcrV.   
KB001: Pegylated FabÕ against PcrV from humaneering 
murine MAb 166 
Protective against strains expressing PcrV.   
Anti-PS human IgG2 against 9 O-specific side chains 
(different serotypes) 
Serotype specific.  Protective in an immunocompromised sepsis mouse model.   
Gamimmune-N
¨
 and Gammagard
¨
 S/D Dose-dependent survival (10 days) of a burn model infected with of M2 (73%), MSR17072 (47%), and IFO3455 
strain (82%).  (% of surviving mice).   
Ps-IVIg Pooled human plasma, which has elevated titres against P. aeruginosa.  Showed transient clinical improvement.   
Antibiotic and passive immunisation 
Piperacillin and human anti-LPS IgG and pooled plasma 
Ig preparation 
Strain specific in murine thigh infection.   
Ceftazidime and murine MAb Ld3-2F2 to LPS Used for MDR and non-MDR strains in burn models.   
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1.4.1 SUMMARY 
P. aeruginosa is an opportunistic bacterium with innate resistance to many available 
antibiotics.  The pathogen causes clinical complications in burns, wounds, and CF.  
Therapeutic options are now limited to isolation of infected patients and aggressive antibiotic 
therapy.  The pathogen is difficult to treat due to the effective resistance mechanisms, 
consequently, the selection of anti-pseudomonal antibiotics is slowly shrinking due to 
emerging MDR strains.   
 
P. aeruginosa efficiently adapts to the site of infection and it seems that the pathogen cleverly 
selects the virulence factors appropriate for the environment, thus presenting diverse 
phenotypes with varying susceptibility to antibiotics.  Immunological targeting of virulence 
factors through active or passive immunisation, acts to neutralise the damaging effects of 
virulence factors, and effectively attenuates the pathogenicity.  Extensive research has been 
conducted into anti-pseudomonal vaccines and therapeutic antibodies, but none have remained 
on the market.   
 
The disadvantage of the anti-pseudomonal vaccines and therapeutic antibodies listed in Table 
1-4 (p 33) is the conferred protection is specific for the strain and this may limit the viability of 
active and passive immunisation in all P. aeruginosa disease pathologies.  In other words, 
immunisation may only be suitable in conditions infected with the specific strains, it may not 
be protective against the diverse phenotypes presented by each strain.  Targeting conserved 
antigens such as OprF-OprI appears to be the better option, further study will indicate if cross-
strain conferred protection is possible.   
 
It should be noted that for the production of toxic virulence factors (Table 1-2, p 17), P. 
aeruginosa has to colonise and establish.  Flagella and pilin help this process, and targeting 
such virulence factors increases survival of strain-specific infected models (Table 1-4, p 33).  
A secondary response, which is relatively quicker than the primary response, still requires 
day(s) to produce protective antibodies, P. aeruginosa can colonise, establish and form 
biofilms (and no longer express flagella at this point) within hours.  A similar situation is 
applicable to all the virulence factors (Table 1-2, p 17).  However, active immunisations 
against bacterial infections have been successful; the prospect of long-lived immunity against 
P. aeruginosa emphasises the benefits of active immunisation.  An alternative target is needed, 
so the host has sufficient time to generate protective antibodies, which are still useful before 
the pathogen has released virulence factors, resulting in unmanageable pathogenicity.  
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1.5 REGULATORY SYSTEM FOR VIRULENCE FACTOR PRODUCTION - 
POTENTIAL TARGET 
1.5.1 QUORUM SENSING 
Quorum sensing (QS) is a system used by Gram-positive and Gram-negative bacteria for intra- 
and inter-species communication, a method to sense the immediate environment.  Several 
systems have been characterised, such as those from Vibrio fischeri, P. aeruginosa, and S. 
aureus.  Essentially, bacteria release small quorum sensing system molecules (QSSM) into the 
immediate environment (Figure 1-4, p 36), as bacteria proliferate the concentration of the 
QSSMs increase until a particular concentration is reached.  This indicates that the bacteria 
have reached the quorum, with this ÔinformationÕ bacteria can act as a co-ordinated entity, 
participating in social behaviours (62), which benefit the pathogen; such as colonisation of the 
site of infection without alerting the hostÕs immune system.  The pathogenÕs virulence factors 
are immunogenic, therefore if only released when the pathogen has established and the number 
of bacterial cells is higher, the immune system once stimulated is unable to contain and 
eradicate the pathogen effectively, which may have otherwise been possible during 
colonisation.  Thus, the quorum sensing system (QSS), a highly adaptable system, regulates the 
production of virulence factors in accordance with various factors such as nutrition, pH, and 
growth phase.   
 
P. aeruginosa uses QS for inter-species communication.  As briefly mentioned, P. aeruginosa 
is a co-infector in many conditions, in particular CF.  Burkholderia cenocepacia complex 
encompasses approximately 15 species and is common in older CF patients (63).  Equally as 
difficult to treat as P. aeruginosa, the bacterium can communicate quite effectively with P. 
aeruginosa as it also produces derivatives of P. aeruginosa QSSMs (Table 1-5, p 38).   
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Figure 1-4:  Depiction of QS in P. aeruginosa.  
QS contributes to the pathogenÕs covert colonisation of the host.  As the bacterium grows, QSSM are released into the environment.  The optimum concentration of QSSM indicates the quorum 
has been reached.  Bacteria act as a single entity and initiate co-ordinated QS-controlled responses, such as the maturation of biofilm and other damaging virulence factors.  At this stage, the 
immune effectors are ineffective.   
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1.5.2 QSSM OF P. AERUGINOSA 
QSSMs are termed auto-inducers (AI) as the molecule, as part of the transcriptional regulator 
protein complex, controls its own synthesis.  In Gram-positive bacteria, the signal molecules 
are post-translationally modified proteins; S. aureus, for example, utilises cyclic oligopeptides.  
Other AI have been reported; AI-2, a furanosyl diester, is thought to be a common QSSM; 
certain Gram-positive bacteria such as S. aureus and Gram-negative bacteria such as 
Salmonella typhi produce AI-2.  P. aeruginosa does not produce AI-2 but does respond to the 
QSSM.  Enterohemorrhagic E. coli produce AI-3, which may be structurally similar to 
noradrenaline/adrenaline and is involved in inter-kingdom communication.  P. aeruginosa, on 
the other hand, produces acylated homoserine lactones (AHL) QSSMs (Figure 1-5), N-3-
oxododecanoyl-L-homoserine lactone 1, and N-butanoyl-L-homoserine lactone 2 (64, 65).   
 
P. aeruginosa produces approximately 55 2-alkyl-4(1H)-quinolones (HAQs), which have 
antimicrobial activity (66, 67).  Two HAQs (Figure 1-5, 3 and 4) are involved in QS, 2-heptyl-
4(1H)-quinolone (3, HHQ) and 2-heptyl-3-hydroxy-4(1H)-quinolone (4, PQS; Pseudomonas 
quinolone signal).  PQS is specific to P. aeruginosa, however, Burkholderia spp. use HHQ as a 
QSSM in inter-species communication (68) and produce a variety of 2-alkyl-3-methyl-4(1H)-
quinolones (HMAQs) that may be used in QS (69, 70).   
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Figure 1-5: The QSSM of P. aeruginosa.   
N-3-oxododecanoyl-L-homoserine lactone, (OdDHL, PAI-1, 3OC12-HSL), 1; N-butanoyl-L-homoserine 
lactone, (BHL, PAI-2, C4-HSL), 2; 2-heptyl-4(1H)-quinolone, (HHQ), 3; and 2-heptyl-3-hydroxy-4(1H)-
quinolone, (PQS, Pseudomonas quinolone signal), 4. 
 
1.5.2.1 QSSM OF OTHER GRAM-NEGATIVE BACTERIA  
Table 1-5 lists the Gram-negative bacteria that have been reported to produce QSSM and have 
homologue QSSs, which contribute to the regulation of the pathogenÕs pathogenicity.  Gram-
negative bacteria produce AHLs that differ in acyl chain length and saturation, and by the 
substitution on the third carbon of the acyl chains.  HAQs and HMAQs have been reported in 
only a few Gram-negative bacteria such as B. cenocepacia and B. pseudomallei.   
 Introduction 
 - 38 - 
Table 1-5: Examples of Gram-negative bacteria that have been reported to use AHL and HAQ derivatives.   
Adapted from (71-73).   
Bacteria 
O
O
N
H
OR
n
R = O, OH
n = 0 -9, satuarated/unsaturated  
N
H
O
R
HHQ: R = H
PQS: R = OH  
Significance 
Acinetobacter baumannii 3OHC12-HSL  MDR strains; nosocomial infections; wounds; burns; pneumonia.   
Aeromonas hydrophila C4-HSL  Gastroenteritis and cellulitis in humans.   
Burkholderia  
cenocepacia complex 
C6-HSL; C8-HSL Cystic fibrosis.   
Burkholderia pseudomallei C8-HSL; C10-HSL; 3OHC8-HSL; 
3OHC10-HSL; 3OHC14-HSL 
Biological warfare agent.   
Burkholderia mallei C8-HSL; C10-HSL 
HHQ; 
HMAQS: 
N R
O
R = CH2(CH2)n, R' = H, n = 3 - 9
R = CH2(CH2)n, R' = O, n = 3 - 9
R = CH:CH(CH2)n, R' = H, n = 3 - 9
R = CH:CH(CH2)n, R' = O, n = 3 - 9
R'
 
 
Glanders; biological warfare agent. 
Pseudomonas aeruginosa C4-HSL; 3OC12-HSL; 3OC8-HSL; 
3OC10-HSL 
HHQ; PQS Nosocomial infections; cystic fibrosis; wounds; burns.   
Serratia marcescens SS-1 C6-HSL; 3OC6-HSL  
Nosocomial infections; wounds; urinary and gastro infections as well as 
catheter associated infections.   
Yersinia enterocolitica C6-HSL; 3OC6-HSL; 3OC10-HSL; 
3OC12-HSL; 3OC14-HSL 
 Yersiniosis.   
Yersinia pestis C6-HSL; C8-HSL; 3OC6-HSL; 3OC8-
HSL 
 Plague; biological warfare agent.   
Yersinia pseudotubuculosis C6-HSL; 3OC6-HSL; C8-HSL  Pathogen of animal and human.   
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1.5.3 THE QUORUM SENSING SYSTEM (QSS) OF P. AERUGINOSA 
The QSS of P. aeruginosa has three interlinked divisions, the Las, Rhl, and Pqs system.  Each 
division is controlled by a specific QSSM.   
 
1.5.3.1 INTERNAL QSS REGULATION 
The protein components of the Las system are expressed by the transcriptional regulator gene, 
lasR and the synthase gene, lasI, which expresses LasI, responsible for the synthesis of the 
QSSM, 3OC12-HSL 1 (Figure 1-5, p 37), which complexes with the LasR protein to control its 
synthesis by stimulating lasI, creating a positive feedback loop.  LasR-3OC12-HSL activates 
the expression of several virulence factors, as well as positively activating rhlR, pqsH, and 
pqsR of the Pqs QSS (Figure 1-6, p 42).   
 
The transcriptional regulator rhlR, and the synthase rhlI express the protein components of the 
Rhl system.  RhlI synthesises the AHL QSSM, C4-HSL 2 (Figure 1-5, p 37), which complexes 
with RhlR to positively control its synthesis and activate or repress the production of virulence 
factors.  This complex negatively regulates the Pqs system, although one report suggests that 
the complex has positive control over this system (74).   
 
The Pqs system consists of the pqsABCDE and phnAB operons, which are stimulated under 
different conditions, but activate the biosynthesis of HHQ 3.  HHQ  is the precursor to many of 
the HAQs produced by P. aeruginosa, but is converted by PqsH to PQS 4.  HHQ is also 
considered to have QSSM activity in P. aeruginosa and Burkholderia spp., which is one of the 
co-infectors in CF (63).  PQS is specific to P. aeruginosa and complexes with PqsR to regulate 
specific virulence factors, which are also under the control of the Las and Rhl systems (Table 
1-6, p 44) (71-73, 75).   
 
1.5.3.2 GLOBAL REGULATION OF QSS 
The global regulators of the QSS have been presented in Figure 1-4 (p 36).  The QSS has two 
orphan transcriptional regulators, quorum sensing control regulator (QscR) and virulence and 
quorum sensing regulator (VqsR), which respond to AHLs of the P. aeruginosa QSS.  QscR 
can repress or activate the Las/Rhl system under specific conditions to prevent early induction 
of QSS-controlled gene products, whilst VqsR positively controls the Las/Rhl system.   
 
1.5.3.3 ENVIRONMENTAL REGULATION OF QSS 
The environment controls the QSS and global regulators, contributing to the adaptability of P. 
aeruginosa; many QSS-controlled genes will only be activated in specific growth phases or in 
specific environments.  Under conditions of iron deficiency, instigated by the host as a defence 
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mechanism (for example, the iron-binding lactoferrin) many QSS processes are up regulated.  
Low phosphate can lead to Las-independent activation and up-regulation of the Pqs system via 
the PhoB regulator (76-79).   
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Figure 1-6: The quorum sensing system (QSS) of P. aeruginosa.   
This diagram illustrates the quorum sensing system of P. aeruginosa and the complex global 
regulatory system of QS.  The dashed line ( ) has been used to illustrate a figurative upper 
level separating the QSS and the global regulatory system.  The global regulatory system 
regulates the quorum sensing system; the global regulatory system and the QS is dependent on 
the environment, native or of the host, at the site of infection (  ).  QscR and VqsR are 
transcriptional regulators, whilst the virulence and quorum sensing modulator (VqsM) 
positively modulates the Las and Rhl system.  RelA is important in essential amino acid 
deficiency whilst DksA is a co-factor of the substrate of the RelA protein.  AlgR2 represses 
expression of RhlI and PPK1 (polyphosphate kinase) regulates the synthesis of AHLs.  The 
virulence factor regulator (VfR) controls LasR and RhlR systems and corresponding virulence 
factors.  PtxR negatively regulates Pqs and Rhl but positively regulates the Las system.  Global 
antibiotics and cyanide (GacA/GacS) is a two-component regulatory system and positively 
regulates the QSS through RNA regulatory proteins (regulator of secondary metabolites, 
RsmAYZ).  Hfq is also involved in this system and has positive regulatory effects on QscR and 
pqsH; RpoS and RpoN are stationary-phase sigma factors involved in stationary phase 
regulation of QSS.  MvaT is important in biofilm and represses synthesis of HSL in low cell 
densities, PmpR negatively regulates Pqs and Rhl, and PpyR negatively regulates PQS 
synthesis.  HHQ complexed with PqsR positively controls its synthesis and may have QSSM 
activity (represented by ?).  PqsE may also regulate the virulence factors, pyocyanin and 
rhamnolipid independent of the PQS-PqsR complex, but still requires activation by this 
complex.  Adapted from (72, 75-80). 
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1.5.4 QSS AND VIRULENCE 
It is estimated that QSS controls up to 11% of the P. aeruginosa genome (81, 82), which 
consists of genes that control the expression of virulence factors.  Table 1-6 lists the virulence 
factors and the controlling QSS.  This is not an exhaustive list, especially as it has been shown 
that there may be genes, which have elements of QSS control but only under certain conditions 
(81, 82).   
Table 1-6: QSS-controlled virulence factors.   
(* repressed).  Adapted from (5, 7, 83, 84).   
 
Las Rhl PQS 
Alkaline protease Alkaline protease   
Biofilm Biofilm Biofilm  
Rhl  Rhl 
Elastase Elastase Elastase  
Lipase Lipase  
 Pyocyanin Pyocyanin 
Hydrogen Cyanide Hydrogen Cyanide  
Motility (Swimming, 
Swarming and Twitching)  
Motility (Swarming and 
Twitching) 
 
 Siderophores Siderophores 
PQS PQS HAQ 
 Lectins Lectins 
 Type III secretion system* Type III secretion system* 
 Rhamnolipids Rhamnolipids 
Exotoxin A   
Alginate   
Neuraminidase   
 Xcp secretion  
 Chitinase  
  RsmZ 
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1.5.4.1 QSSM AS VIRULENCE FACTORS 
Immune modulatory activity of the QSSMs, 3OC12-HSL and PQS, have been reported with 
suggestions that the QSSMs appear to influence the adaptive behaviour of P. aeruginosa, thus 
are considered as virulence factors per se.  3OC12-HSL induces apoptosis in dendritic cells and 
CD4
+
 TH-lymphocytes (85); Jurkat T-lymphocytes (86); murine fibroblasts (87); mast cells 
(88); murine derived bone-marrow macrophages and neutrophils (89) at 6-100 µM in vitro.  
PQS was cytotoxic to murine monocyte/macrophage J774A.1 at approximately 4 µM in vitro 
(90).  Although these data demonstrate apoptotic effects, it seems to be cell-line and study 
specific, as there are conflicting reports that suggest that 3OC12-HSL and PQS do not induce 
apoptosis (91, 92).  
 
3OC12-HSL, PQS and HHQ reduced cytokine TNF-! production (90-93); indeed 1 µM [PQS] 
was sufficient to inhibit the production of TNF-! and IL-6 in vitro (90).  This is possibly 
physiological relevant as concentrations of up to 2 µM [PQS] have been detected in CF sputum 
and bronchoalveolar lavage (94).  IL-12 and IL-2 were negatively affected by 3OC12-HSL and 
PQS.  These chemokines promote the TH1-lymphocyte-dependent immune responses specific 
for intracellular bacteria.  3OC12-HSL increased the release of IL-4 and IL-10 (85) and IgG1 
(93, 95), indicators of the TH2-lymphocyte-dependent response.  3OC12-HSL interferes with 
dendritic cell maturation preventing the APC functionality as well inhibiting the differentiation 
of nave T-lymphocytes, whilst both PQS and 3OC12-HSL inhibit activated T-lymphocyte 
proliferation (92).  These data suggest that 3OC12-HSL and PQS induce a TH2-lymphocyte-
dependent immune response, albeit with different mechanisms (92).  This response is 
protective against parasites and clearly beneficial for P. aeruginosa as presumably the typically 
induced TH1-lymphocyte-dependent immune effector responses are inhibited.  In addition, 
3OC12-HSL (96) and the metabolite, C12-tetramic acid (97) have anti-microbial activity against 
S. aureus.  PQS is involved in the regulation of HAQs, which have anti-microbial activity (67).   
 
In contrast, 3OC12-HSL promotes a TH1 response.  3OC12-HSL stimulated the release of COX-
2 and PGE2, pro-inflammatory cytokines, as well as IL-1! and IL-6.  These cytokines are 
involved in activation of macrophage release of pro-inflammatory mediators and antibody 
production respectively.  Indeed, 1 µM [3OC12-HSL], which may also be within the 
physiological concentrations (up to 600 µM [3OC12-HSL] has been detected in biofilms in 
vitro), was sufficient to induce significant inflammation and tissue damage in vivo (98-100).  
The QSSM is a strong PMN chemotactant (101) and induces the release of chemotactant IL-8, 
at high concentrations (50 µM) as well as demonstrating antagonistic activity towards 
peroxisome proliferators activated receptor (PPAR)-! that inhibit pro-inflammatory processes 
(102).  This appears to be detrimental to P. aeruginosa, as the QSSM promotes the bacteria 
specific immune effector response.  However, P. aeruginosa has specific virulence factors 
(Table 1-2, p 17), which destroy immune cells, for example rhamnolipids, which causes 
apoptosis of PMNs.  Ritchie et al. (103) surmised that the conflicting immune modulatory 
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responses of 3OC12-HSL was because the QSSM emphasises the pre-disposition of the 
immune system, which can be either TH1 or TH2 biased, thus contributing to P. aeruginosa 
adaptation to the hostÕs environment (103).  Collectively, the data suggests that 3OC12-HSL 
and PQS contribute to the protection of P. aeruginosa from host defences (83) whilst ensuring 
that the pathogen is the dominant species in infection.  C4-HSL does not appear to have 
immune modulatory activity. 
 
PQS acts as an iron trap due to its iron-chelation properties; 60% of PQS is associated with the 
bacterial cell membrane allowing siderophores, such as pyoverdine, which are under the 
control of the Pqs system, to transport iron trapped by PQS into the cells.  This mechanism 
prevents P. aeruginosa from wasting resources, such as siderophores, while still benefiting 
from iron acquisition (104).  PQS has been termed a Ôcellular trainerÕ by regulating endogenous 
stress, bacteria that have survived this ÔstressÕ are protected from reactive oxidative species 
released by phagocytes, by the anti-oxidant effect of PQS (105).  In fact, excess PQS caused P. 
aeruginosa cell autolysis (106), which may be an example of the endogenous stress.  
 
1.5.5 QS AND BIOFILMS 
QS has an important role in the differentiation and maturation of the mushroom-shaped 
biofilms.  A lasI mutant produced a thin and uniform biofilm that was susceptible to sodium 
dodecyl sodium (SDS) treatment, however in the presence of exogenous 3OC12-HSL, the same 
mutant strain was able to form biofilms similar to that of the wild-type (WT) strain that were 
unaffected by the detergent, showing that LasR-3OC12-HSL was involved in biofilm 
development (107).  In addition, biofilms of the pqsA mutant strain were thin and flat (108), 
suggesting that PQS has a role in biofilm development.   
 
Certain biofilm components are under the specific control of QS.  Exopolysaccharide matrices 
of biofilms can be alginate- (alg), glucose- (pel) or mannose-rich (psl); the pel gene is thought 
to be under the control of the Las system (109).  Extracellular DNA (eDNA) is a cohesive 
factor in early biofilm formation, but is also important in mature biofilms, which were 
susceptible to DNAase treatment (110).  There is a basal level of eDNA that is released in a 
QS-independent manner.  However, during late log phase high concentrations of eDNA is 
released, which is thought to be under QS-control; Allesen-Holm and colleagues (110) 
observed that !lasI !rhlI (unable to produce 3OC12-HSL and C4-HSL respectively) mutant and 
!pqsA (reduced production of HAQs) mutant strains produced low levels of eDNA compared 
to WT strains (110).  It has been speculated that PQS is involved in cell lysis (106) causing the 
release of eDNA (111).  Rhamnolipids, which are regulated by PQS and C4-HSL, are involved 
in the maintenance of open channels that allow transport of nutrients, oxygen, and waste 
products within the biofilm as well as structure, microcolony formation and detachment (109, 
112).  It has been suggested that rhamnolipids deactivate neutrophils (113), protecting the 
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biofilm from the innate immune response.   
 
P. aeruginosa can convert to anaerobic metabolism utilising nitrogen-based metabolites 
through denitrification (114).  This is useful as the biofilm in chronic CF infections has an 
oxygen gradient.  The Rhl system is thought to regulate growth during anaerobic metabolism 
in order to protect bacteria from metabolic nitric oxide (NO) suicide (108, 114).   
 
1.5.6 QS AND DISEASE 
Guina et al. (115) investigated five clinical isolates (CF259, CF1488, CF1641, CF471 and 
CF1153) from CF patients aged 24-36 months and noted that these isolates produced relatively 
more PQS than isolates from urinary tract infections.  The authors concluded that in young CF 
patients, P. aeruginosa might induce QSS, specifically the Pqs system, as a response to certain 
nutrient deficiencies, such as limited magnesium (115).  It has been reported that the ratio of 
C4-HSL to 3OC12-HSL is higher in the CF sputum and lung tissue than in other P. aeruginosa 
infections (5, 116).  CF P. aeruginosa isolates eventually lost QSS activity (years) however C4-
HSL production persisted into late infection (years), correlating with rhamnolipids levels 
(117).   
 
It has been found that the pathogenicity of a double QSS mutant, P. aeruginosa PAO1-JP2 
(!lasI !rhlI, mutant cannot synthesise 3OC12-HSL and C4-HSL) was significantly 
compromised in a burn mouse model.  The strain could not achieve efficient local and systemic 
spread when compared to a WT strain.  This could not be attributed to loss of the expression of 
a particular virulence factor; therefore, it was concluded that this reduced virulence was due to 
the collective loss of QSS-controlled virulence factors (118).   
 
As described (1.1.4, p 19), LPS and flagella contribute to the continuous stimulation of innate 
immune responses, in ulcerative keratitis, which leads to eventual blindness.  P. aeruginosa 
has been documented to produce C4-HSL, 3OC12-HSL and C6-HSL resulting in expression of 
virulence factors such as elastase, alkaline protease and protease IV, including exoS and exoU, 
which are negatively regulated by QS in certain conditions.  Conversely, a QSS mutant was 
unable to induce murine ocular damage (119).  Pyelonephritis, caused by the QSS mutant 
PAOI-JP3 (!lasI !rhlR, mutant cannot synthesise 3OC12-HSL or express the RhlR protein, 
required to form the complex with C4-HSL) was cleared within three days compared to an 
infection caused by the WT strain that persisted for twelve days (120).  It appears that strains 
that have compromised QSS have reduced lethality (83) and cause milder pathologies.  This 
was noted in a rat lung model infected with P. aeruginosa PAO1-JP2, which had mild lung 
pathology compared to the WT infection, attributed to less virulence factor production.  
Additionally, an early but stronger and quicker immune response was induced leading to the 
rapid clearance of the QSS mutant bacteria (121).   
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1.6 THE QSS Ð ALTERNATIVE THERAPEUTIC TARGET 
The above mentioned published reports show that compromised QSSs did not affect the 
growth but severely limited the pathogenicity of P. aeruginosa in most disease states due to the 
multiple loss of virulence factors.  This resulted in mild pathologies and most importantly, the 
pathogen was rapidly cleared from the host.  
 
Inhibition of QSS has attenuated multiple virulence factors irrespective of the pathogen 
virulence phenotype and reflected the avirulence of mutant QSS P. aeruginosa strains.  Growth 
was not affected, therefore, the selective pressure, the accompaniment to antibiotic treatment, 
is absent, thus minimising resistance.  QSS inhibition was proposed as a novel therapeutic 
approach against P. aeruginosa.   
 
1.6.1 QSS INHIBITION 
Inhibition of QSS will prevent the intra- and inter-species communication; P. aeruginosa will 
be unaware of the quorum or the environment and cannot co-ordinate unified QSS-controlled 
responses (Figure 1-7).  The immune system will be able to manage the pathogen more 
effectively, with or without the adjunct antibiotic therapy.  
 
 
Figure 1-7: QSS inhibition.   
Quorum sensing system inhibitors (QSSi) that affect (a) production of QSS proteins and/or (b) production 
of the QSSMs and/or (c) activity of the QSSMs.  If given as prophylactics or adjuncts in antimicrobial 
therapy, QSSi may prevent the production of virulence factors and reduce the pathogenicity of P. 
aeruginosa.  Therapy, inherent (immune system) or chemotherapy (antibiotics) is more efficacious, 
resulting in a mild to non-existent pathology and rapid clearance of the pathogen.   
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1.6.2 QUORUM SENSING SYSTEM INHIBITORS (QSSI) 
1.6.2.1 NATURAL INHIBITORS 
AHLs are degraded by lactonases that target the lactone ring (122), acylases that hydrolyse the 
amide bond (123) and AHL oxidase or reductase, which target the acyl chain.  Prokaryotes 
release such enzymes as part of a defence or regulatory mechanism.  Certain eukaryotic cells 
such as specific epithelial cells and mammalian serum contain enzymes such as paraoxanase 
(124), which degrade AHLs (125).  Arthrobacter nitroguajacolicus dioxygenase HOD can 
degrade PQS but can be competitively inhibited by HHQ (126).  Delisea pulchra produces 
halogenated furanones, which have anti-QSS activity in Vibrio fischeri and V. harveyi (127) 
but have no activity in P. aeruginosa.  However, the synthetic furanone-C30 increases P. 
aeruginosa biofilm susceptibility to SDS and tobramycin resulting in rapid clearance of P. 
aeruginosa in a murine infection model (128).  Clove oil (129), furocoumarins in grapefruit 
juice (130), honey (131), garlic (132), patulin, and penicillic acid (133) have demonstrated 
anti-QSS activity.   
 
1.6.2.2 CHEMICAL INHIBITORS 
S-adenosylmethionine (SAM) and anthranilic acid are biochemical precursors of AHLs and 
PQS respectively.  Derivatives of SAM and anthranilic acid reduced in vitro production of 
AHLs and HAQs respectively.  The substrate specificity of purified RhlI, which synthesises 
C4-HSL, was tested using derivatives of SAM resulting in the inhibition of RhlI activity (134).  
Halogenated anthranilic acid derivatives increased the survival of thermal injured mouse model 
by 35-50%, although protection was transient (135), whilst methyl anthranilate reduced the 
expression of elastase in vitro (135-137).  However, there is an alternate biosynthetic route to 
HAQs, which utilises amino acid tryptophan (138), therefore may overcome any inhibition of 
biosynthesis of these QSSMs.  
 
There has been considerable work in producing libraries of AHL derivatives with agonist or 
antagonist activity (139-141).  Geske et al. (139) noted that QSS antagonist was able to reduce 
biofilm formation by 75% in a dose-dependent manner using in vitro green fluorescent protein 
(GFP) reporter P. aeruginosa strain.  Ishida et al. (142) focussed on N-acyl cyclopentylamides, 
these inhibitors reduced !-galactosidase activity in response to expression of rhlA and lasB, in 
a dose-dependent (0-250 µM) manner.  These genes encode for rhamnolipids and elastase 
respectively, suggesting that synthesis of these virulence factors were reduced, this anti-QSS 
activity was comparable to halogenated furanones (143).  Liu et al. (144) observed that 
halogenated furanones were able to inhibit the formation of the QscR-3OC12-HSL complex.  
The QscR is part of the global regulatory system (Figure 1-6, p 42) and inhibition at this level 
may lead to disruption of the QSS.   
 
Using GFP reporter strains (WT and an isogenic lasR mutant P. aeruginosa rhlA::gfp (ASV) 
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and P. aeruginosa pqsA::gfp (ASV)), salicylic acid, nifuroxazide, and chlorzoxazone reduced 
fluorescence in response to rhlA and pqsA expression in vitro, demonstrating anti-QSS activity, 
which was partially directed at the Rhl and Pqs system (the synthesis of rhamnolipids and 
PqsA, needed for PQS synthesis, are under Rhl and PQS control respectively).  Salicylic acid 
was able to prevent the in vitro production of rhamnolipids at 200 µg/mL (145).   
 
Sub-inhibitory concentrations of macrolide antibiotics have been used as QSSi.  Azithromycin 
(2 µg/mL) reduced the !-galactosidase activity in response to the expression of lasI by 80% 
and by 50% in response to rhlI expression (146).  Furthermore, other anti-pseudomonal 
antibiotics such as ciprofloxacin (fluoroquinolone), and the ceftazidime (cephalosporin) as well 
as azithromycin were able to reduce QSS-controlled virulence factors - rhamnolipids, elastase 
and protease (147).  However, prolonged exposure of azithromycin was needed (146), and 
long-term treatment with azithromycin has resulted in S. aureus resistance against the 
antibiotic (147).  As bacteria, particularly P. aeruginosa, are adept at acquiring resistance, 
promoted by continued exposure to the antibiotic, the use of antibiotics at sub-inhibitory 
concentrations as QSSi should not be recommended.   
 
1.6.2.3 IMMUNOLOGICAL INHIBITORS 
1.6.2.3.1 ANTI-AHL VACCINES AND ANTIBODIES 
Kende et al. (148) produced an anti-QSS conjugate vaccine based on 3OC12-HSL.  
Immunisation of Balb/c mice with the conjugate resulted in polyclonal immune sera that 
reduced the release of !-galactosidase by 70%, in response to the expression of lasI in a !-
galactosidase reporter assay.  The corresponding 618.4 Mab was able to reduce the release by 
80% in the same assay (148).   
 
Charlton et al. (149, 150) produced a single chain antibody (scAb) using phage technology and 
the probe, dDHL-COOH (C12-HSL-COOH).  The scAbs, G3G2 and G3B12, were able to 
reduce P. aeruginosa mediated nematode killing by over 90% in a 60-80 hour incubation 
period, the inventors applied the same technology to develop an anti-AI-2 antibody.  The 
scAbs were efficient in reducing biofilm formation in a concentration dependent manner, 70 
nM was sufficient to cause an 80% reduction, and in addition the inventors observed that 
tetracycline and scAb had an additive inhibitory effect on biofilm formation (149, 150).   
 
Charlton et al. (151) hypothesised that the bacterial load could be reduced using anti-AHL Abs 
without direct bactericidal activity, thus avoiding the imposition of selective pressure.  The 
inventors assumed as excess PQS would cause cell lysis, this will automatically lead to a 
reduction in bacterial cell density, but as an additional measure, P. aeruginosa will slow down 
growth as a counter-defence mechanism, in order to prevent further cell death by autolysis.  
This excess PQS could be achieved by either addition of exogenous PQS or by the disruption 
of the AHL:PQS balance.  Charlton et al. (151) noted a decrease in bacterial load after 24 
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hours post-infection in the presence of scAbs, G3G2 or G3B12, and in combination with 
gentamicin.  It is understood that the inventors were working on the assumption that 
neutralisation of the AHLs with the specific antibodies, would result in the physical disruption 
of the AHL:PQS balance rather than effects at the molecular level.  Although, data has shown 
that excess PQS caused autolysis the mechanism is unknown and it was concluded that PQS 
has an undefined role in the mechanism (106).  The importance of the AHL:PQS ratio has not 
been discussed in the literature presented in this study.  Therefore, the inventorsÕ interpretation 
that the reduced bacterial load was due to excess PQS or that the bacteria sensed an ÔexcessÕ of 
PQS as the result of the neutralisation of the AHLs by the scAbs, needs further clarification.   
 
Miyairi e  al. (152) produced an anti-QSS vaccine with specificity for 3OC12-HSL.  Immunised 
mice (36%) were able to survive a P. aeruginosa infection for four days compared to no 
survivors in the non-immunised mice.  TNF-! levels were reduced, as was the concentration 
(pmol) of 3OC12-HSL, in serum and lung homogenates.  The immune serum inhibited 3OC12-
HSL induced apoptosis in macrophages in vitro (152).   
 
Kaufmann 
e 
 al. (153), using the Mab RS2-G19, were able to show a decrease in fluorescence 
in response to 3OC12-HSL, in a GFP assay using WT and QS mutant reporter strains; the Mab 
was able to inhibit 3OC12-HSL mediated apoptosis of bone marrow derived macrophage (154).  
De Lamo Marin 
e 
 al. (155) generated the catalytic monoclonal antibody, XYD-11G2, against 
squaric monoester 5 (Figure 1-8) which hydrolysed the lactone ring of 3OC12-HSL with 
Ômoderate catalytic activityÕ, the Mab demonstrated anti-QSS activity by reducing pyocyanin 
levels (155).  Preliminary data on the synthesis of a probe that mimics the transition state of 
AHL lactone hydrolysis so other catalytic antibodies in phage libraries can be identified has 
also been published (156).   
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Figure 1-8: Squaric monoester monoamide, 5. 
Taken from (155). 
 
1.6.3 SUMMARY 
The development and use of anti-pseudomonal vaccines in CF has not been recommended 
(37).  This was based on results from the phase III trials with Aerugen
¨
, however reports have 
shown that attenuation of multiple virulence factors leads to reduced pathogenicity of P. 
aerunsa allowing the immune system to contain and eradicate the pathogen with or without 
adjuvant antibiotic therapy.   
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Significant attenuated virulence is characteristic of QSS mutants.  QSS is the communication 
system used by P. aeruginosa to assess the immediate environment and population.  The 
quorate P. aeruginosa are able to co-ordinate and stimulate QSS-regulated production of 
virulence factors, which includes the QSSM 3OC12-HSL and PQS, at the opportune moment 
most beneficial to the pathogen.   
 
QSSi have been developed which disrupt the QSS, effectively mirroring the avirulence of QS 
mutants.  No effect was seen on growth therefore the risk of resistance appears to be low.  
Importantly, anti-AHL vaccines and antibodies have been developed that conferred protection 
against P. aeruginosa infection in vivo.   
 
1.7 IMMUNOGENICITY OF ANTI-AHL VACCINE ANTIGENS 
Anti-AHL vaccines and Mabs have successfully reduced the virulence of P. aeruginosa and 
enhanced natural eradication, even though QSSM and other such small molecules (Mr of 1500 
Da and below) (157), are not recognised by the immune system as antigens.  They lack the 
immunogenicity needed to stimulate innate and adaptive immune responses.   
 
Immunogenicity of AHL has been improved through haptenisation, which is the conjugation of 
a non-immunogenic antigen to a carrier to produce an immunogen.  The anti-AHL antibodies 
described in 1.6.2.3.1 (p 50) were produced against an AHL hapten (Figure 1-9, p 53).  
Haptens are antigens that have been chemically or biologically modified for subsequent 
conjugation to an immunogenic carrier.  Carrier molecules are usually large macromolecules 
such as tetanoid (55), exotoxoid A, bovine serum albumin (BSA) or keyhole limpet 
haemocyanin (KLH) (158).   
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Figure 1-9: Published haptens based on natural AHLs. 
These have been successfully conjugated to carrier proteins and have been used to generate antibodies to 
the relevant AHL, 6, PAI-1 (148); 7, Hap-2 (149, 150); 8, 3OC12HSL-COOH (152); 9, RS2 (153).   
 
1.7.1 HAPTEN DESIGN 
1.7.1.1 HAPTEN STRUCTURE 
Landsteiner established the fundamental principles for efficient haptenisation (159); the hapten 
must replicate or share the conserved structural components (the key epitopes) with the chosen 
antigen.  Antibodies can cross-react with haptens that have subtle differences in structure; 
however, Landsteiner determined that the significant changes in chemical composition, 
stereoisomerism or positions of functional groups prevent antibody recognition (160).  For 
example, Landsteiner used various azoproteins as antigens to generate antibodies, he noted that 
antibodies generated against a Ôcarboxylic acid antigenÕ would recognise Ôsulfonic acid 
antigensÕ however, this was not applicable to sera generated against sulfonic acid antigens, 
which displayed specificity towards sulfonic acid antigens only.  Landsteiner observed that 
sera generated against L-, D- and meso-tartaric acid showed specificity and only weakly reacted 
with the other stereoisomers (159).  The L-configuration of the homoserine lactone chiral 
centre was maintained for all the published haptens (Figure 1-9).   
 
Haptens 6-9 (Figure 1-9) have been designed so the molecules closely resemble the natural 
AHLs, including the conserved lactone ring.  However, the lactone ring of AHLs hydrolyses at 
increasing pH and temperature, the rate of hydrolysis largely depends on the chain length 
(161).  Conversely, Kaufmann and colleagues documented half-lives of 13.1 - 18.1 hours in 
phosphate buffer saline (PBS), pH 7.4, for specific AHL derivatives, which were independent 
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of increasing chain length or the oxidation state of C3 of the acyl chain (153).  Following this 
observation, Kaufmann et al. (153) substituted the lactone ring for a lactam ring (Figure 1-9, 9, 
p 53), which was stable during haptenisation and immunisation.  The antibodies generated 
against 9 (Figure 1-9, p 53) recognised the cognate 3OC12-HSL in competitive indirect ELISA 
(Kd: 150 nm to 5 µM) (153).   
 
1.7.1.2 LINKER 
Haptens have an appropriate functional group to form covalent bonds with the carrier protein.  
The AHL haptens (Figure 1-9, 6-9, p 53) have a carboxylic acid moiety at the terminus of the 
acyl chain for conjugation to the carriers via amide bonds.  The carrier proteins have numerous 
amino acid residues available for conjugation such as !-lysine residues, which bind to 
carboxylic acid groups.   
 
The antigen needs to be sufficiently immunogenic to stimulate both the T- and B-lymphocyte 
directed responses and to establish immune memory (8, 158).  The AHL haptens are 
degradable, which is essential for processing within the APC prior to presentation to T-
lymphocytes.  Landsteiner observed that antibodies were generated to the important epitopes if 
the hapten was completely accessible to the immune system (159).  A distance of 3-6 carbons 
between the epitope(s) and the carrier protein is considered optimal and can be achieved by a 
linker system (162).  In regards to the published AHL haptens (Figure 1-9, 6-9, p 53) the acyl 
chain, a conserved structural component of AHLs, doubles as the linker making any antibodies 
generated specific to the linker useful.   
 
1.7.2 THE ÔMANYÕ QSS OF P. AERUGINOSA 
It is accepted that the QSS is an interlinked system (Figure 1-6, p 42), however, specific 
reports allude to the independent activation of certain divisions of the QSS.  Under certain 
growth conditions, PQS production and Rhl activation can occur without LasR activation (74, 
163).  For example, in an iron-limited medium the expression of rhlR and rhlI increased and in 
a CF-supplemented media (M9 minimal media with glucose supplemented with 2.5 and 5% CF 
sputum extract), a concentration-dependent increase in QSS-regulated gene expression was 
noted (164).  PQS was seen to induce rhlA, the rhamnolipid gene, in the presence of RhlR and 
PqsE but without the AHL QSSM (165).  PqsE has been shown to control rhamnolipid and 
pyocyanin production independently from PqsR-PQS through the Rhl system (Figure 1-6, p 
42) (80).   
 
The QSS hierarchy, where Las is the pinnacle, may only be one variation of the QSS, typical in 
laboratory culture conditions, but is subject to change depending on environmental factors 
(164).  Inhibition of QSS has largely focused on the AHL controlled branches of the QSS, in 
particular, the Las system.  Inhibition of one QSSM, does not inhibit QS but merely allows the 
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bacteria to adapt and compensate by using an alternative QSSM or up-regulate the active 
divisions of QSS, which could be translated as QSSi resistance (166).  For example, V. fischeri, 
which uses 3OC6-HSL, was able to utilize exogenous C8-HSL and C4-HSL (in vitro) after only 
a small number of mutations (167).  Clinical isolates of P. aeruginosa can produce 3OC10-HSL 
and 3OC8-HSL, 3OC6-HSL and C6-HSL (168) and can respond to AHLs produced by other 
Gram-negative species.  Inhibition of each division of the QSS may prevent these potential 
compensatory mechanisms.   
 
1.7.2.1 DISADVANTAGES OF ANTI-AHL VACCINES 
The benefits of immune memory indeed favours the development of vaccines, and AHL 
hapten-carrier conjugates have been successful vaccine candidates, however, the resultant 
antibodies lack significant reactivity towards the shorter AHLs in particular, C4-HSL, which 
regulates the Rhl system (Figure 1-6, p 42).  Kende et al. (148) generated polyclonal immune 
sera and 618.4 Mab against hapten 6 (Figure 1-9, p 53), which recognised the cognate 3OC12-
HSL but no information was given in regards to avidity towards the other natural AHLs (148).   
 
Miyairi et al. (152) conjugated hapten 8 (Figure 1-9, p 53) to ovalbumin (OVA), which 
resulted in decreased 3OC12-HSL levels in vivo, yet was associated with an increase in 
pyocyanin production (152).  This may be a compensatory mechanism adopted by P. 
aeruginosa, up-regulating the Pqs and Rhl systems, in response to the presumed Las system 
inhibition, although in contrast, the pyocyanin levels were lowered in response to anti-AHL 
antibodies in other studies (153, 155).   
 
The Mab RS-1G29 (generated against 9, Figure 1-9, p 53) cross-reacted with 3OC12-HSL but 
showed a 1000-fold lower affinity for C4-HSL (153) due to loss of Ab-Ag interactions (169).  
Charlton et al. (149) were able to produce a scAb against 7, (Figure 1-9, p 53), which cross-
reacted with C14-HSL (IC50: 21 µM), but had an IC50 of mM with 3OC6-HSL and C4-HSL in 
competitive indirect ELISA studies.  There are no published reports detailing the haptenisation 
with derivatives of PQS for the generation of anti-PQS antibodies.   
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2 MULTI-COMPONENT ANTI-QSS VACCINE Ð COMPLETE QSS INHBITION 
Attenuated pathogenicity of P. aeruginosa is due to multiple loss of virulence factors, the 
result of a compromised QSS.  Infections with such strains cause mild pathologies and are 
easily cleared by the immune system.  QSSi have been developed and have effectively 
disrupted the QSS.   
 
Inhibition of the QSS however, has focussed on inhibiting the Las system as it is regarded as 
the top of the supposed QSS hierarchy.  However, the QSS is highly adaptable and the 
hierarchical QSS may only be typical in the laboratory environment.  The pathogen may be 
able to compensate for the inhibition of one division of the QSS, by the up-regulation of the 
Rhl and/or Pqs system, which remain active.   
 
Complete inhibition of the QSS is possible if all three divisions of the QSS, Las, Rhl and Pqs 
systems, are inhibited minimising compensatory mechanisms.  There are only a few examples 
of potential inhibitors of the Pqs and Rhl system.  Immunological targeting of the AHL has 
been studied, and effective anti-AHL vaccine and therapeutic antibodies have been developed.  
One such vaccine, produced by Miyairi et al. (152) has shown that protective immunity was 
achieved.  For complete QSS inhibition, a prophylactic multi-component QSS vaccine, which 
targets the QSSM will provide long-lived immunity due to immune memory.  The QSSM are 
the target antigens, therefore upon recognition, the immune system will be able to initiate the 
secondary immune response, the concentration of QSSM will always be low thus P. 
aeruginosa cannot sense the quorum or the environment, preventing release of virulence 
factors and efficient adaptation.  The immune system will be able to contain and eradicate with 
or without adjunct antibiotic therapy.   
 
Figure 2-1 (p 58) illustrates the envisaged effects of the multi-component anti-QSS vaccine 
and therapeutic antibodies.  By targeting the QSSM, prophylactic anti-QSS vaccines and 
therapeutic anti-QSS antibodies are not dependent on the virulence phenotype, strain, or 
disease pathology as QSS is a conserved system.  The passive immunisation with the 
anticipated therapeutic anti-QSS antibodies would offer immediate therapy, however the anti-
QSS vaccine will be appropriate as a prophylaxis given to those hosts most susceptible to P. 
aeruginosa infections, in other words, hosts with a compromised immune system resulting 
from disease or treatment.  For example, as P. aeruginosa colonises young CF patients, the 
vaccine would be given at the time when cystic fibrosis was diagnosed and so forth.  It is 
anticipated that a multi-component QSS vaccine would be suitable for MDR strains.  Most 
importantly, as with QSSi, growth is not affected, therefore resistance through selective 
pressure is minimal.   
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2.1 AIMS AND OBJECTIVES 
The aim of this study is to develop a multi-component anti-QSS vaccine, consisting of a 
hapten-carrier conjugate that stimulates antibodies that cross-react with both the natural AHLs, 
3OC12-HSL and C4-HSL, and a hapten-carrier conjugate that targets PQS.  
 
This may be achieved by the synthesis of an AHL hapten and a PQS hapten, which are stable 
for conjugation to the carrier and immunisation.  The AHL hapten-carrier and PQS hapten-
carrier conjugate formed upon haptenisation of the protein carriers will be used to immunise 
mice, and if proven successful, rabbits.  The haptens will be conjugated to KLH using N-
hydroxysuccinimide (NHS) in an active ester method, and used for immunisations. 
 
The generated polyclonal antibodies (pAbs) will be tested for cross-reactivity with the natural 
QSSMs of P. aeruginosa.  A competitive indirect ELISA will be appropriate for this 
characterisation.  For this purpose, hapten-BSA conjugates will be useful as the coating antigen 
(Figure 5-3, p 89).  The two carriers are phylogenetically dissimilar; therefore, no significant 
cross-reactivity is anticipated between generated anti-hapten-KLH pAbs and BSA.   
 
Characterisation of the anti-QSSM activity, specifically against 3OC12-HSL, C4-HSL and PQS, 
of the generated pAbs will serve as an indication for potential in vivo QSS inhibition.  The 
viability of the AHL hapten-carrier and PQS hapten-carrier conjugate, as anti-QSS vaccine 
candidates will be demonstrated in vitro and in vivo anti-QSS assays, designed to test for the 
inhibition of virulence factor production which require the complete QSS, such as biofilms.   
 
.
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Figure 2-1: Immunological targeting of the QSS with the multi-component QSS vaccine. 
The multi-component anti-QSS vaccine would generate pAbs against the natural AHL QSSM, 3OC12-
HSL and C4-HSL and the QSSM PQS.  The QSSM would be neutralised or opsonised, essentially unable 
to perform its function.  P. aeruginosa cannot QS therefore effectively isolated from the quorum and 
environment.  The immune system will be able to contain and eradicate the pathogen, with or without 
adjunct antibiotic therapy.  The dashed line ( ) represents a figurative upper level separating the 
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QSS and the global regulatory system; the global regulatory system and therefore the QS is dependent 
on the environment, native or of the host, at the site of infection (  ) and the use of (?) indicates that 
HHQ may also act as a QSSM.   
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3 RESULT 1 Ð HAPTEN SYNTHESIS 
3.1 HAPTEN DESIGN 
3.1.1 AHL HAPTEN, AP1 
The chosen AHL hapten, AP1, (Figure 3-1), was based on 3OC8-HSL, a natural QSSM 
produced by P. aeruginosa to accommodate the optimum 3-6-carbon distance between key 
epitopes and the carrier.  The lactone ring and the external amide moiety are conserved 
structural components of the AHLs (Figure 1-5, 1 and 2, p 37).  For stability during 
haptenisation and immunisation, the lactone ring was substituted with a lactam ring as 
described by Kaufmann and colleagues (153), therefore the lactam ring and external amide 
moiety of AP1 were considered as the key epitopes.  It was anticipated that any antibodies 
generated against these epitopes will react with the long and short chain 3-oxo and un-
substituted AHLs; particularly resulting in significant cross-reactivity with C4-HSL, not 
reported with the published haptens, (6-9, Figure 1-9, p 53) with the implication of Rhl system 
inhibition as well as the Las system (Figure 2-1, p 25).  Additional anticipated epitopes have 
been highlighted in Figure 3-1, the acyl chain is the linker as with the published haptens 
(Figure 1-9, p 53).   
 
 
Figure 3-1: 7-((S)-2-oxopyrrolidin-3-ylcarbamoyl)-6-oxoheptanoic acid, AP1.   
 
3.1.2 PQS HAPTEN, AP2 
The PQS hapten, AP2 (Figure 3-2, p 61), had a carboxylic acid moiety at the terminus of the 
acyl chain for attachment to the carrier.  It was believed that this would make the molecule 
more soluble.  PQS is extremely hydrophobic and sparingly soluble in aqueous solutions.  
Improvement in aqueous solubility will ensure efficient conjugation to the carrier.  The key 
epitope was thought to be the quinolone structure as this is the conserved component of the 
HAQs. 
Synthesis of the haptens 
 - 61 - 
 
Figure 3-2: 7-(1,4-dihyro-3-hydroxy-4-oxoquinolin-2-yl)heptanoic acid, AP2.   
 
The objective was to produce AP1 and AP2 in sufficient quantities for haptenisation.  There 
are established synthetic strategies (170-173) used to produce QSSMs and derivatives.  Indeed, 
Kaufmann et al. (153) have synthesised hapten 9 (Figure 1-9, p 53) in good yields and Purcell 
(173) has reported the synthesis of ethyl 2-(1,4-dihydro-3-hydroxy-4-oxoquinolin-2-yl)acetate, 
which is a derivative of AP2 with a yield of 31% by cyclisation of an aminobenzoate 
intermediate, 2-oxopropyl 2-aminobenzoate.   
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Figure 3-3: Aims and objectives.   
(1) Synthesis of AP1 and AP2; (2) Haptenisation of immunogenic carrier, KLH, with AP1 and AP2; (3) 
Immunisation of mice and rabbit; (4) Characterisation of generated antibodies to hapten-carrier conjugate; 
(5) Test for anti-QSSM and anti-QSS activity. 
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3.2 SYNTHESIS OF AP1, 7-((S)-2-OXOPYRROLIDIN-3-YLCARBAMOYL)-6-
OXOHEPTANOIC ACID, 37 
3.2.1 AMIDATION METHOD A  
The !-keto dicarboxylate 22 (Scheme 3-1), formed by refluxing acylated MeldrumÕs acid 18 in 
anhydrous methanol (174), underwent selective base-mediated hydrolysis to generate 29.  Acid 
29 was coupled to (S)-3-amino-pyrrolidin-2-one (AP) (175) 35 using DIC to afford amide 36 in 
10% yield.  Acid-mediated deprotection of the t-butyl ester afforded 37 in near-quantitative 
yields.   
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37: R = t-butyl, n = 0
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13: R = t-butyl, n = 0
14: R = t-butyl, n = 2
15: R = t-butyl, n = 4
16: R = Me, n = 0
O
OO
O
17
a
b-d
e
 
Ragents and conditions: (a) DIC, DMAP, CH2Cl2, tert-BOH, 0 ¡C to rt, (26-70%); (b) DIC, 
DMAP, CH2Cl2, (18-21, crude >100%); (c) i) (COCl)2, cat. DMF, CH2Cl2, rt; ii) C5H5N, 17, 
CH2Cl2, (21, 5%); (d) EDC, DMAP, CH2Cl2, 0 ¡C to rt, (18, 97%); (e) ROH, reflux, (13-
86%); (f) 
R
Õ
 = Me, 1 M NaOH, H2O; (g) R
Õ
 = Bn, 10% Pd-C, MeOH, H2, rt; (h) R
Õ
 = Bn, 10% 
Pd-C, THF, 0 ¡C, (96%); (i) R
Õ
 = t-butyl, TFA/CH2Cl2 (1:1), rt; (j) DIC, DMAP, CH2Cl2, 0 ¡C 
to rt, (10%); (k) TFA/CH2Cl2 (1:1), (98%); (l) 26, (CH2OH)2, cat. CSA, CH(OEt)3; (m) 26, 
toluene, (CH2OH)2, rt to reflux; (n) 26, BF3.Et2O, MeOH, rt; (o) 26, BF3.Et2O, (CH2OH)2, 
CH2Cl2, rt; (p) 10% Pd-C, H2 THF, 0 ¡C.   
Scheme 3-1: Amidation method A 
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3.2.2 AMIDATION METHOD B  
Using the protocol reported by Chhabra et al. (171) the acid adduct 18 (Scheme 3-2) was 
stirred with the free amine 35 for two hours at room temperature (rt) and then refluxed for a 
further three hours.  The reaction resulted in trace amounts of amide 36.  Stirring the reaction 
overnight did not improve the yield but omitting Et3N benefited the reaction.  Amide 36 was 
detected by 
1
H NMR however could not be isolated in appreciable quantity.  The method was 
modified by adopting the protocol reported by Xu et al. (176), in pilot studies, adduct 18 was 
heated in MeCN with amine 35 with and without the addition of catalytic TFA.  There was a 
concern that the inclusion of TFA would lead to the acidolysis of the t-butyl ester, however, the 
ester remained intact.  Notably, in the presence of 0.3 molar equivalent TFA, !-keto acid 29 
was detected as well as amide 36.   
 
On a larger scale (without TFA), the reaction was heated at 40 ¡C overnight then the 
temperature increased to 60 ¡C until completion, though no improvement in yield was 
observed.  Conversely, a complex mixture was produced which was difficult to purify, 
nonetheless amide 36 was obtained in 20% yield.  Deprotection of amide 36 proceeded 
smoothly with TFA/CH2Cl2 (1:1), giving acid 37 in near-quantitative yields (method A, step 
k).  
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HO
OO
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Reagents and conditions: (a) MeCN, Et3N, rt to reflux; (b) MeCN, rt to reflux; (c) MeCN, 40-
60 ¡C, (20%); (d) TFA/CH2Cl2 (1:1), (20%).   
Scheme 3-2: Amidation method B 
 
3.2.2.1 SYNTHESIS OF NATURAL QSSM 
Both method A and the method presented by Chhabra et al. (171) were used to synthesise the 
natural 3-oxo substituted QSSMs of P. aeruginosa (1.7.2, p 54) and 3OC8-AP for use in 
competitive indirect ELISA (6.1, p 98).  In this study, the synthesis was unsuccessful, often 
producing the equivalent unsubstituted QSSM as a by-product.   
 
3.2.3 DISCUSSION 
Synthesis of 7-((S)-2-oxopyrrolidin-3-ylcarbamoyl)-6-oxoheptanoic acid 37 began with the 
mono-protection of adipic acid 10 (Scheme 3-1) via Steglich esterification (177, 178).  tert-
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Butyl esters are robust protecting groups for carboxylic acids, and stable to the conditions used 
in the synthesis.  Acid mediated deprotection using trifluoroacetic acid (TFA) affords the free 
acid in good yields (179).  Use of diisopropylcarbodiimide (DIC), with catalytic 4-
(dimethylamino)pyridine (DMAP), proved an effective alternative to the typical reagents, 
dicylohexylcarbodiimide (DCC) and DMAP, whereas a combination of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and catalytic DMAP was not (180).  The mono-
protection of dicarboxylic acids 10-12 was controlled by using one equivalent of DIC in excess 
tert-butanol.  The mono-protected dicarboxylic acids 13-16 were easily isolated by short path 
vacuum distillation, using Kugelrohr apparatus.  Traces of the side product diisopropylurea 
(DIU) were removed by silica gel column chromatography.  This method gave a reasonable 
yield for 13, (70%) but much lower yields for 14 and 15 (26-37%).  
 
3.2.3.1 ACYLATION OF MELDRUMÕS ACID  
Initially 13-16 were coupled with MeldrumÕs acid 17, using DIC/DMAP to obtain the adducts 
18-21 as crude products (Scheme 3-1, p 64).  Purification by crystallisation was reported for 
derivatives of 18 (170), however, crystallisation attempts proved unsuccessful as did 
purification by silica gel column chromatography, which resulted in poor yields.  It was 
anticipated that DIU would not interfere in subsequent reactions and therefore the crude 
products were used without further purification.   
 
In an attempt to optimise the yield for this step, the acid chloride of 13 (formed by treatment 
with oxalyl chloride under Vilsmeier conditions) (181), was reacted with MeldrumÕs acid 17 in 
the presence of pyridine (174).  Although this was suitable for small-scale reactions, use of 
EDC and stoichiometric amounts of DMAP or hydroxybenzotriazole (HOBt) proved to be 
more effective for large-scale reactions, as the by-products were water-soluble.  The crude 
product was sufficiently pure after an acidic aqueous workup to proceed to the next step.   
 
3.2.3.2 !-KETO DICARBOXYLATES  
!-Keto dicarboxylates 22-26 were synthesised using the method of Oikawa et al. (174).  
Briefly, acylated MeldrumÕs acid adducts 18-21 (Scheme 3-1, p 64) were refluxed in 
anhydrous alcohol and purified by Kugelrohr distillation.  The authors reported good yields for 
the conversion of MeldrumÕs acid adducts to the corresponding !-keto carboxylates but in this 
study, the results were variable, with yields of 12-86%.  Surprisingly, in some cases, diesters 
27-28 were obtained.  This is unusual as the expected side-product would be ketones 30-32 
resulting from thermal decarboxylation.  The mechanism remains unknown but it was noted 
that extending reaction times to beyond completion (TLC) resulted in increased formation of 
diesters 27-28.  Wierenga and Skulnick (182) documented an alternative method for the 
formation !-keto carboxylates, and produced a variety of compounds using a directed C-
acylation of mono-ethyl malonate lithium enolates by acid chlorides.  Kaufmann et al. (153) 
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used a variation of this method for the formation of 1-benzyl-9-trimethylsilyl ether-3-
oxononandioate, a derivative of 22, in good yields.  This route was not investigated in the 
present study, but may offer improved yields of !-keto dicarboxylates 22-26 (Scheme 3-1, p 
64) for any future reaction optimisation.   
 
3.2.3.3 PROTECTING GROUP STRATEGY 
Orthogonal protecting strategies were necessary to obtain the !-keto dicarboxylic acid 
monoester 29.  Base-mediated hydrolysis of methyl esters is an established deprotection 
strategy (179), however methyl esters 22 and 24 (Scheme 3-1) were surprisingly resistant to 
saponification.  The !-keto-dicarboxylate 22 was subjected to variety of saponification 
methods (183, 184) but these usually resulted in decarboxylation to give 30.  Acidolysis of 
ester 25 with TFA also led to the decarboxylation product 30.  A similar reaction has been 
reported where decarboxylation was the desired outcome (185).  Attempts at protecting the 
ketone function of 26 as a cyclic ketal 32 (186-188), in order to avoid decarboxylation during 
selective deprotection and consequent amidation (Scheme 3-1) were unsuccessful.  
Hydrogenolysis of 23 in MeOH using catalytic Pd-C produced a mixture of acid 29 and ketone 
30.  However, by changing the solvent to THF, and cooling to 0 ¡C, 29 was obtained in 
excellent yields (96%) (153).   
 
Selective deprotection of the !-keto dicarboxylate esters has highlighted the instability of the 
resulting !-keto acid products.  !-Keto carboxylic acids are known to decarboxylate under 
thermal conditions (189), !-keto dicarboxylic acids, however, can decarboxylate spontaneously 
in aqueous conditions, particularly at pH 4 at ambient temperatures (190).  Studies have shown 
that decarboxylation in aqueous conditions can be catalysed by the presence of metal cations 
such as Mg
2+ 
 (191) or in ethanol with salts such as LiCl (192).   
 
It is believed that simple !-keto dicarboxylic acids such as oxosuccinic acid 38 (Scheme 3-3), 
decarboxylate through a six-membered transition state (193) as the keto-tautomer, and more 
rapidly as a mono anion (190), presumably, as the anion is stabilised by the second carboxylic 
acid group.  This is not limited to simple !-keto dicarboxylic acids but has been reported in 
other !-keto dicarboxylic acids (193).   
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Scheme 3-3: Proposed mechanism for decarboxylation of oxosuccinic acid, 38.   
 
As an alternative strategy, selective deprotection could be restricted to neutral methods.  As 
noted, acid or base catalysed ester hydrolysis led to partial or complete decarboxylation but 
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hydrogenolysis of benzyl esters afforded acid 29 with trace amounts of ketone 30 (Scheme 3-1, 
p 60).   
 
3.2.3.4 FORMATION OF !-KETO AMIDE 36 
It appeared that in the present study, neither DIC nor EDC were efficient reagents for amide 
bond formation in regards to yield.  Kaufmann et al. (153) reported a 50% yield using EDC, 
however, in the coupling of acid 29 to amine 35 (Scheme 3-1), using EDC and 
hydroxybenzotriazole (HOBt) (as described by the authors), no appreciable improvement was 
noted.  Other peptide coupling agents were investigated such as N,N,N!,N!-tetramethyl-O-(7-
azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU) (194) but this reaction was 
unsuccessful.  The acyl chloride of 29, obtained under Vilsmeier conditions (181), failed to 
react with the amine 35 although this method has been successful in generating the 
unsubstituted derivatives of 37 as well as the natural QSSM, C4-HSL.  
 
The data presented by Bruice et al. (195) may be relevant, as it suggested that as well as 
primary and secondary amines (196, 197), tertiary amines can catalyse the decarboxylation of 
"-keto dicarboxylic acids through imine and iminium intermediates.  Indeed, only 30 (Scheme 
3-1) was isolated after use of the peptide-coupling reagent, HATU and the tertiary base, N,N-
diisopropylethylamine, (DIPEA).  Such reagents are part of a diverse range of new and more 
effective peptide coupling reagents, however, tertiary bases are usually needed in the activation 
step.  Currently the amidation step (Scheme 3-1) is the yield-limiting step and further 
optimisation is necessary.  Peptide coupling reagents that require tertiary bases will have to be 
excluded, however, the possible effects of the secondary amine 35 should be investigated 
before any other approaches are considered.   
 
The substitution and concomitant decarboxylation of acylated MeldrumÕs acid 18 (Scheme 3-4) 
is believed to begin with the nucleophilic addition by the free amine 35 at room temperature, 
which drives the elimination of acetone and CO2 that is promoted by heat.  The inclusion of 
Et3N in method B (Scheme 3-2) hinders the reaction as it has been suggested that 18 is forced 
to remain as the unreactive enolate (Figure 3-4) (176).   
 
O
O
O
O
R
O
NuH
O
O
HO
O
R
O
Nu
R Nu
O O
+
O
- CO2
!
 
NuH = RNH2, ROH 
Scheme 3-4: Proposed nucleophilic addition-elimination. 
Adapted from Oikawa et al. (174). 
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Figure 3-4: Enolate form of acylated MeldrumÕs acid. 
 
In contrast, Xu et al. (176) suggested that the acylated MeldrumÕs acids decarboxylate to form 
an !-oxo-ketene 39 (Scheme 3-5) that reacts with nucleophilic species, specifically, RNH2.  
Furthermore, catalytic TFA promotes this decarboxylation at lower temperatures.  However, in 
a published report (198) the method presented by Xu et al. (176) was used to produce natural 
AHLs, however yields of <30% with poor enantiometric purity were reported, it was also noted 
that the acidic conditions caused the formation of the unsubstituted QSSM as a side-reaction.  
This was suppressed by substituting TFA with Et3N, however, this does not correlate with the 
idea that the unreactive enolate species (Figure 3-4) is formed in basic conditions, in this study, 
the unsubstituted QSSM by-products resulted in the presence of Et3N (171).   
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NuH =RNH2 
Scheme 3-5: Proposed reaction mechanism between !-oxo-ketene 39 and nucleophilic species.   
Adapted from Xu et al. (176).   
 
3.2.4 SUMMARY 
AP1
^
 (37) was produced in sufficient quantities to continue with haptenisation.  Method A 
(Scheme 3-1, p 64) produced in a cumulative yield of 10% over seven steps; method B 
(Scheme 3-2, p 65) produced 37 in a cumulative yield of 4% over two steps.  Method A is the 
preferred method, further optimization is required including the protection of the !-keto 
function of 22-26, essential for protection against decarboxylation through subsequent 
deprotection and amidation.  
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3.3 SYNTHESIS OF AP2, 7-(1,4-DIHYDRO-3-HYDROXY-4-OXOQUINOLIN-2-
YL)HEPTANOIC ACID 47 
3.3.1 METHOD A  
A method adapted from Hradil et al. (199) was used to synthesise 7-(1,4-dihydro-3-hydroxy-4-
oxoquinolin-2-yl)heptanoic acid 47 (AP2) (Scheme 3-6).  Commercially available mono 
methyl suberate 40 was converted to the corresponding acyl chloride under Vilsmeier 
conditions (181), which was transformed to the ketone 41 with GilmanÕs reagent, Me2CuLi 
(200) via a nucleophilic substitution of the acyl chloride (201).  Subsequent bromination of the 
terminal !-carbon was possible using bromine under acidic conditions (202) to furnish 
bromoketone 42, which was used to alkylate N-formyl anthranilic acid 44 (203).  The !-keto 
diester 45 was cyclised in excess ammonium formate (NH4HCO2) and formic acid (HCO2H) 
(199) using microwave irradiation to form a mixture of ester 46 and acid 47.  Final acid-
mediated deprotection and subsequent crystallisation afforded acid 47 in a cumulative yield of 
33% over six steps (Scheme 3-6).  
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Reagents and conditions: (a) i) (COCl)2, CH2Cl2, cat. DMF ii) MeLi, CuI, Et2O, -78 ¼C, 
(75%); (b) Br2, MeOH, -10 ¼C to rt, aq. H2SO4 (crude yields > 100%); (c) Et3N, (CH3)2CO 
(crude yields > 100%); (d) NH4HCO2, HCO2H, MW, 120 ¼C (46/47, 60%); (e) 98% HCO2H, 
reflux; 98% HCO2H, rt (52%); (f) THF, conc. HCl, rt, (73%).   
Scheme 3-6: Formation of AP2, 47, via method A.   
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3.3.2 METHOD B  
Using the protocol reported by Purcell (173), the acylated MeldrumÕs acid derivative 48 
(Scheme 3-7) was refluxed in MeOH to form the !-keto diester 49 in good yield (73%).  This 
was treated with sulfuryl chloride to form the chlorinated !-keto diester 50, which in pilot 
studies was transformed to the chloroketone 51 after refluxing in aqueous H2SO4.  However, 
when the same reaction was repeated, hydrolysis of the methyl ester resulted.  Reprotection by 
esterification with t-butanol and EDC or acid-catalysed esterification with MeOH was 
unsuccessful, preventing synthesis of 47 by this method.   
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Reagents and conditions: (a) DIC, DMAP, CH2Cl2, 0 ¡C to rt (crude >100%); (b) EDC, 
DMAP, CH2Cl2, 0 ¡C to rt, (qualitative); (c) MeOH, reflux (73%); (d) SO2Cl2, 0 ¼C to rt; (e) 
aq. H2SO4, reflux; (f) i) K2CO3, 43, DMF, 90 ¼C to rt; ii) 51, rt to 50 ¼C; (g) NMP, reflux; (h) 
THF, conc. HCl.   
Scheme 3-7: Formation of AP2, 47, via method B.   
 
3.3.3 METHOD C 
Method C is based on the adaptation by Pesci et al. (66) of a Conrad Limpach reaction (204).  
The !-keto diester 53 (Scheme 3-8, p 72) was condensed with aniline 54 under Dean-Stark 
conditions to form the Schiff base 55, an enamine-imine intermediate.  Isolation of 55 was not 
possible, as attempted purification resulted in rapid degradation.  Consequently, 55 was 
generated in situ, and cyclised without isolation, to afford ester 56.  Base-mediated hydrolysis 
of ester 56 afforded the HHQ derivative, 7-(1,4-dihydro-4-oxoquinolin-2-yl)heptanoic acid 57.  
Formylation of 56 by the Duff method (66), to give the desired product 58 was not possible, as 
was the conversion of 56 to ester 46 via Elbs oxidation (205) and Rubottom reaction (206), 
thus preventing the synthesis of acid 47 by this route.   
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Reagents and conditions: (a) DIC, DMAP, CH2Cl2, 0 ¡C to rt, (crude >100%); (b) EtOH, 
reflux (63%); (c) 54, toluene, cat. p-TsOH, reflux; (d) Ph2O, 250 ¡C (22%); (e) EatonÕs 
reagent, 90 ¡C; NMP, reflux; (f) Ph2O, MW, 250 ¡C; (g) NMP, MW, 250 ¡C (11%); (h) 
EatonÕs reagent, MW, 90 ¡C; (i) 1 M NaOH, (CH3)2CO:H2O (70%); (j) i) (CH2)6N4 , TFA, 
reflux ii) aq. MeOH, reflux iii) 3M HCl, reflux; (k) i) 1.6 M NaOH, K2S2O8, rt, ii) HCl, reflux 
to rt; (l) i) DIPEA, THF, n-BuLi, -15 ¡C to 0 ¡C to -15 ¡C to rt, 56, TMSCl, N2 ii) THF, m-
CPBA, -78 ¡C to rt; iii) CH2Cl2, Et3N.3HF, rt; (m) H2O2, aq. EtOH, rt; (n) THF, conc. HCl. 
Scheme 3-8: Formation of AP2, 47, via method C.   
 
3.3.4 DISCUSSION 
3.3.4.1 !-HALO-KETONES 
3.3.4.1.1 METHOD A 
Formation of the methyl ketone 41 (Scheme 3-6, p 70) was facile, taking advantage of the 
GilmanÕs reagent reactivity towards acyl halides.  GilmanÕs reagents tend not to react with 
esters, amides and ketones thus further transformation of the ketone is avoided.  In contrast, 
Grignard reagents will further react with the ketone formed initially (189).  Gilman reagents 
are prepared in situ, one equivalent of CuI and two equivalents of RLi (for example, R = Me) 
forming one equivalent of GilmanÕs reagent, R2CuLi.  Exact stoichiometry needs to be 
observed, as excess CuI resulted in the formation of MeCuLi, which is a coloured inert 
compound, whereas excess MeLi led to several competing side-reactions.  Subsequent 
bromination was successful without affecting the protected methyl ester.   
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3.3.4.2 CYCLISATION 
3.3.4.2.1 METHOD A AND B 
The aniline 43 (Scheme 3-6, p 70) is a relatively poor nucleophile due to the delocalisation of 
the lone pair of electrons of nitrogen into the aromatic ring, with a further mesomeric 
deactivation from the ortho-acid group, which may be alleviated somewhat by alkylation.  
However, the high temperatures (250 ¡C) in method B (Scheme 3-7, p 71) are still necessary to 
disrupt the mesomeric effect of the aromatic ring and allow the amine, the poor nucleophile, to 
participate in the intramolecular condensation resulting in the 4-(1H)-quinolone (173, 207, 
208).  The intermediate 52 (Scheme 3-7), upon cyclisation would form the unstable 7-
membered ring which rearranges to the preferred 6-membered ring with further proton 
rearrangement to form 2-substituted-3-hydroxy-4(1H)quinolone (Scheme 3-9) (173).   
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Scheme 3-9: Mechanistic view of intramolecular condensation to form 2-substituted-3-
hydroxy-4(1H)-quinolones.   
Adapted from (173, 207, 208).   
 
Formylating anthranilic acid 43 to form N-formyl anthranilic acid 44 may reduce the 
delocalisation of the lone pair of electrons into the aromatic ring.  Presumably, less energy 
therefore lower temperatures would be needed to promote the intramolecular condensation.  
However, the N-formamide is a poor nucleophile as the formyl group exerts mesomeric effect.  
Yet, in this study, method A (Scheme 3-6, p 70) was successful.  In the original method (199), 
the authors refluxed the reaction mixture in a microwave reactor, using sealed vessels.  
Mindful of the volatile by-products, ammonia and carbon dioxide, it was known that the 
reaction would generate pressure; this was solved by employing a batch method but on a large 
scale this may be impractical.   
 
3.3.4.3 METHOD C 
Copious amounts of petroleum ether (60-80 ¡C) were required to precipitate 56 (Scheme 3-8, p 
72) from diphenyl ether (Ph2O) followed by additional column chromatography to remove 
residual Ph2O.  Although the use of a high-vacuum centrifuge instrument (Genevac) was 
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effective in removing most of the Ph2O, this took considerable time (18 hours) and further 
purification was always needed to remove remaining traces of Ph2O.   
 
Use of EatonÕs reagent (209), a methansulfonic-phosphorus oxide mixture (210), under 
microwave irradiation, was useful for cyclisation of 55, though it was not possible to isolate 
pure 56.  Use of NMP aided cyclisation and was easier to remove than Ph2O, but the yield was 
comparatively lower (11%).  Other methods were tried such as acetic anhydride and H2SO4 
(211) and polyphosphoric acid (PPA) (212), but were unsuccessful. 
 
3.3.5 SUMMARY  
The synthesis of PQS has advanced since the strategy proposed by Pesci et al. (66).  
Hodgkinson et al. (208) have used microwave irradiation and high through-put methods to 
advance PurcellÕs method (173).  Although the mechanism remains unknown, method A is 
another approach to produce the 3-hydroxy HAQs and, AP2
^
 was produced in a cumulative 
33% yield over six steps, which provided sufficient quantity to continue with protein 
conjugation.   
 
In this study, method C (Scheme 3-8, p 72) was not useful for the syntheses of PQS and 
derivatives, due to the failed formylation attempts of the C3 position of the quinolone.  
However, acid 57 is a potential hapten.  The cyclisation is the yield-limiting step and attention 
should be given to the optimisation of method C in future work and development of the 
alternate approach (Scheme 3-11, p 75).   
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3.4 SYNTHESIS OF OTHER MOLECULES OF INTEREST 
3.4.1 PQS 
Method B (Scheme 3-7) was used to produce PQS 4 (173) as described however in this study, 
the chloroketone 59 (Scheme 3-10) failed to alkylate anthranilic acid 43.  Alkylation was 
possible with bromoketone 60, to give !-keto ester 61.  Unfortunately, cyclisation in NMP was 
not successful.  Using method A (Scheme 3-6), PQS 4 was obtained in 45% yield (Scheme 
3-10). 
 
NRH
N
H
O
OH
4OH
O
O
NRH
O
O
O
X
43: R = H
44: R = CHO
59: X = Cl
60: X = Br
c-d
61: R = H
62: R = CHO
a-b
 
 
Reagents and conditions: (a) i) K2CO3, DMF, 90 ¼C to rt, 43; ii) 59, rt to 50 ¼C; (b) 60, 44, 
Et3N, (CH3)2CO, rt; (c) 61, NMP, reflux; (d) 62, NH4HCO2, HCO2H, MW, 120 ¼C, (45%).   
Scheme 3-10: Formation of PQS 4 via method A and B.   
 
3.4.2 HHQ  
CampÕs quinoline synthesis (178) has been used to prepare 2-aryl-4-quinolone derivatives 
(213-215).  It was anticipated that by adopting this approach, HHQ 3 (Scheme 3-11) could be 
generated and validate this method as a strategy to generate ester 56 (Scheme 3-8, p 72), 
avoiding the sensitive intermediate; 65 was obtained in high yields but subsequent cyclisation 
to HHQ 3 failed.  The inductive effect of the alkyl chain diminishes the polarization effect of 
the carbonyl, thus the electophilic character of the carbonyl carbon is relatively reduced - the 
nucleophilic enolate is less likely to attack this position.   
 
O
NH
O
a
N
H
O
63
64
O
Cl
O
NH2
65 3
N
OH
b-c
 
 
Reagents and conditions: (a) 1,4-dioxane, Et3N, rt (86%); (b) 1,4-dioxane, NaOH, MW 120 ¡C; 
(c) tert-BuOK, tert-BuOH, MW, 120 ¡C. 
Scheme 3-11: Alternate synthesis of HHQ 3.   
 
This strategy can still be useful practically.  Quinolin-4-(1H)-one (214) has been substituted on 
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the C2 position of the quinolone by Grignard reagents (216).  The development of this strategy 
is of interest as it can be a robust method to produce the HHQ derivatives, which are potential 
haptens.   
 
3.4.3 HMAQS OF BURKHOLDERIA SPP. 
Using the Conrad-Limpach reaction, Moon et al. (217) have produced the saturated HMAQs in 
high yields.  However, it is probable, as the cyclisation method is similar to that tried in 
method C (Scheme 3-8, p 72), that it may be difficult to replicate the authorsÕ results (217).  A 
retro-synthesis of HMAQs shows that unsaturated and saturated acyl chains can be introduced 
at the C2 position of the quinolone by a Grignard reaction (216).  Huang et al. (214) have 
reported the synthesis of quinolin-4(1H)-one through CampÕs quinoline synthesis, which is 
appropriate for the production of the synthon 74 (Scheme 3-12, p 77).  A Grignard reaction is 
also useful to afford 68 and 70 from acyl chlorides 67 and 69 respectively.  However, in this 
pilot study, 69 could not be converted to the ketone 70 and the reaction with 67 resulted in a 
complex mixture as the nitro group is also sensitive to Grignard reagents.   
 
The Grignard reagent, EtMgBr, was produced in situ and used in a 3:1 ratio to the substrate 2-
aminobenzonitrile 71 (Scheme 3-12) to compensate for the reaction of the amine moiety with 
the Grignard reagent (216).  The reagent, through a nucleophilic addition, forms an 
organometallic imine intermediate.  The ketone 72 was obtained from the acidic hydrolysis of 
the intermediate in disappointing yields (14%).  Subsequent N-formylation (218) and 
cyclisation in basic conditions using microwave irradiation afforded 3-methyl-quinolin-4(1H)-
one 74.  Protection with benzyloxycarbonyl group (Cbz) (219) was restricted by limited 
solubility in THF.  The pilot studies indicate that this procedure requires further investigation.  
Adjustments to the current strategy may be necessary, in particular, an alternative method for 
the formation of 1-(2-aminophenyl)propan-1-one 73, which was obtained in unexpectedly low 
yields.  It is anticipated that this will still be a robust method but further development is 
needed.  There were some minor contaminants present in 74 that could not be removed, for the 
purpose of this study, 74 was used in competitive indirect ELISA studies (6.2, p 100).   
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Reagents and conditions: (a) (COCl)2, cat. DMF, CH2Cl2, rt; (b) i) EtBr, Mg, Et2O, -78 ¡C; ii) 
71, (14%); (c) Catalytic reduction; (d) 5% CuI, K3PO4, HO(CH2)2OH, isopropanol, 80 ¡C ; 
(202) (e) HCO2H, 50 ¡C  (37%); (f) NaOH, 1,4-dioxane, MW, 120 ¡C, (36%); (g) i) NaH, 
THF, 50-60 ¡C ii) C6H5CH2O2CCl, 50-60 ¡C; (h) i) 75, TIPSOTf, rt ii) CH3(CH2)5CH2Br, 
Mg, Et2O, -78 ¡C iii) CH2Cl2, 2,6-lutidine; (i) 10% Pd-C, MeOH, rt.   
Scheme 3-12: Synthesis of 2-heptyl-3-methyl-quinolin-4(1H)-one, 77.   
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4 MATERIALS AND METHODS 
GENERAL 
MALDI-TOF spectra were recorded using a Ultraflex III MALDI-TOF instrument using 
samples (100 µg) prepared in pure H2O with sinapinic acid ((in TFA:H2O:MeOH, 0.1:50:50%) 
200 µg/mL).  Matrix was spotted to the loading plate and dried, the matrix:sample solution was 
then spotted on the loading plate.  The absorbance (recorded as optical density (OD)) was read 
at the specified wavelength using the MRX plate-reader.  Bioluminescence was recorded in 
arbitrary units using a Parkard Bell Top-Count reader, (temperature 37 ¼C).  Reagents, unless 
specified, were obtained from Sigma Aldrich and Alfa Aesar.  All buffers and reagents were 
prepared using laboratory standard operating procedures or used as received by the 
manufacturers.  LB broth and regents used for M9 minimal media were autoclaved before use.  
M9 minimal media (5 mL M9 minimal media: 1 mL M9 salts (48 mM Na2HPO4.7H2O, 22 mM 
KH2PO4, 19 mM NH4Cl, and 8.6 mM NaCl), 0.5 µL CaCl2; 10 µL MgSO4 and 3.88 mL dH2O) 
was aseptically prepared.  AHL QSSMs were kindly donated by A Truman, Pr Paul Williams, 
University of Nottingham.  Reporter strains, P. aeruginosa PAO1!pqsA CTX-
luxCDABE::pqsA, E. coli S17.1 pSB1075, E. coli S17.1 pSB536 and WT Nottingham P. 
aeruginosa PAOI were kindly donated by Dr Diggle, University of Nottingham.  P. aeruginosa 
PACY1 (PAO1-lausanne PKm-lux) was kindly donated by Pr Miguel Cmara, University of 
Nottingham.  All procedures were planned and executed in a Category 2 laboratory in 
accordance with local regulations including standard operating procedures and risk and safety 
assessments.   
 
GENERAL PROCEDURE FOR THE SYNTHESIS OF NHS ESTERS 
N-hydroxysuccinimide (NHS) (10.1 mg, 0.09 mmol) was added to an ice-cold stirred solution 
of the hapten (21 mg, 0.08 mmol) and EDC (18.4 mg, 0.10 mmol, Fluorochem Ltd) in 
anhydrous 1,4-dioxane (0.73 mL).  Anhydrous DMF was added drop-wise until the solution 
was clear.  The reaction was stirred at room temperature (rt) under an atmosphere of N2 for 16 
h until the reaction was complete (TLC, EtOAc).  The solvent was rotary evaporated and the 
crude mixture was dissolved in EtOAc and washed with dH2O followed by brine.  The solution 
was dried over MgSO4.  The solvent was removed by rotary evaporation and triturated with 
EtOAc and hexane.  The precipitate was carefully collected and transferred to a pre-weighed 
oven dried vial and kept under N2 until further use.  (NHS esters can be stored for long periods 
under N2 in a dessicator, but it was noted that the best results were obtained with immediate 
use.  NHS esters are sensitive to moisture, therefore, the compound was minimally handled).   
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HYDROXYSUCCINIMIDE-7-((S)-2-OXOPYRROLIDIN-3-YLCARBAMOYL)-6-OXOHEPTANOATE 
7-((S)-2-oxopyrrolidin-3-ylcarbamoyl)-6-
oxoheptanoic acid (37) was used in the above 
procedure to afford the title compound as an 
off-white solid (21 mg, 74%).  HR-ESI-MS-
ESI: m/z 368.1529 [M + H], 391.0886 [M + H + Na]
+
, 328.0858, C16H21N3O7 requires 
367.1380 and [C16H22N3O7Na]
+
 requires 390.1277.   
 
HYDROXYSUCCINIMIDE-7-(1,4-DIHYDRO-3-HYDROXY-4-OXOQUINOLIN-2-YL)HEPTANOATE 
 N-hydroxysuccinimide (NHS) (13.5 mg, 0.12 
mmol) was added to an ice-cold stirred solution 
of the 7-(1,4-dihydro-3-hydroxy-4-oxoquinolin-2-
yl)heptanoic acid (47, 30 mg, 0.1 mmol) and 
EDC (24 mg, 0.13 mmol) in anhydrous 1,4-
dioxane (0.73 mL) was used to prepare the final NHS ester.  The contaminant (methyl-7-(1,4-
dihydro-3-hydroxy-4-oxoquinolin-2-yl)heptanoate, (46) could not be removed during the 
purification of 47, but was removed after conjugation and subsequent ultracentrifugation.  The 
subsequent procedure was followed as described as above to afford the title compound as a 
beige solid (crude >100%).  
1
H NMR was conducted, the distinct multiplet (
1
H NMR (CDCl3): 
! 2.74 (m, 4H, (CH2)2)) indicated that the N-hydroxysuccinimide ester had formed.  The 
sample degraded during MS analysis.   
 
GENERAL PROCEDURE FOR PROTEIN HAPTENISATION  
BSA/KLH 
NHS ester (4.18 mg, 0.0114 mmol) was dissolved in DMSO (81 µL) and added drop-wise to 
carrier KLH (11.4 mg, (100 000 g is equivalent to 1 mole)) or BSA (10.3 mg) in filtered 
phosphate buffer solution (1.32 mL, 50 mM, pH 7.4).  The reaction solution was agitated at 
200 rpm at 4 ¡C for 24 h.  The solution was purified using Vivaspin ultrafiltration cartridges 
with 10 000 MWCO with filtered phosphate buffer solution (50 mM, pH 7.2) to afford the 
hapten-carrier conjugate as a concentrated solution.  Protein estimation using Bio-rad
¨
 
Bradford assay was conducted.  BSA was used as standard known concentrations (0-1000 
µg/mL) were titrated against the sample as a neat, 1:10, 1:20 and 1:100 (v/v) dilutions (n = 3).  
Briefly, 5 µL of standard or sample was transferred to a 96-well polystyrene flat-bottomed 
microtitre plate to which 250 µL of Bio-rad
¨
 Bradford reagent (1:4, reagent:dH2O) was added.  
This was left for 5 min and the absorbance was recorded at 590 nm.  The samples were 
interpolated from the standard curve.   
 
The sample was prepared for MALDI-TOF analysis by exchanging the buffer with pure H2O 
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using Vivaspin ultrafiltration cartridges with 10 000 MWCO (100 µL capacity).   
 
2D-SDS PAGE 
The protein sample (30 µg) was dissolved in 125 µL rehydration buffer (7 M urea, 2 M 
thiourea, 1% (w/v) ASB-14, 40 mM Tris, 0.001% bromophenol blue, 0.2% ampholytes, 0.5% 
DTT).  The solution was transferred to the rehydration tray and the IPG strip (Bio-rad, pH 3-
10, 7 cm) was placed gel facing onto the sample.  Once covered with mineral oil, the tray was 
covered with the lid and rehydrated under active conditions and focused using the Protean IEF 
cell (Bio-rad
¨
).  Upon completion, the mineral oil was carefully removed from the IPG strip 
using dH2O.  The IPG strip was transferred gel facing upwards to the equilibrium buffer tray 
and incubated at rt in Equilibrium buffer I (Bio-rad
¨
) for 10 min.  After washing with dH2O, 
the strip was incubated in Equilibrium buffer II (Bio-rad
¨
) for a further 10 min.  The buffer 
was removed by washing the strip with dH2O and adjusted to the appropriate size by cutting 
the edges of the strip.  This was transferred to the pre-set stacking gel (4% 
polyacrylamide)/resolving SDS-gel (10% polyacrylamide)), secured in place with 5% agarose.  
After the electrophoresis (20 mV) was complete, the gel was stained with Coomasie blue in 
destain buffer (MeOH/glacial acetic acid/H2O, 25:0.1.75%) and incubated at rt for 16 h.  The 
excess stain was removed using destain buffer.   
 
IMMUNISATION PROTOCOL 
Mouse 
Three CD1 female mice and three Balb/c female mice were immunised (s/c) with 100 µg of 
hapten-KLH conjugate in FreundÕs complete adjuvant (FCA) in two divided doses.  Three 
booster injections in incomplete FreundÕs adjuvant (IFA) were given at 2-week intervals.  Test 
bleeds were taken seven days after each immunisation.  The mice were euthanised seven days 
after the 3
rd
 booster and terminal bleed was taken.  Immunisations were carried out by BMSU, 
Queens Medical Centre, Nottingham using standard procedures; test bleeds were collected on-
site within 1 h.  The serum was separated from each bleed by centrifugation and characterised 
separately; the terminal bleed was then pooled for further tests.   
 
Rabbit 
One New-Zealand white female rabbit was immunised with 200 µg hapten-KLH conjugate in 
FCA.  Five boosters in IFA were given at 2-week intervals, and test bleeds were taken seven 
days post immunisation.  The rabbit was euthanised on the 77
th
 day and the terminal bleed was 
collected.  Harlan Laboratories, UK, conducted the immunisations using standard procedures.  
The serum was used as received.   
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STANDARD INDIRECT ELISA PROCEDURE 
A 96-well polystyrene flat-bottomed microtitre plate was coated with 100 µL hapten-BSA 
conjugate in PBS, (20 mM, pH 7.2) at pre-determined concentrations (checkerboard titrations, 
CBT) and incubated overnight at 4 ¡C.  This was washed three times with PBST (pH 7.2, 
0.05% Tween) and tapped dry.  Each well was blocked with 300 µL 5% PBST-M (PBS, 0.05% 
Tween and 5% milk powder) for 1 h at rt.  The microtitre plate was washed four times and 
dried as described above, 50 µL of the test sample in specific concentrations were added to the 
appropriate wells.  This was incubated at rt for 2 h and washed four times as above.  After 
drying as described above, 50 µL of HRP conjugated secondary antibody (R&D System) was 
added to the appropriate wells and incubated for 2 h at rt.  The microtitre plate was washed 
four times and 50 µL of the substrate solution (3,3Õ,5,5ÕÐtetra-methylbenzidine dihydrochloride 
tablet (1 mg)) in 10 ml of 0.05 M phosphate-citrate buffer, pH 5.0 and 2 µL of 30% hydrogen 
peroxide) was added and incubated whilst protected from light, at rt for 10 min.  The reaction 
was stopped by the addition of 2.5 M H2SO4 (25 µL) and the OD was recorded at 450 nm.  
Anti-BSA:HRP secondary antibody (AbD Serotec) was used to confirm success of antigen 
coating. 
Checkerboard titrations (CBT) 
The above protocol was followed, however, the hapten-BSA conjugates were prepared in 1 in 
2 serial dilutions (v/v) from 30 µg/mL.  The anti-hapten serum was prepared as 1 in 10 serial 
dilutions in PBST.   
Specificity 
BSA, KLH, PBS, and hapten-BSA were used to coat the appropriate wells of a 96-well 
polystyrene microtitre plate at the pre-determined concentration of hapten-BSA.  The indirect 
ELISA protocol was followed as described.   
Competitive indirect ELISA  
The QSSM (3OC12-HSL, 3OC8-HSL, 3OC6-HSL, C8-HSL, C6-HSL, C4-HSL, PQS, HHQ and 
HSL, and tetramic acid, AP, anthranilic acid and 3-methyl-quinolin-4(1H)-one) were prepared 
in 100 µL stock solutions with a concentration of 5% DMSO.  These were diluted to the test 
concentrations, 1000 µM, 100 µM, 10 µM, 1 µM, 0.1 µM and 0 µM with 100 µL of stock anti-
hapten serum in PBST so the final working concentrations were: 2.5% DMSO and 1 in 2 
dilution of stock anti-hapten antibody.  Subsequent procedure was followed as described 
above.  The controls were 2.5% DMSO-PBST and mouse or rabbit anti-serum in PBST.  
 
AFFINITY CHROMATOGRAPHY USING PROTEIN G-SEPHAROSE  
The protein G-Sepharose and PD10 columns were flushed with sodium phosphate buffer (20 
mM, pH 7.2).  The rabbit serum was added to PD10 column and eluted with sodium phosphate 
buffer in 1 mL fractions.  The absorbance for each fraction was read at 280 nm, and fractions 
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with OD of over 0.40 were collected and combined, this was added to the protein G-Sepharose 
column via a 20 ml syringe and eluted with sodium phosphate buffer in 1 mL fractions.  This 
was continued until the OD was 0.05 and below (280 nm).  The pooled fractions were collected 
and tested negative for pIgG using the standard indirect ELISA protocol.   
  The column was eluted with 0.1 M glycine HCl (pH 2.3) in 1 mL fractions into eppendorfs 
with 20 µL 1 M Tris buffer (pH 9).  The fractions were collected until the OD was < 0.40 (280 
nm).  These fractions were collected and dialysed (membrane, MWCO 10 000) against PBS 
(20 mM, pH 7.2) for two days at 4 ¡C with one buffer change per day.  The dialysed sera were 
tested for: protein content using the Bio-rad
¨
 Bradford assay; and pIgG using the standard 
indirect ELISA protocol.  The pIgG were stored in fractions at -20 ¡C until use.   
 
BSA ADSORPTION USING NITROCELLULOSE MEMBRANE 
This procedure was only used for small-scale adsorption.  Two strips of nitrocellulose 
membrane were added to filtered BSA solution (20 % w/v in PBS) and rotary mixed for 24 h at 
4 ¡C.  One strip was used as a control and tested for BSA adsorption using a modified Western 
blot procedure.  The second strip was added to 0.5 mL anti-hapten pIgG in PBS, and the 
volume was increased to 1 mL with PBS, Tween was added so the final solution was 0.05% 
PBST.  This was gently rotary mixed at 4 ¡C for 24 h.  The solution was removed and 
concentrated using Vivaspin ultrafiltration cartridges with 10 000 MWCO and tested for BSA 
specific pIgG using the specificity ELISA procedure.   
  The control strip was blocked with 5% PBST-M for 1 h at rt.  This was washed with PBS 
three times and incubated with 1 in 500 (v/v) diluted solution of anti-BSA:HRP secondary 
antibody for 2 h.  This was washed three times with PBS and once with dH2O.  The substrate 
(50 mg 4-chloro-1-naphthol in EtOH:PBS, 10:40 mL and 30 µL 30% H2O2) was added to the 
strip, incubated until visual colour detection and the reaction was stopped by replacing the 
solution with water.    
 
BIOLUMINESCENCE 
Reporter strains 
5ml of sterile LB broth containing 128 µL of 5 mg/mL tetracycline in 70% EtOH was 
inoculated with P. aeruginosa PAO1!pqsA CTX-luxCDABE::pqsA; 5 mL of sterile LB broth 
and 20 µL of 5 mg/mL tetracycline was inoculated with E. coli S17.1 pSB1075; 5 mL of sterile 
LB broth and 12.5 µL of 20 mg/mL ampicillin was inoculated with E. coli S17.1 pSB536; 5 
mL of sterile LB broth was inoculated with P. aeruginosa PACY1 (PAO1-lausanne PKm-lux), 
and were incubated at 37 ¡C and agitated to maintain planktonic growth on a shaker at 200 rpm 
for 16 h.   
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Assay 
The test samples contained: QSSM (PQS, 3OC12-HSL, C4-HSL and HHQ) in DMSO at the 
indicated concentrations, (final concentration of DMSO was kept constant (2 µL for AHLs and 
1 µL for HAQs)); anti-hapten rabbit pIgG sera was diluted with PBS (20 mM, pH 7.2), tested 
at 1, 10, 100, 200, 300, 400, 500 µg/mL (the final volume of PBS was kept constant for each 
test sample and was based on the PBS volume that contained 500 µg/mL of anti-hapten rabbit 
pIgG); and 14 µL of a 1 in 100 (v/v) solution of the appropriate reporter strain in fresh LB 
broth.  All solutions were made up to 200 µL using fresh LB broth.  Pre-bleed pIgG was 
diluted with PBS (20 mM, pH 7.2) and tested at 200 µg/mL.  50 µL of the test solution was 
removed and transferred to the appropriate 96-well black flat-bottomed microtitre plate (n = 3).  
A time point zero was taken and the microtitre plate was wrapped in cling-film and incubated 
in a humid environment at 37 ¡C.  Readings were taken every 60 min until the end-point 
(decrease in positive control bioluminescence).  The readings were corrected by subtracting the 
values from time point zero.  
 
STATIC BIOFILM ASSAY 
WT Nottingham P. aeruginosa PAO1 strain was grown in 5 mL sterile LB broth at 37 ¡C 
(agitated at 200 rpm) for 16 h.  The culture was diluted to a 1 in 100 using sterile M9 minimal 
media supplemented with glucose (5 mL M9 minimal media: 1 mL M9 salts (48 mM 
Na2HPO4.7H2O, 22 mM KH2PO4, 19 mM NH4Cl, and 8.6 mM NaCl); 100 µL filtered (0.2 µm 
syringe filter) 20% glucose; 0.5 µL CaCl2; 10 µL MgSO4 and 3.88 mL dH2O).   
 
The anti-hapten rabbit pIgG were diluted with PBS and tested at the concentrations indicated.  
The pre-bleed rabbit pIgG was tested at 200 µg/mL.  The final volume of PBS was kept 
constant.  The test solutions containing sera were inoculated with 3.5 µL of 1 in 100 culture 
were prepared (final concentration of culture was 1 in 1000) as 350 µL solutions with fresh 
sterile M9 media supplemented with glucose.  100 µL of the test solution (n = 3) was 
transferred to a 96-well (rounded) tissue culture microtitre plate and incubated in a humid 
environment at 37 ¡C for 24 h.   
  The supernatant was carefully removed and the microtitre plate was gently washed three 
times with dH2O to remove any planktonic cells.  The microtitre plate was gently tapped dry, 
300 µL of filtered 1% crystal violet solution was added, and the microtitre plate was incubated 
for 15 min at rt.  Excess crystal violet was removed and the microtitre plate was washed three 
times with dH2O or until no excess stain remained.  150 µL of destain buffer (MeOH/glacial 
acetic acid/H2O, 25:0.1.75%) was added to the appropriate wells and gently mixed, 75 µL of 
this solution was transferred to a 96-well (flat bottomed) polystyrene microtitre plate and the 
OD was recorded at 595 nm.   
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5 RESULT 2 Ð HAPTENISATION AND CHARACTERISATION 
AP1 and AP2
^ 
were produced in sufficient yields to continue with the haptenisation of 
immunogenic carrier, KLH using the NHS activated method.  Hapten-BSA conjugates were 
also prepared for characterisation purposes as well as use in ELISAs.   
 
5.1 HAPTEN-CARRIER CONJUGATE  
5.1.1 HAPTEN AND CARRIER CONJUGATION 
Within the immunogenic proteins BSA and KLH !-lysine residues are the most abundant 
amino acids (BSA Ð 59 and KLH Ð 2000) (157).  Coupling reagents, such as EDC, are used to 
form covalent bonds between the carrier and the hapten.  The procedure is performed in situ 
and by-products can be removed by ultracentrifugation or dialysis.  However, EDC will 
activate all carboxylic acid groups, increasing the risk of cross-linking between the carrier 
molecules.  This causes aggregation, which can affect the efficiency of the conjugation.  An 
alternative method is to activate the carboxylic acid group of the hapten prior to carrier 
conjugation.  NHS activates carboxylic acid groups by forming an NHS ester, which reacts 
with the amine residues of the carrier protein to form an amide bond.  In this study, the NHS 
esters were generated using EDC, however to minimise any EDC-mediated cross-linking, the 
NHS esters of the haptens were isolated prior to protein conjugation.  NHS esters have half-
lives of a few minutes at alkaline pH even at low temperatures, this hydrolysis reaction 
competes with the amide bond formation but can be limited by a high protein concentration, 
and a lower pH, such as pH 7.4 (158).   
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5.1.2 EPITOPE DENSITY  
The epitope density refers to the number of hapten groups per carrier molecule, which depends 
on the number of residues available for modification as well as the hapten; for instance in 
BSA, only 30Ð35 !-lysine residues of the 59 are reportedly available for conjugation (158).  
There are examples of highly substituted haptens, dinitrophenyl (DNP)50/60-BSA, which 
produced a strong IgM response (220).  The optimum epitope density results in antibodies with 
a strong specificity towards the hapten.  An epitope density of 15-30 haptens per BSA 
molecule equates to high antibody titres but compromised antibody avidity for the hapten (221-
223).  Conversely, a 13:1 hapten-BSA conjugate produced lower titres of antibodies compared 
to the 7:1 conjugate (224).  Moderate hapten substitution of the carrier ensure that there are 
sufficient carrier epitopes available for presentation to the carrier dependent T-lymphocytes 
(225).  The immune response largely depends on the nature of the hapten, carrier, and dose, but 
the optimum epitope density must still be considered to avoid tolerance against the hapten 
(221-223), a situation in which the immune system has become desensitised to the hapten-
carrier conjugate.  
 
5.1.3 CHARACTERISATION METHODS 
Hapten-carrier conjugates have been characterised by a variety of methods including UV 
absorbance spectroscopy, 2,4,6-trinitrobenzenesulfonic acid (TNBS) titration of free lysine 
residues, mass spectrometry (MS) or sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) (223, 226, 227).  Mass spectrometry (MS), specifically matrix-
assisted laser desorption ionization-time of flight (MALDI-TOF), is a relatively more effective 
and accurate method (226).  The matrices used in MALDI-TOF MS absorb the energy from the 
laser and form reactive species that ionise the sample.  MALDI-TOF MS analyses the 
distribution of the generated ion Mr, and records the Mr of the most abundant ion, the median 
Mr.  Haptenisation resulted in a heterogeneous mixture in regards to Mr, due to the variable 
number of haptens per protein. 
 
Each hapten-carrier conjugate has a different isoelectric point (pI) relative to unconjugated 
BSA.  The pI corresponds to the pH at which the protein carries no net charge.  Unconjugated 
BSA has a net positive charge, due to the number of lysine residues; modification of the lysine 
residues will result in an overall negative charge, and a different pI.  2D-SDS PAGE was used 
to confirm conjugation based on the pI and Mr of the conjugated protein.   
 
The characterisation of hapten-KLH conjugates is limited due to the mass and heterogeneity 
(227) of KLH, the recorded mass of KLH is between 450 and 13 000 KDa and the protein can 
dissociate into individual subunits (158).  As BSA and KLH were conjugated simultaneously, 
using the same conditions, the characterisation of the hapten-BSA conjugate and the immune 
response to the hapten-KLH conjugate was sufficient for the purpose of this study (222, 228).   
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5.2 RESULTS Ð HAPTEN-CARRIER CONJUGATE CHARACTERISATION 
5.2.1 CONJUGATION 
The NHS esters were dissolved in anhydrous DMSO prior to reaction and the solutions were 
added drop-wise to the carrier protein dissolved in phosphate-buffered solution, pH 7.4.  The 
NHS esters are stable under anhydrous conditions but it was found that conjugation results 
were better if the NHS esters were used within 24 h.  Slight precipitation occurred when the 
NHS ester was added to the KLH and BSA solutions but no adverse effects on the conjugation 
reaction were noted.  The reaction was left for 24 h after which the conjugates were purified by 
ultracentrifugation using Vivaspin ultrafiltration cartridges with 10 000 MWCO and 3 000 
MWCO membranes, into phosphate buffer solution, pH 7.2.  Recovery was variable ranging 
from 43-91%.  The proteins adsorb readily to surfaces and the membranes needed to be washed 
repeatedly with minimal phosphate buffer solution, pH 7.2 to increase recovery.   
 
5.2.2 MALDI-TOF MS 
The matrix, sinapinic acid, was prepared in a 2:1 ratio to sample solution however resolution 
improved if the matrix was also spotted on the loading plate prior to the matrix/sample 
solution.  Each sample was tested without a BSA standard for detection of unconjugated BSA 
and then repeated as a spiked sample with unconjugated BSA used as an internal standard. 
 
Haptenisation depended on the conditions used; in slightly alkaline conditions, pH 8 is quite 
effective as the !-lysine residues are most reactive, however, the stability of the hapten has to 
be considered.  In this study, a pH 7.4 was an acceptable pH to conduct haptenisation, resulting 
in (median) 13 AP1 and 18 AP2 conjugated to the BSA molecule (Figure 5-1, p 87).  For the 
rabbit immunisation, the haptenisation of KLH with AP1 was repeated in conjunction with 
haptenisation of BSA with AP1. The median of 13 AP1 per BSA molecule was calculated 
(spectra not shown).  Unfortunately, the spectra indicated that there was some unconjugated 
BSA in the sample, implying that conjugation was incomplete and by default, unconjugated 
KLH was present in the AP1-KLH conjugate solution used for rabbit immunisation.  
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Figure 5-1: MALDI-TOF MS spectra.   
(a) AP1-BSA MALDI-TOF MS: m/z 69 758 [M]
+ 
with unconjugated BSA MALDI-TOF MS: m/z 66 444 
[M]
+
; (b) AP2-BSA MALDI-TOF MS: m/z 71 875 [M]
+ 
with unconjugated BSA MALDI-TOF MS: m/z 
66 451 [M]
+
.  
 
5.2.3 2D-SDS PAGE 
In the first dimension, the conjugate moved towards the positive electrode due to the overall 
net negative charge, and the positively charged BSA standard migrated towards the negative 
electrode.  Migration occurred through the pH gradient, so no further migration occurred once 
the pI was reached (the protein no longer carried a net charge).  The second dimension, which 
is SDS-PAGE, separated according to the Mr of the protein.  The protein acquired a negative 
charge, from the interaction with the detergent, SDS, and migrated towards the positive 
electrode.  The migration was restricted by the pore size controlled by the percentage of 
polyacrylamide used in the preparation of the gel.  The technique was not sensitive enough to 
resolve proteins with only small increases in Mr (Figure 5-2, p 88).   
 
Conjugation was confirmed by the different pI relative to the unconjugated BSA standard.  
Figure 5-2 (c) represents AP1-BSA (prepared in conjunction with AP1-KLH used for rabbit 
immunisation) did not show any unconjugated BSA recorded by MALDI-TOF.  It was 
concluded that the amount of unconjugated BSA was insignificant to present problems in the 
bioassay, and thus by default the amount of unconjugated KLH was also insignificant to 
present problems in generation of antibodies in nave rabbits.   
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Figure 5-2: 2D-SDS PAGE analysis of hapten-BSA conjugates (pH 3-10, 10%).   
For illustration purposes only - the gel of the hapten-BSA conjugate was overlaid on the gel of standard 
BSA (unconjugated) to show the difference in pI.  (a) AP1-BSA conjugate; (b) AP2-BSA conjugate; (c) 
AP1-BSA conjugate (prepared in conjunction with AP1-KLH used for rabbit immunisation).   
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5.3 RESULTS - ANTIBODY CHARACTERISATION 
5.3.1 MOUSE IMMUNISATION 
Three out-bred (CD1) mice and in-bred (Balb/c) mice (identified sequentially 1-6) per 
conjugate were immunised with AP1-KLH and AP2-KLH.  The standard immunisation 
protocols were followed using FCA for primary immunisation and IFA for the booster 
immunisations.  Unfortunately, due to unforeseen and unrelated circumstances, one Balb/c 
mouse (mouse 6) died of undetermined but natural causes during the immunisation protocol 
with the AP1-KLH conjugate.   
 
The response of the mice to the hapten-KLH conjugate (Figure 5-4, p 90) and subsequent titres 
(Figure 5-5, p 91) were determined using an indirect ELISA technique (Materials and methods, 
p 81), illustrated in Figure 5-3.  A secondary Ab conjugated to an enzyme, such as horseradish 
peroxide (HRP), is used to detect the quantity of bound primary anti-hapten pAbs to the 
immobilised hapten-BSA conjugate.  The secondary antibody is specific for the antibodies 
generated by the animal used for immunisation.  
 
 
Figure 5-3: Depiction of an indirect ELISA.  
The HRP conjugated to secondary Ab:primary anti-hapten Ab:hapten-BSA would metabolise the 
substrate resulting in a visible modification such as colour, which is proportional to the amount of bound 
primary Ab to the immobilised hapten-BSA. 
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Figure 5-4: The anti-hapten antibody response by CD1-1 and Balb/c-4 mice to each 
immunisation measured by indirect ELISA.   
(a) Anti-AP1 antibody response by CD-1-1 and Balb/c-4 mice to each immunisation with 
AP1-KLH and (b) Anti-AP2 antibody response by CD-1-1 and Balb/c-4 mice to each 
immunisation with AP2-KLH.  (Data is represented as mean ± SD, n = 4).  Pre-bleed has no 
anti-AP1 or anti-AP2
^
 pAbs.  The mice responded to the hapten-KLH conjugates in a typical 
manner, i.e. the antibody titre increased after each booster compared to the primary 
immunisation.  Generally, the out-bred (CD1) mice responded better; AP1-KLH conjugate 
generated higher titres in both sets of mice compared to the more substituted AP2-KLH. 
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Figure 5-5: Titres of the sera derived from the terminal bleed using indirect ELISA. 
(a) Anti-AP1ÐpAb mouse serum from CD1-1-3; (b) Anti-AP1ÐpAb mouse serum from Balb/c 5-6; (c) 
Anti-AP2-pAb mouse serum from CD1-1-3 and (d) Anti-AP2
^
-pAb mouse serum from Balb/c 4-6.  (Data 
is represented as mean ± SD, n = 4). 
 
Mouse strain and ID Anti-AP1-pAb Anti-AP2-pAb 
CD1-1 1:59 078 1:10 680 
CD1-2 1:372 759 1:13 895 
CD1-3 1:100 000 1:15 849 
Balb/c-4 1:484 969 1:26 827 
Balb/c-5 1:15 849 1:10 680 
Balb/c-6 Deceased 1:4 850 
Table 5-1: Mean titres obtained from the terminal bleed for each mouse per conjugate.   
The titres were recorded as the dilution of pAb at which the optical density (OD) at 450 nm was 50% of 
the maximal OD.  (Data is represented as mean ± SD, n = 4).   
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5.3.1.1 SPECIFICITY  
The mice used for immunisation should be nave to P. aeruginosa, their natural QSSM and the 
carriers, therefore have no pre-existing memory cells or antibodies with specificity to these 
antigens.  This was confirmed by analysis of the pre-bleed serum, which showed no 
recognition of the hapten-BSA conjugate (Figure 5-4, p 90 and Figure 5-5, p 91) whereas the 
generated antibodies against hapten-KLH showed recognition for the hapten-BSA conjugate.  
The carriers are phylogenetically different, but may share similar epitopes, it was anticipated 
that the signal indicating the presence of anti-hapten-KLH pAbs was due to pAb avidity to the 
hapten and not to BSA.  This was investigated using unconjugated BSA and KLH as coating 
antigens in indirect ELISAs (Figure 5-6), in addition to PBS and hapten-BSA.   
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Figure 5-6: Schematic of indirect ELISA for antibody specificity.   
The anti-hapten-KLH pAb should not recognise unconjugated BSA.  No binding occurs and the unbound anti-hapten pAb are washed away.  The secondary anti-mouse IgG:HRP cannot bind 
and is washed away.  The substrate is added but cannot be enzymatically modified, no colorimetric change occurs, implying anti-hapten pAb shows no avidity for unconjugated BSA and does 
not bind in a non-specific manner (indicated by PBS).   
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Figure 5-7: Indirect specificity ELISA of pooled serum from CD1 and Balb/c mice. 
Serum from CD1-1 and Balb/c-4 mouse for each hapten-carrier conjugate was tested for specificity to 
BSA.  Tests were negative and taken as a representation for the strain.  The test was repeated when the 
serum from each mouse was pooled per conjugate.  (Data is represented as mean ± SD, n = 4).   
 
5.3.2 RABBIT IMMUNISATION 
Unfortunately, in preliminary studies, pre-bleed mouse serum showed significant negative 
effect in the anti-QSS assay (8.1.1, p 125).  This complicated the characterisation of the 
potential anti-QSS activity of generated pAb.  It was necessary to isolate polyclonal 
immunoglobulin G (pIgG) from the serum, which was not possible with the small volumes of 
blood obtained from mice.  Immunisation in rabbits, however, provided adequate quantities of 
serum and confirmed that the conjugates were immunogenic in other species. 
 
Each hapten conjugate was used to immunise one New Zealand white, female rabbit.  The 
pIgG of the serum from the pre- and terminal bleeds were purified by affinity chromatography 
on protein G-Sepharose column using standard protocols (Materials and methods, p 81).  The 
protein content of the pIgG preparations were estimated using the Bio-rad
¨
 Bradford assay 
with BSA as the standard. 
 
5.3.2.1 SPECIFICITY 
The pIgG isolated from the pre-bleed of each rabbit showed no avidity to unconjugated BSA, 
KLH, or the hapten-BSA (data not shown). 
 
5.3.2.1.1 AHL 
Unfortunately, the anti-AP1-KLH rabbit serum and subsequent rabbit pIgG were positive for 
specificity to unconjugated BSA (Figure 5-8, p 95).  It was suspected that there may have been 
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A contamination in the AP1-carrier conjugate, anti-A IgG:HRP was incubated with 
immobilised AP1-K	H conjugate in an indirect ELISA (Figure 5-3, p 8
), however, the 
conjugate tested negative for SA contamination.  This suggested that the pAbs bound non-
specifically to SA.   
 
Figure 5-8: Anti-AP1-K	H specificity ELISA.   
(a) Whole rabbit serum containing anti-AP1 pAbs (b) Anti-AP1 pIgG isolated using protein G-Sepharose 
affinity chromatography.  oth assays show significant avidity towards unconjugated SA, (data is 
represented as mean ± SD, n   4).   
 
The pIgG displaying non-specific binding to SA was adsorbed from the anti-AP1-
K	
H 
serum using a SA coated nitrocellulose membrane (Materials and methods, p 8).  
Adsorption was successful, and the binding to unconjugated BSA was reduced to satisfactory 
levels indicated by the low OD (450 nm) (Figure 5-9).  The non-specific pIgG binding was 
above the expected levels, but this anomaly was attributed to slight contamination of the PBS, 
as further assays showed no further non-specific binding.   
 
Figure 5-9: Specificity ELISA for rabbit anti-AP1-pIgG.   
(Data is represented as mean ± SD, n = 4). 
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5.3.2.1.2 PQS 
Non-specific binding was recorded for anti-AP2-H serum as with anti-AP2 pIgG sera.  
AP2-H was negative for BSA contamination, as confirmed by the specificity assays used to 
test mouse serum (Figure -7, p 94).  pIgG was isolated from rabbit serum using protein G-
Spharose affinity chromatography (Materials and methods, p 81).  Non-specific binding was 
reduced as the pIgG concentration became more dilute, therefore, further purification (non-
specific pIgG adsorption) was deemed unnecessary.   
 
 
Figure -10: Indirect EISA specificity of rabbit serum against AP2-H conjugates.   
Results showed no significant avidity to A, particular at lower concentrations of serum.  The titre was 
calculated as the dilution of antibody at which the OD was 0% of the maximal OD at 40 nm.  The titre 
was calculated as 1:100 000.  (Data is represented as mean ± D, n = 4).   
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5.4 DISUSSIN 
5.4.1 HAPTEN-CARRIER CONJUGATES AND CHARACTERISATION 
AP1- and AP2
^
-carrier conugates were successfully synthesised using the NHS active ester 
method.  Characterisation of the hapten-A conugates by MALDI-TF MS and 2D-SDS-
PAGE confirmed con

ugation and epitope density, 13 AP1 and 18 AP2 (median) were 
conugated to the A molecule.  The hapten-KLH conugates could not be characterised, 
however immunogenecity of these coﬀugates were shown in mouse and rabbit.   
 
5.4.2 CHARACTERISATION OF ANTI-HAPTEN ANTIBODIES 
The mouse anti-hapten serum showed no avidity for uncoﬀugated SA and titres were 
reasonable, however, due to the unforeseen non-specific binding seen with rabbit anti-AP1-
KLH serum, the antibody titre has yet to be established.  Time restrictions prevented further 
purification of the rabbit anti-AP1-KLH serum by adsorption method.  However, unlike rabbit 
anti-AP1-KLH serum, rabbit anti-AP2-KLH serum showed insignificant avidity for SA and 
the titre of rabbit anti-AP2 pAb was determined as 1ﬁ100 000. 
 
5.4.3 FUTURE WORK 
Labelled haptens will have to be used for characterisation of hapten-KLH conugates as only 
the hapten-A conugates could be characterised by MALDI-TF MS; MALDI-TF MS can 
only tolerate certain concentrations of Na
+
 and K
+
, therefore non-NaCl buffers were used for 
conugation and ultracentrifugation with the intention of immediate analysis with MALDI-
TF
.  However, it was found that resolution was better with samples in purified water.  Native 
KLH requires high NaCl content to remain in solution (158), although no adverse effects on 
solubility of KLH was noted during the small-scale conugation, on a larger scale, low NaCl 
buffer may cause solubility issues, therefore future conugation reactions will be done in PS, 
pH 7.ﬂﬃ  
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6 RESULT 3 Ð CROSS-REACTIVITY 
Anti-hapten pAbs have been generated against AP1 and AP2.  After appropriate purification, 
the anti-hapten pAbs showed insignificant binding to unconjugated BSA but significant 
binding to the appropriate immobilised hapten-BSA conjugate in indirect ELISA 
demonstrating that the anti-hapten pAbs were specific for the hapten.   
 
P. aeruginosa produces various QSSMs, specifically 3OC12-HSL 1, C4-HSL 2 and PQS 4#.  
The anti-hapten pAbs cross-reactivity to these QSSM had to be established in order to confirm 
the viability of this approach.   
 
6.1 CROSS-REACTIVITY OF ANTI-HAPTEN ANTIBODIES 
The cross-reactivity profile of anti-hapten pAb was established using a series of competitive 
indirect ELISA.  The natural QSSMs were used as the competitive ligands, it was anticipated 
that the anti-hapten pAb would exhibit avidity for the QSSM, therefore interfere with anti-
hapten pAb binding to hapten-BSA (Figure 6-1, p 99).  
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Figure 6-1: Competitive indirect ELISA used to study the cross-reactivity of anti-hapten pAb.   
The controls were test pAb with no QSSM/DMSO and test pAb with 2.5% [DMSO] !/!.  QSSM used: C4-HS", C6-HS", C8-HS", 3OC6-HS", 3OC8-HS", 3OC12-HS" and PQ# in addition to 
AP, HS".HCl, tetramic acid (anti-AP1 pAbs); PQS, HHQ, 3OC12-HS" anthranilic acid and 3-methyl-q$&nolin-4(1H)-one 74 (anti-AP2 pAbs).  The coating antigen: 0.5 µg/m" [AP1-BSA] or 
[AP2-BSA]; 1:20 000 [mouse anti-AP1 pAb] and 1:25 600 [mouse anti-AP2 pAb] !/!.  Controls (n = 9) were test pAb/no QSSM/no DMSO, test pAb/DMSO, and an anti-BSA secondary 
pAb:HRP 
w
as used to confirm that hapten-BSA (n = 2) had coated the plate as an additional control, (data not sh'
w
n). The assays 
w
ere repeated using rabbit anti-AP2 pAb.  CBT 
w
ere used to 
optimise the coating hapten-BSA, 0.5 µg/m
"
 
[
AP2-BSA
]
 and 1:125 000 
[
rabbit anti-AP2 pAb
] !
/
!
. 
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6.1.1 OPTIMISATION 
Using checkerboard titrations (CBT), serial dilutions of the hapten-BSA (coating Ag), were 
titrated against serial dilutions of test anti-hapten pAb, the optimum concentration of anti-
hapten pAb and hapten-BSA that gave an OD between 0.5-0.6 at 450 nm, for anti-hapten 
pAb:hapten-BSA, were determined.  
 
6.1.2 QSSM AND SOLVENT EFFECT 
3OC12-HSL and PQS are moderately hydrophobic and have limited solubility in aqueous 
solutions; therefore, DMSO was used to increase the QSSM solubility in aqueous solutions.  
CBT optimisations indicated that DMSO affected hapten-BSA coating in a dose-independent 
manner.  Additionally, DMSO interfered with the binding of anti-hapten pAb with hapten-BSA 
at dilute concentrations.  The minimum concentration of DMSO was 2.5% v/v that caused no 
significant effects on anti-hapten pAb binding to hapten-BSA however, this restricted the range 
of QSSM concentrations studied.  HHQ, PQS, and 3OC12-HSL precipitated at 1 mM, thus 
higher concentrations were not tested, for this reason, an IC50 could not be calculated.   
 
6.2 RESULTS 
STATISTICAL ANALYSIS 
The effect of 2.5% [DMSO] v/v (n = 9) on anti-hapten pAb binding was analysed using one-
way analysis of variation (ANOVA) with DunnettÕs post-test using the test anti-hapten pAb/no 
QSSM/no DMSO (n = 9) as the control.  Results from test anti-hapten pAb/QSSM (n = 3) were 
analysed using one-way ANOVA and DunnettÕs post-test with anti-hapten pAb:no 
QSSM/DMSO (n = 3) as the control, (p = < 0.05, *; p = < 0.01, **; and p = < 0.001, ***).  All 
statistical analysis was performed using Graphpad Prism
¨
 5, Graphpad Software, La Jolla, CA, 
USA.   
 
6.2.1 CROSS-REACTIVITY PROFILE OF MOUSE ANTI-AP1 ANTIBODIES  
A concentration-dependent inhibition of the binding of anti-AP1 pAb to AP1-BSA was seen 
with the QSSMs; except for 3OC12-HSL, which significantly (p = < 0.05) inhibited the binding 
of anti-AP1 pAbs to AP1-BSA at 0.1 µM.  This inhibitory effect was lost at 1 µM (Appendix 
1, p 149), significant inhibition of the pAb binding was seen at the higher concentrations (! 10 
µM).  This is yet to be explained.  Nonetheless, the anti-AP1 pAbs showed a 1000-fold greater 
response to 3OC12-HSL in comparison to the shorter 3-oxo substituted AHLs (Table 6-1, p 
101).  The anti-AP1 pAbs demonstrated cross-reactivity for C4-HSL, but the anti-AP1 pAbs 
have a 10-fold greater response to the longer unsubstituted AHLs, which is comparable to 3-
oxo AHLs counter-parts.   
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The anti-AP1 pAbs cross-reacted with the natural QSSM of P. aeruginosa (Appendix 1, p 148-
151) including the cognate 3OC8-HSL.  No significant cross-reactivity with AP, HSL.HCL, 
and tetramic acid was seen (data not shown).  The pAbs did not distinguish between the 3-oxo 
and unsubstituted AHLs, suggesting that the key epitope was the lactam ring-external amide 
moiety.   
 
QSSM Concentration at which significant (p = < 0.05) 
inhibition occurred (µM) 
3OC6-HSL ! 100 
3OC8-HSL¥
 
! 100 
3OC12-HSL ! 0.1 
C4-HSL ! 1000 
C6-HSL ! 100 
C8-HSL ! 100 
Table 6-1: Concentration at which significant (p = < 0.05) inhibition of the anti-AP1 pAb 
binding to AP1-BSA occurred (µM).   
All data has been graphically represented and shown in Appendix 1 (p 148-151).  (Data is represented as 
mean ± SD, n = 3).  ¥ All experiments have been repeated in triplicate except for 3OC8-HSL, DMSO 
showed significant effect on the binding of the pAbs to AP1-BSA (data not shown), the experiment could 
not be repeated due to time constraints.   
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6.2.2 CROSS-REACTIVITY PROFILE OF ANTI-AP2 ANTIBODIES  
A concentration-dependent inhibition of the binding of mouse and rabbit anti-AP2 serum to 
AP2-BSA was demonstrated by PQS, HHQ, and the HMAQ synthon, 3-methyl-quinolin-
4(1H)-one 74 (Appendix 1, p 153-155).  Mouse serum showed a 10-fold greater response to 
HHQ in comparison to PQS, however rabbit serum binding to AP2-BSA was significantly (p = 
< 0.05) inhibited at 0.1 µM [HHQ or PQS] (Table 6-2).  However, the rabbit pAb response to 
3-methyl-quinolin-4(1H)-one 74 was considerably less than that for the HAQs, interestingly, 
the response of mouse pAbs to PQS and 3-methyl-quinolin-4(1H)-one 74 is comparable. 
 
Anti-AP2 pAbs generated in mice or rabbit show significant cross-reactivity towards the 
natural QSSM of P. aeruginosa, (PQS and HHQ) with PQS being the cognate of AP2.  3-
Methyl-quinolin-4(1H)-one 74 was able to significantly ( p = < 0.05) inhibit pAb binding to 
AP2-BSA, suggesting that the key epitope of AP2 is the quinolone ring.   
 
QSSM Concentration at which significant (p = < 0.05) 
inhibition occurred (µM) 
 Mouse serum  Rabbit serum 
PQS 4 ! 100 ! 0.1 
HHQ 3 ! 10 ! 0.1 
3-methyl-quinolin-4(1H)-one 74 ! 100 ! 100 
Table 6-2: Concentration at which significant (p = < 0.05) inhibition of the binding of anti-AP2 
pAb to AP2-BSA occurred (µM).   
All data has been graphically represented and shown in Appendix 1 (p 153-155).  (Data is represented as 
mean ± SD, n = 3).  All experiments have been repeated in triplicate.  
 
6.3 DISCUSSION 
6.3.1 CROSS-REACTIVITY 
Competitive indirect ELISAs were useful for characterisation of the cross-reactivity of anti-
hapten pAbs with the natural QSSMs of P. aeruginosa.  Mouse anti-AP1 pAbs demonstrated 
cross-reactivity with the natural AHL QSSMs, and did not discriminate on structural variations 
such as acyl chain length, 3-oxo or unsubstituted AHLs.  The pAbs showed specificity as no 
cross-reactivity was detected with AP, HSL.HCl, and tetramic acid (data not shown).  In the 
absence of IC50, the avidity could not be determined, however using the concentration at which 
the AHL QSSMs were able to significantly (p = > 0.05) inhibit the anti-AP1 pAb:AP1-BSA 
binding, anti-AP1 pAbs displayed strong cross-reactivity for 3OC12-HSL, but comparatively 
weaker cross-reactivity for C4-HSL.   
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The published haptens (Figure 1-9, 6-9, p 53), had acyl chain lengths of 9-12 carbons, AP1 had 
a chain length of 8 carbons (Figure 3-1, p 60).  These data suggest that reduction of one carbon 
and the lactam ring had no negative impact on the cross-reactivity of the generated anti-AP1 
pAbs with natural QSSM.  Therefore, it is possible that the AHL based hapten could tolerate 
significant changes in acyl chain length (compared to the published haptens), for example, 5-7 
carbon length without affecting cross-reactivity with the longer AHLs but improving the cross-
reactivity towards C4-HSL. 
 
Anti-AP2 pAb demonstrates strong cross-reactivity with PQS and HHQ.  The assays were 
repeated with 3OC12-HSL and anthranilic acid, starting material for the biochemical synthesis 
of PQS (not shown), but these molecules did not affect anti-AP2 pAb:AP2-BSA binding, 
unlike 3-methyl-quinolin-4(1H)-one 74, which caused significant inhibition of pAb binding at 
high concentrations.  This confirms that the quinolone structure is the key epitope of AP2 
(Figure 3-2, p 61).  Interestingly, 3-methyl-quinolin-4(1H)-one 74, which has no acyl chain 
and a methyl group at the C3 of the quinolone, is a chemical synthon for the HMAQs of 
Burkholderia spp.   
 
6.3.1.1 LIMITATIONS OF THIS TECHNIQUE 
The competitive indirect ELISA (Appendix 1, p 148-151) were also repeated with BSA 
adsorbed rabbit anti-AP1 pIgG.  CBT optimisation indicated that high concentrations, 1:200-
1:800 [rabbit anti-AP1 pIgG] v/v were needed to obtain an OD (450 nm) of 0.5-0.6.  The assay 
was not considered sensitive using these concentrations.  Concentration of rabbit anti-AP1 
pIgG improved the sensitivity to some degree, (1:4 000 [rabbit anti-AP1 pIgG] v/v against 0.79 
µg/mL [AP1-BSA]), however, data (not shown) indicated that the concentration of rabbit anti-
AP1 pIgG was too high for any discernable inhibition by the QSSM at the test concentrations.   
 
The IC50 should be calculated as the value can provide information on avidity of the anti-
hapten-pAb towards the QSSMs.  However, the end-point was not reached in any of the 
experiments due to the limited concentration ranges of QSSM tested, which was due to the 
poor aqueous solubility of certain QSSM.  
 
6.3.2 FUTURE WORK 
The cross-reactivity profile of rabbit anti-AP1 pIgG will be characterised using the competitive 
indirect ELISA technique, however, using an alternative antibody detection system, 
streptavidin-biotin system, which uses a secondary Ab conjugated biotin instead of HRP 
antibody used in this study.  Streptavidin conjugated to HRP is added which has a high affinity 
for a single biotin molecule, may bind up to four streptavidin molecules subsequently resulting 
in signal amplification.  Lower concentrations of rabbit anti-AP1 pIgG and QSSM can be used, 
with concentrations of DMSO lowered accordingly.  This revised system will allow 
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characterisation of the cross-reactivity of rabbit anti-AP1 pIgG and more importantly, the IC50 
can be calculated.   
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7 RESULT 4 - ANTI-QSSM ACTIVITY 
Competitive indirect ELISA have shown that anti-hapten pAbs can cross-react with the natural 
QSSMs, however the assay was not designed to test the anti-QSSM activity of the anti-hapten 
pAbs.  The anti-QSSM activity refers to the pAbs capacity to bind and inhibit the function of 
QSSMs.  In vivo, this would imply that the pAbs opsonised the QSSMs.   
 
Reporter plasmids have been constructed and inserted into bacterial strains (Dr Diggle, 
University of Nottingham), E. coli S17.1 and P. aeruginosa PAO1, which are then 
bioluminescent in response to exogenous 3OC12-HSL, C4-HSL and PQS.  It is anticipated that 
the bioluminescence will be reduced when the strains are grown in the presence of exogenous 
QSSM and the corresponding anti-hapten pAbs, as the pAbs bind to the QSSM and inhibit the 
function.   
 
7.1.1 BIOLUMINESCENCE 
7.1.1.1 BIOLUMINESCENCE REPORTER 
Bioluminescence is a biochemical reaction involving the oxidation of reduced flavin 
mononucleotide (FMNH2) and a long chain fatty aldehyde in the presence of oxygen, catalysed 
by luciferase.  Luciferase is encoded by the Photorhabdus luminescens genes luxAB whilst the 
fatty aldehyde is encoded by luxCDE (229-231).  Reporter plasmids have been constructed that 
feature the luxCDABE fused to a specific promoter (Figure 7-1, Figure 7-3, and Figure 7-5).  
 
7.1.2 RESULTS 
Using the modified protocol (232), the appropriate reporter strain was grown at 37 ¡C with the 
appropriate exogenous QSSM at the indicated concentrations, with or without the 
corresponding anti-hapten rabbit pIgG.  Bioluminescence was measured in arbitrary units (AU) 
at hourly time points.  The assay was stopped when bioluminescence of the positive control 
began to decrease.  The time point at which the bioluminescence of the positive control was 
maximal has been presented in this study (Materials and methods, Bioluminescence, p 82).  
The variability of this assay was high, and this time point differed for each experiment thus, the 
data for each experiment have been represented separately for analysis.  Due to time 
constraints, the assays (n = 3) have only been repeated twice.  
 
STATISTICAL ANALYSIS 
Positive control is the appropriate reporter strain in PBS/LB media and QSSM (n = 3).  
Negative control is the reporter strain/PBS/LB media/DMSO (n = 3).  Pre-bleed pIgG was a 
limited resource therefore was tested in one assay for each reporter (n = 3) at 200 µg/mL 
Anti-QSSM activity 
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against 1 and 10 µM [QSSM]#.  Results from test pAb/QSSM/reporter strain (n = 3) were 
analysed using one-way ANOVA and DunnettÕs post-test against the positive control, (p = < 
0.05, *; p = < 0.01, **; and p = < 0.001, ***).  All statistical analysis was performed using 
Graphpad Prism
¨
 software 5, Graphpad Software, CA, USA.   
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7.1.2.1 3OC12-HSL AND RABBIT ANTI-AP1 pIgG 
 
Figure 7-1: E. coli S17.1 reporter strain with the pSB1075 
plasmid.   
The E. coli S17.1 reporter strain has the pSB1075 plasmid and 
does not produce 3OC12-HSL due to the absence of lasI.  The 
biosensor is bioluminescent in response to exogenous 3OC12-HSL.  
The lasR expresses the LasR protein that binds to exogenous 
3OC12-HSL, this complex (LasR-3OC12-HSL) binds to the 
promoter (mutated lasI
Õ
) fused to the luxCDABE construct.  This 
stimulates the expression of luciferase controlled by the luxAB and 
the long chain fatty aldehyde, expressed by luxCDE.  Luciferase 
catalyses the oxidation of reduced FMNH2 and long chain fatty 
aldehyde in the presence of oxygen, resulting in bioluminescence.  
Rabbit anti AP1-pIgG should bind to exogenous 3OC12-HSL, 
preventing the LasR-3OC12-HSL complex.  No activation of the 
luxCDABE should occur via the promoter and bioluminescence 
will not result.   
Anti-QSSM activity 
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The rabbit pre-bleed pIgG does not significantly affect bioluminescence in response to 
exogenous 3OC12-HSL at 1 and 10 µM (Figure 7-2, b) suggesting that it has no effect on the 
biochemical reaction and confirmed previous ELISA data, which showed that that the pre-
bleed pIgG has no avidity for 3OC12-HSL.   
 
The positive controlÕs bioluminescence was considerably lower in response to 10 and 25 µM 
[3OC12-HSL] compared to 1 µM [3OC12-HSL] (Figure 7-2).  This was not expected, as it was 
anticipated that increasing concentrations of QSSM would increase bioluminescence.  
However, the data did show that rabbit anti-AP1 pIgG reduced bioluminescence in a 
concentration-dependent manner.  Significant reduction (p = <0.001, ***) in bioluminescence 
was seen at 200 Ð 400 µg/mL [rabbit anti-AP1 pIgG] with 1 and 10 µM [3OC12-HSL], but only 
experiment b shows significant reduction in bioluminescence in response to 25 µM [3OC12-
HSL].  Experiment b (Figure 7-2) shows that ! 200 µg/mL [rabbit anti-AP1 pIgG] decreases 
bioluminescence below that of the negative control, however the negative controls have 
surprisingly high bioluminescence levels in comparison to experiment a (Figure 7-2), in light 
of this, it was inappropriate to calculate an IC50 without further experimental repetitions.   
 
The results suggest that pre-bleed had no significant effect on bioluminescence, the reductions 
in bioluminescence by anti-AP1 pIgG in response to exogenous 3OC12-HSL was due to a 
specific anti-3OC12-HSL effect.  It is assumed that the pAbs bound to 3OC12-HSL and 
prevented entry into the cell, therefore no LasR-3OC12-HSL complex was formed and 
bioluminescence was not stimulated.  This is concentration-dependent up to 200 µg/mL [rabbit 
anti-AP1 pIgG]; greater concentrations did not reduce bioluminescence any further.  This may 
be the anticipated end-point, however, this seems unlikely, as the bioluminescence of negative 
controls has been recorded to be lower.  Nonetheless, anti-AP1 pAb has demonstrated specific 
anti-3OC12-HSL effect.   
 
 
 
 
Figure 7-2: The bioluminescence response of E.coli S17.1 reporter strain pSB1075.   
The bioluminescence response of E. coli S17.1 reporter strain pSB1075 in response to exogenous 3OC12-
HSL and rabbit anti-AP1 pIgG.  (a) and (b) Rabbit anti-AP1 pIgG (µg/mL) (x-axis) was titrated against 1 
(i), 10 (ii) and 25 (iii) µM [3OC12-HSL].  Graphs (i), (ii) and (iii) show significance (ANOVA) of 
bioluminescence inhibition by the rabbit anti-AP1 pIgG compared to the positive control.  Negative 
control was the E.coli S17.1 reporter strain pSB1075 in LB broth/PBS and 2 µL [DMSO]; Positive 
control was the E.coli S17.1 reporter strain pSB1075 with LB broth/PBS and 1 (i), 10 (ii) and 25 (iii) µM 
[3OC12-HSL]. (b) Pre-bleed was a limited resource and tested (data is represented as mean ± SD, n = 3) in 
only one assay, 200 µg/mL [rabbit pre-bleed pIgG] was titrated against 1 (i) and 10 (ii) µM [3OC12-HSL].  
The data has been represented for the time point at which bioluminescence of the positive control was 
maximal. 
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7.1.2.2 C4-HSL AND RABBIT ANTI-AP1 pIgG 
 
Figure 7-3: E. coli S17.1 reporter strain contains the pSB536 
plasmid.   
 
E. coli S17.1 reporter strain contains the pSB536 construct, which 
is bioluminescent in response to exogenous C4-HSL but contains 
the Aeromonas hydrophyla ahyR, which expresses AhyR and forms 
a complex with C4-HSL.  E. coli does not produce the QSSM.  The 
AhyR-C4-HSL binds to the promoter, ahyI, which is fused to the 
luxCDABE construct.  The cross-reactivity profile of rabbit anti-
AP1 pIgG could not be tested in competitive indirect ELISA, but it 
is anticipated that it would exhibit a similar profile as the mouse 
anti-AP1 serum and show cross-reactivity towards C4-HSL.  
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The rabbit pre-bleed pIg( did not significantly affect bioluminescence in response to 
exogenous C4-HSL at 1 and 10 µM (Figure 7-4, p 112), as seen in (Figure 7-2, p 108) 
suggesting that the pre-bleed pIg( did not exhibit avidity for C4-HSL.   
 
Surprisingly, the bioluminescence (AU) for the positive control in response did not increase in 
response to increasing exogenous concentrations of C4-HSL.  However, unlike the experiments 
shown in Figure 7-2 the negative controls were low.  There is a tentative indication of a 
concentration-dependent reduction of bioluminescence in response to 1 µM )C4-HSL* by rabbit 
anti-AP1 pIg( up to 200 µg,mL, however it seems that this inhibitory effect lessens with 
greater concentrations of anti-AP1 pIg(.  This trend is reflected to some degree with 10 and 25 
µM )C4-HSL* in experiment b (Figure 7-4).   
 
Data from competitive indirect ELISAs suggest that although the pAbs have avidity for C4-
HSL, it is not as strong as seen for 3OC12-HSL.  It is suspected that higher concentrations of 
anti-AP1 pIg( will need to be tested in this assay for 10 and 25 µM.  The increase in 
bioluminescence seen in experiment a (Figure 7-4) for 25 µM is considered anomalous due to 
the low bioluminescence recorded for the positive control, as the data collectively shows that 
rabbit anti-AP1 pIg( decreases bioluminescence. 
 
The increase in bioluminescence with greater concentrations (> 200 µg,mL) of anti-AP1 pIg( 
suggests that the interaction of pAb with C4-HSL may be weak, in comparison to pAb and 
3OC12-HSL, it is possible that the pAb:C4-HSL complex dissociated easily in excess molar 
concentration of anti-AP1 pIg(.  Indeed, data from competitive indirect ELISA suggested that 
anti-AP1 pIg( demonstrated weaker cross-reactivity to C4-HSL compared to the AHLs tested, 
implying weaker avidity.  Even so, the data has shown that anti-AP1 pIg( reduces 
bioluminescence in response to 1 µM )C4-HSL* up to 200 µg,mL, this effect appears to be 
specific anti-C4-HSL effect as pre-bleed pIg( did not significantly affect bioluminescence in 
response to exogenous C4-HSL.   
 
 
Figure 7-4: The bioluminescence response of E. coli S17.1 reporter strain pSB536.   
The bioluminescence response of E. coli S17.1 reporter strain pSB536 in response to exogenous C4-HSL 
and rabbit anti-AP1 pIg-.  (a) and (b) Rabbit anti-AP1 pIg- (µ/0mL) (x-axis) was titrated against 1 (i), 
10 (ii) and 25 µM (iii) 1C4-HSL2.  -3aphs (i), (ii) and (iii) show significance (A79;A< of 
bioluminescence inhibition by the rabbit anti-AP1 pIg- compared to the positive control.  Negative 
control was the E. coli S17.1 pSB536 reporter strain in LB broth0PBS and 2 µL 1DMSO2; positive control 
was the E. coli S17.1 reporter strain pSB536 with LB broth0PBS and 1 (i), 10 (ii) and 25 µM (iii) 1C4-
HSL2.  (b) Pre-bleed was a limited resource and tested (data is represented as mean ± SD, n ? 3) in only 
one assay, 200 µ/0mL 1rabbit pre-bleed pI/-2 was titrated 1 (i) and 10 µM (ii) 1C4-HSL2.  (Data is 
represented as mean ± SD, n ? 3).  The data has been represented for the time point at which 
bioluminescence of the positive control was maximal. 
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7.1.2.3 PQS AND RABBIT ANTI-AP2 pIgG 
 
Figure 7-5: P. aeruginosa PAO1!pqsA CTX-
luxCDABE::pqsA reporter 
The CTX-luxCDABE::pqsA construct has been inserted into the 
mutated P. aeruginosa PAO1!pqsA strain and is bioluminescent 
in response to exogenous HAQs.  Due to the deletion of pqsA, 
the reporter strain cannot produce HAQs.  This reporter will be 
used with exogenous PQS, which will form the PqsR complex 
activating the lux cassette via the fused promoter pqsA.     
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A clear trend cannot be seen in the data from experiment a and b (Figure N-6) for 1 and 25 µM 
VX@SYZ  Ho\eMer, both experiments a and b, did sho\ that rabbit anti-AP2 pIg_ significantly 
reduced bioluminescence in response to 10 µM VP@SY at 10 µg/m`, certainly, in experiment b 
(Figure N-6) increasing concentration to 200 µg/m` has significant inhibitory effect on 
bioluminescence.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure N-6: The bioluminescence response of P. aeruginosa PAO1!pqsA CTb-
luxCDABE::pqsA reporter strain.   
The bioluminescence response of P. aeruginosa PAO1!pqsA CTc-luxCDABE::pqsA reporter strain in 
response to exogenous PdS and rabbit anti-AP2 pIgf (x-axis).  (a) and (b) Rabbit anti-AP2 pIgf 
(µg/mi) kas titrated against 1 (i), 10 (ii) and 25 (iii) µM lPdSmp  fraphs (i), (ii) and (iii) shok 
significance (ANOrA) of bioluminescence inhibition by the rabbit anti-AP2 pIgf compared to the 
positite control.  Negatitx control kas the P. aeruginosa PAO1!pqsA CTc-luxCDABE::pqsA reporter 
strain in iB broth/PBS and 1 µi lDMSOm; Positite control kas the reporter strain kith iy broth/PBS and 
1 (i), 10 (ii) and 25 (iii) µM lPdSm.  (Data is represented as mean ± SD, n= 3).  The data has been 
represented for the time point at khich bioluminescence of the positite control kas maximal. 
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In contrast, experiment c (Figure 7-7) 200 µg/mL [rabbit anti-AP2 pIgG] was added to the 
reporter strain in media and exogenous PQS at the first indication of bioluminescence (3 h).  
The results indicate that the bioluminescence was significantly reduced in response to 1, 10, 
and 25 µM [PQS].   
 
Figure 7-7: The bioluminescence response of P. aeruginosa PAO1!pqsA CTX-
luxCDABE::pqsA reporter strain.   
The bioluminescence response of P. aeruginosa PAO1!pqsA CTX-luxCDABE::pqsA reporter strain in 
response to exogenous PQS and rabbit pre-bleed or anti-AP2 pIgG.  (c) Pre-bleed was a limited resource 
and tested (data is represented as mean ± SD, n = 3) in only one assay, 200 µg/mL [rabbit pre-bleed pIgG] 
was titrated against 1, 10 and 25 µM [PQS].  (c) Positive control, reporter strain/PBS/LB media with PQS 
was incubated until bioluminescence was detected (3 h), 200 µg/mL [rabbit anti-AP2 pIgG] was added 
and bioluminescence was recorded at hourly intervals.  The data has been represented for the time point at 
which bioluminescence of the positive control, (pale green) was maximal.  Horizontal bars show 
significance (ANOVA) of bioluminescence inhibition by the rabbit anti-AP2 pIgG compared to the 
positive control. 
 
These data did not present a clear trend, however anti-AP2 pIgG has shown anti-PQS activity 
by reducing bioluminescence as seen in experiments a and b (Figure 7-6, data for 10 µM 
[PQS]) and experiment c (Figure 7-7) at 10 Ð 200 µg/mL.  This effect appeared to be specific 
as rabbit pre-bleed IgG showed no inhibitory effect on bioluminescence in response to 
exogenous PQS (Figure 7-7).  Data from competitive indirect ELISAs clearly showed that anti-
AP2 pIgG strongly cross-reacted with PQS, but this was not reflected in this bioluminescence 
assay, unlike anti-AP1 pIgG, which demonstrated strong cross-reactivity towards 3OC12-HSL 
in both competitive indirect ELISA and bioluminescence assays.   
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Data from competitive indirect ELISA (Appendix 1, p 153 - 155) showed that rabbit anti-AP2 
pIgG cross-reacted with HHQ.  The P. aeruginosa PAO1!pqsA CTX-luxCDABE::pqsA 
reporter strain was bioluminescent in response to exogenous HHQ, therefore, the assay was 
repeated using exogenous HHQ.  This assay was conducted once and could not be repeated due 
to time constraints.   
 
The bioluminescence (AU) for the positive controls increased with increasing concentrations of 
exogenous [HHQ].  Rabbit anti-AP2 pIgG reduced bioluminescence in response to 1 and 10 
µM [HHQ] in a concentration-dependent manner, 100 µg/mL was sufficient to reduce 
bioluminescence in response to 1 µM [HHQ] to below that of the negative control.  The IC50 (n 
= 3) has been calculated to be 14.8-42.8 µg/mL (3 s.f, r
2
 = 0.979); 500 µg/mL [anti-AP2 pIgG] 
significantly reduced bioluminescence in response to 10 µM [HHQ] to near negative control, 
but the IC50 has been calculated just outside the tested concentration range.  No clear trend was 
seen for 25 µM [HHQ], it is suspected that greater concentrations of pAbs are needed.   
 
Anti-AP2 pIgG has demonstrated anti-HHQ effect, which appears to be specific anti-QSSM 
activity as pre-bleed IgG increased bioluminescence.  This correlates with the cross-reactivity 
seen in competitive indirect ELISA (Appendix 1, p 153 - 155).  The concentrations of anti-
AP2 pIgG at which inhibition of bioluminescence in response to 1 and 10 µM [HHQ] are in a 
0.3:1 (pAb:HHQ) molar ratio, it was expected that the pAbs would be in a 1:1 (pAb:QSSM) 
molar ratio, it is possible that the AP2 is multi-valent, i.e. the quinolone ring may not be the 
only epitope.   
 
 
 
 
 
Figure 7-8: The bioluminescence response of P. aeruginosa PAO1!pqsA CTX-
luxCDABE::pqsA reporter strain.   
The bioluminescence response of P. aeruginosa PAO1!pqsA CTX-luxCDABE::pqsA reporter strain in 
response to exogenous HHQ and rabbit pre-bleed or anti-AP2 pIgG (x-axis).  (a) Rabbit anti-AP2 pIgG 
(µg/mL) was titrated against 1 (i), 10 (ii), and 25 (iii) µM [HHQ].  Pre-bleed (200 µg/mL [rabbit pre-bleed 
pIgG]) was titrated against 1 (i), 10 (ii), and 25 (iii) µM [HHQ].  The data has been represented for the 
time point at which bioluminescence of the positive control was maximal. Graphs (i), (ii) and (iii) show 
significance (ANOVA) of bioluminescence inhibition by the rabbit anti-AP2 pIgG compared to the 
positive control.  Negative control was the P. aeruginosa PAO1!pqsA CTX-luxCDABE::pqsA reporter 
strain in LB broth/PBS and 1 µL [DMSO]; positive control was the P. aeruginosa PAO1!pqsA CTX-
luxCDABE::pqsA reporter strain with LB broth/PBS and 1 (i), 10 (ii), and 25 (iii) µM [HHQ].  (Data is 
represented as mean ± SD, n = 3).   
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7.2 DISCUSSION 
7.2.1 ANTI-QSSM ACTIVITY 
The bioluminescence assay was considered appropriate for the determination of anti-QSSM 
activity by the rabbit anti-hapten pI|}, as reporter strains were bioluminescent in response to 
exogenous QSSM.  Anti-AP1 pI
|}
 exhibited significant anti-3OC12-HSL activity by reducing 
bioluminescence in response to 1 µM ~3OC12-HSL by 53% (200 µ|mL ~rabbit anti-AP1 
pI|}.  This concentration-dependent anti-QSSM activity was more pronounced with 1 µM but 
was reflected in data for 10 and 25 µM 
~
3OC12-HSL.  In contrast, although the pAbs showed 
anti-C4-HSL activity, the inhibitory effect was significantly diluted as the concentration of anti-
AP1 pIg} increased.  This implied, in conunction with data from competitive indirect ELISA, 
that the avidity of anti-AP1 pIg} for C4-HSL might be weaker in comparison to 3OC12-HSL.   
 
Rabbit anti-AP2 pIg} indicated possible anti-PQS activity, as significant inhibition of 
bioluminescence was only apparent in one assay, when the pI|} were added during the assay.  
The pAbs demonstrated strong PQS cross-reactivity.  The action of the pIg} on the 
bioluminescence emitting biochemical reaction was tested using a P. aeruginosa PAC1 
reporter strain (PAO1-lausanne PKm-lux), which was constitutively bioluminescent (Pr 
mara, University of Nottingham).  Results showed that the pIg} had no effect on 
bioluminescence therefore the implied anti-PQS activity was a specific effect, even though it 
was not replicated in assays that had the pAbs at time zero.  The anti-AP2 pIgG showed strong 
anti-HHQ activity in a concentration dependent manner, confirming the strong cross-reactivity 
seen in competitive indirect ELISA studies.   
 
PQS is a hydrophobic molecule, 86% of PQS is reportedly transported by membrane vesicles 
(233).  PQS interacts with lipid A of LPS and is incorporated into these vesicles with no loss of 
biological activity (234).  Figure 7-9 illustrates an explanation for the lack of anti-PQS activity 
seen with bioluminescence assay.  
Anti-QSSM activity 
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Figure 7-9: PQS bioavailability and anti-AP2 pIgG  
Exogenous PQS interacts with LPS of the P. aeruginosa PAO1!pqsA-CTX-luxCDABE::pqsA reporter 
strain forming membrane vesicles.  This limits the availability of PQS, thus preventing rabbit anti-AP2 
pIgG binding.  Competitive indirect ELISA has shown that rabbit anti-AP2 pIgG has avidity for PQS.  
 
This presents a problem for the anti-AP2
^
 pAbs if PQS is unavailable for binding.  Conversely, 
exogenous PQS could not restore the WT P. aeruginosa level of membrane vesicle formation 
in a PQS negative strain (235), which could mean that PQS may be transported by other 
means.  The anti-AP2 pIgG have demonstrated anti-PQS activity, therefore provided PQS has 
not entered the cell, the pAbs still have the potential to inhibit the Pqs system.   
 
Masburn et al. (234) noted that 2-heptyl and 3-hydroxyl group of PQS were needed for 
membrane vesicle formation; HHQ is not transported in this manner and diffuses freely in and 
out of the cell.  HHQ is the precursor for PQS and may have QSSM activity in P. aeruginosa 
and Burkholderia spp. (68).  Anti-AP2 pIgG showed strong anti-HHQ activity by reducing 
bioluminescence in response to 1 and 10 µM [HHQ] in a concentration-dependent manner, in a 
ratio of 0.3:1 pAb:HHQ.  Therefore it is possible that anti-AP2 pIgG can inhibit Pqs system by 
disrupting the conversion of PQS, achieved by inhibiting HHQ, which also serves to reduce the 
formation of HHQ (Figure 1-6, p 42) and PQS-PqsR formation.   
 
7.2.2 FUTURE WORK 
The variability of this assay is high, therefore, further repetitions are needed, in particular for 
3OC12-HSL, as the controls were irregular.  It is of interest to test greater concentrations of 
anti-hapten pIgG than those used in this study.  The bioluminescence assay (Figure 7-7, p 119) 
in which anti-AP2 pIgG was added during the assay needs to be repeated as this provided data 
indicating significant anti-PQS activity.  It will be of benefit to investigate if membrane 
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vesicles are indeed the cause for the lack of anti-PQS activity in experiment a and b (Figure 
7-6, p 116).   
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8 RESULT 5 - ANTI-QSS ACTIVITY 
The anti-pAbs cross-react with the QSSMs of P. aeruginosa shown by a series of competitive 
indirect ELISA, as these QSSMs were able to significantly (p = < 0.05) inhibit the formation of 
the anti-hapten pAbs:hapten BSA complex.   
 
The anti-hapten pAbs demonstrated anti-QSSM activity by reducing bioluminescence of the 
reporter strains in response to exogenous QSSMs, the anti-hapten pAbs bind to the QSSM and 
inhibit the function.   
 
The QSS controls the production of virulence factors, which cause the pathogenicity of P. 
aeruginosa.  Anti-QSS activity implies that the QSS is compromised, the bacteria cannot sense 
the quorum and the environment and are unable to co-ordinate the production of virulence 
factors.  The anti-hapten pAbs have shown significant anti-QSSM activity, however whether 
this activity translates into anti-QSS activity was yet undefined.   
 
The anti-QSS activity was therefore characterised using assays that measured the production of 
virulence factors.   
 
8.1.1 DETERMINATION OF ANTI-QSS ACTIVITY OF ANTI-HAPTEN pIgG 
QSS appears to be important in biofilm development and maturation (1.5.5, p 46) and is an 
example of the situation where each division of the QSS is active; an impaired QSS causes 
abnormal biofilm formation.  It was hypothesized that with inhibition of the QSSM activity, 
the QSS would be disrupted; the bacteria would remain planktonic, unable to communicate and 
would not convert to the sessile state thus minimising biofilm formation.  
 
Adult human serum acts as a physical barrier preventing the initial attachment and formation of 
biofilm on plastic surfaces such as catheters (236).  Ubiquitous lactoferrin, which has 
bactericidal properties, prevents biofilm formation by sequestering free iron and stimulating 
twitching motility (237).  Complement proteins are known to inhibit biofilm formation (238).  
Indeed, in this study, mouse pre-bleed serum had an inhibitory effect in a preliminary static 
biofilm assay, inhibiting biofilm formation, almost comparable to that seen with the mouse 
anti-hapten serum.  It was concluded that the effect, if any, on QSS of anti-hapten pAbs could 
only be determined if serum components were removed.  The pIgG were used in the static 
biofilm microtitre assay.   
 
An overnight culture of WT Nottingham P. aeruginosa PAO1 strain was grown in M9 media 
in the presence of pIgG for 24 hours in a 96-well microtitre plate, (Materials and methods, 
Static biofilm assay, p 83).  The formation of biofilm, in the presence of rabbit anti-AP1 pIgG 
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or anti-AP2 pIgG and in combination, was quantified by crystal violet staining.  Rabbit pre-
bleed pIgG was used as a negative control.   
 
8.1.2 RESULTS 
STATISTICAL ANALYSIS 
Positive control WT Nottingham P. aeruginosa PAO1 in PBS/M9 media (n = 9).  Negative 
control was M9 media and PBS (n = 9).  Pre-bleed pIgG was a limited resource therefore could 
only be used in two assays (n = 3).  Results from test pIgG/WT Nottingham P. aeruginosa 
PAO1 (n = 3) were analysed using one-way ANOVA and DunnettÕs post-test against the 
positive control, (p = < 0.05, *; p = < 0.01, **; and p = < 0.001, ***).  All statistical analysis 
was performed using Graphpad Prism
¨
 software 5, Graphpad Software, CA, USA.   
 
Cell viability tests (data not shown) indicated that pIgG did not affect bacterial growth.  
Collectively, the data (Figure 8-1, experiment a and b) show that pre-bleed pIgG has no 
significant inhibitory effect on biofilm formation.  The data indicated that rabbit anti-AP1 
pIgG reduced the biofilm formation in a concentration-dependent manner (! 40 µg/mL), which 
was significant at 50 Ð 200 µg/mL, in experiment c only.  Rabbit anti-AP2 pIgG also had 
inhibitory effect on biofilm formation, which was only significant in experiment c at 50 Ð 200 
µg/mL, however, the effect was generally less than anti-AP1 pIgG.   
 
When biofilms were grown with a combination of anti-AP1 and anti-AP2
^
 pIgG at the 
concentrations where an inhibitory effect on biofilm formation was apparent, (! 40 µg/mL), 
there was a notable decrease in biofilm formation (experiment a, 80 µg/mL total pIgG, 40:40 
µg/mL [anti-AP1/anti-AP2 pIgG]).  Experiment b and c showed that a total of 50 µg/mL anti-
hapten pIgG (25:25 µg/mL [anti-AP1/anti-AP2 pIgG]) caused significant inhibition of biofilm 
formation, in a concentration-dependent manner.  However, at 400 µg/mL (200:200 µg/mL 
[anti-AP1/anti-AP2 pIgG]), the reduction in biofilm formation was less than that of the anti-
haptens pIgGs used separately at 200 µg/mL.  This result may be anomalous, this concentration 
was only tested once and greater concentrations were not tested due to limited time.  
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Figure 8-1: Static biofilm formation with and without rabbit anti-hapten pIgG.   
(a), (b) and (c) Anti-QSS activity of rabbit anti-hapten pIgG on biofilm formation of WT Nottingham P. 
(c) 
(a) 
(b) 
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aeruginosa PAO1 strain, grown in M9 media at 37 ¡C for 24 hours (n = 3).  1% [crystal violet] w/v was 
used to quantify biofilm formation and cell-viability plate assay was conducted during assay (a) and (b), 
results showed that the anti-hapten pIgG and pre-bleed pIgG did not affect growth (results not shown).  
Pre-bleed pIgG was a limited resource therefore was used in assay (a) and (b), however no significant 
inhibition of biofilm formation occurred.  Positive control was WT Nottingham P. aeruginosa PAO1/M9 
media and PBS; negative control is M9 media/PBS; and combination was rabbit anti-1 pIgG:anti-2 
pIgG (1:1, µg/mL).  Significance (ANOVA) is shown in comparison to positive control.   
 
Anti-AP1 and anti-AP2 pIgG decreased biofilm formation when used individually, but was 
significant in only one experiment (Figure 8-1 c), anti-AP1 had a greater effect than anti-AP2 
pIgG.  This appears to be specific anti-QSS activity as pre-bleed generally had no inhibitory 
action on biofilm formation, but increased biofilm formation in experiment b at higher 
concentrations.  However, when the anti-hapten pIgGs were used in combination, there was a 
significant concentration-dependent reduction in biofilm formation at ! 50 µg/mL (25:25 
µg/mL [anti-AP1/anti-AP2 pIgG]).  The data suggest that the anti-QSS activity, seen when the 
anti-hapten pIgGs were used in combination, was synergistic.  However, it would be beneficial 
to repeat the assay using greater concentrations ! 400 µg/mL. 
 
8.2 DISCUSSION 
QSSi have been tested in static biofilm formation assays and have shown to reduce biofilm 
formation and tolerance to biocides (132, 150, 239).  The anti-hapten pIgG used separately 
were able to reduce the formation of biofilms but significant inhibition was achieved when the 
anti-hapten pIgG were used in combination.  This effect was attributed to anti-QSS activity, as 
pre-bleed pIgG had no inhibitory effect on biofilm formation.  This is promising, as the data 
suggests that the anti-hapten pIgG, are not antagonistic, proving that the individual hapten-
conjugate of the multi-component anti-QS vaccine would be synergistic.   
 
Published reports suggest that an intact QSS is needed for biofilm development and 
maturation, due to time limitations the structure of the biofilms formed in presence of the anti-
hapten pIgG were not studied nor were the susceptibility to biocides.  It is hypothesised that 
the anti-hapten pIgG will (a) disrupt QS therefore reduce biofilm formation, which has been 
suggested in this study, and (b) increase the susceptibility of any formed biofilms to biocides, 
which is yet to be studied. 
 
8.2.1 FUTURE WORK 
The static biofilm assay was useful in demonstrating the anti-QSS activity of anti-hapten pAb 
when used in combination, however, the effect of anti-hapten pIgG on biofilm structure and 
susceptibility to biocides still needs to investigated, which unfortunately due to time 
restrictions was not possible in this study.   
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The effect of anti-hapten pAbs on other virulence factors needs to be determined, such as 
elastase, rhamnolipids, and pyocyanin.  Attempts have been made (data not shown) to test the 
effects of anti-hapten pIgG on rhamnolipids using the qualitative rhamnolipid plate assay 
described by Pinzon and Ju (240) using M9 media however, initial tests were not successful, 
but with suitable optimisation, this may be a useful assay.  These virulence factors are under 
QSS control therefore will be useful in demonstration of the in vitro anti-QSS effect of the 
anti-hapten pAb.   
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9 SUMMARY OF RESULTS 
Synthesis of the haptens, AP1 and AP2
^
, was conducted using adapted published methods and 
sufficient quantities of each hapten were produced to continue with the haptenisation of the 
immunogenic carrier, KLH.  Chemical synthetic routes require further optimisation and should 
be the focus of future work.   
 
Haptenisation of KLH was successful and the immunogenicity of the AP1-KLH and AP2-
KLH hapten was demonstrated in mice and rabbits.  Characterisation of the mouse anti-AP1-
KLH sera revealed considerable cross-reactivity with 3OC12-HSL confirmed by the anti-QSSM 
seen in the bioluminescence assay.  The cross-reactivity to the long and short AHLs was also 
shown, however, it was apparent that cross-reactivity with C4-HSL was weaker in comparison.  
 
Mouse and rabbit anti-AP2-KLH sera showed strong cross-reactivity with PQS and HHQ, and 
showed potential cross-reactivity with HMAQs produced by Burkholderia spp., indicated by 
cross-reactivity with 3-methyl-quinolin-4(1H)-one 74.  Rabbit anti-AP2-KLH pIgG 
demonstrated anti-HHQ activity but little anti-PQS activity, however this was attributed to 
PQS low availability due to transport by membrane vesicles.  Anti-hapten pIgG were able to 
demonstrate an additive inhibition of biofilm formation when used in combination, suggesting 
that the anti-hapten pIgG have anti-QSS activity.   
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10 FUTURE DIRECTIONS AND CONCLUSION 
10.1 FUTURE DIRECTIONS 
10.1.1 HAPTEN DESIGN 
10.1.1.1 CHAIN LENGTH 
It has been predicted that the acyl chain can be shortened to a 5-7-carbon acyl chain, retaining 
the 3-oxo moiety, producing a hapten which can generate pAbs that still have significant cross-
reactivity with 3OC12-HSL but improved cross-reactivity with C4-HSL, ultimately improving 
the anti-QSS activity (6.3, p 102).  This will be considered as part of hapten design for the 
AHL hapten.  However, this will not be applicable for AP2, as data from the competitive 
indirect ELISA (Appendix 1, p 153) suggests that the quinolone structure is the key epitope.   
 
10.1.1.2 ORIENTATION  
The position of the carrier in relation to the key epitopes is critical for the efficient presentation 
of the hapten-carrier conjugate to the immune system.  It is quite clear that the carrier on 
attachment should not obscure important structural components and cause any chemical 
modification.  Published reports (224, 241, 242) detail significant impacts on antibody titres 
and avidity towards the hapten when the position of the carrier was changed - more epitopes 
were exposed to the immune system.   
 
This study has added to the search for the ideal hapten-conjugate for a multi-component anti-
QSS vaccine.  However, the AHL hapten still needs further optimisation in order to improve 
avidity for C4-HSL.  Thus, in preparation, the designed haptens AP1 and AP2 have been 
modified so the carrier will be attached to the ring via a 3-6-carbon linker.  It is hypothesised 
that adjusting the position of the carrier will change the orientation of the hapten and the 
presentation of this antigen to the immune system.  The conserved structural components, such 
as the ring and external amide moiety (Figure 10-1, a, AP3) and the quinolone structure 
(Figure 10-1, b, AP4), which are the key epitopes, will still be exposed, but it is anticipated 
that the generated antibodies will have a different avidity profile.   
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 (a) 
 
(b) 
 
Figure 10-1: Proposed haptens for the investigation of carrier attachment, (a) AP3, and (b) 
AP4.   
 
10.1.2 SYNTHETIC STRATEGY FOR AP3 AND AP4 
10.1.2.1  (2S,4S)-4-ACYLAMINO-5-OXOPYRROLIDINE-2-CARBOXYLIC ACIDS, AP3 
Malava!i" et al. (243) reported a synthetic strategy, ensuring enantiometric specificity, for 
(2S,4S)-4-acylamino-5-oxopyrrolidine-2-carboxylic acids (243).  Serendipitously, both the 
amine and carboxylic acid moiety of L-pyroglutamic acid 78 could conveniently be protected in 
a one-pot procedure used for the esterification of carboxylic esters en(244).  In pilot studies, 
crude di-protected derivative 79 was treated with tert-butoxy-bis(dimethyl-amino)methane to 
form enamino intermediate 80.  However, nitrosation of 80 in sodium nitrite (NaNO2) under 
acidic conditions to furnish the oxime 81 was not successful.  The derivatives of 84 are 
potential haptens and future work should concentrate on the progression of the synthesis.   
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Reagents and conditions: (a) BOC2O, t-BuOH, cat. DMAP, rt (62%); (b) tet-butoxy-
bis(dimethyl-amino)methane, toluene, reflux (41%); (c) NaNO2, aq. NaHSO4, 0 ¡C; (d) H2/Pd-
C 10%, MeOH, rt; (e) Amidation; (f) TFA: CH2Cl2, (1:1), rt.  
Scheme 10-1: Synthesis of (,Ł)-4-acylamino-5-oxopyrrolidine-2-carboxylic acids (243).  
 
10.1.2.2 2-HEPTYL-1,4-DIHYDRO-3-HYDROXY-4-OXOQUINOLINE-7-CARBOXYLIC ACID, 
AP4 
Using a combination of two strategies reported by Hradil  al. (199) and Soural et al. (245) the 
carboxylic acid moieties of 86 (Scheme 10-2) were di-alkylated  to form the intermediate 90, 
but cyclisation using NH4HCO2 and HCO2H (199) with microwave irradiation was not 
successful.  The strategy (173) used in method B (Scheme 3-7) was useful, affording 2-heptyl-
1,4-dihydro-3-hydroxy-4-oxoquinoline-7-carboxylic acid 91 in modest yields (44%).   
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Reagents and conditions: (a) 86, MeOH, H2SO4, 60 ¡C, (49%) (246); (b) 85, 60, Et3N, 
(CH3)2CO, (95%); (c) 86, 60, Et3N, (CH3)2CO,; (d) 87, 60, Et3N, (CH3)2CO, (54%); (e) 
NH4HCO2, HCO2H, M, 120 ¡C; (f) NH4HCO2, HCO2H, M, 120 ¡C; (g) NMP, M, 250 
¡C, (44%).   
Scheme 10-2: Synthesis of 2-heptyl-1,4-dihydro-3-hydroxy-4-noline--carboxylic acid, 
AP4, 90.   
 
10.1.3 OTHER BACTERIAL TARGETS 
In this study, mouse anti-AP1 pAb has exhibited cross-reactiity to the natural AH SSM 
produced by P. aeruginosa.  It is hypothesised that pAbs generated against the optimised AH 
based hapten ill cross-react ith 3-OH s and longer acyl chains up to 18-carbons.  
Although 74 is only the synthon for HMA

S, the fact that anti-AP2 pAb recognised this 
consered uinolone structure is promising.  Often in disease pathologies, P. aeruginosa is a 
co-infector, for example in CF, the B. cenocepacia complex, hich use AHs and HH in S.  
It is possible that an anti-

S 

accine 

uld be effecti

e against many of the am-negati

e 
bacteria listed in Table 1-5 (p 38).  It 

ill be of interest to pursue the de

elopment of such a 
ccine.  
 
10.1.4 GRAM-POSITIVE AND GRAM-NEGATIVE ANTI-QSS VACCINE 
am-positie bacteria such as S. aureus use S, Park et al. (24) hae used their patented  
hapten (248) to generate a Mab ith specificity for the S. aureus AI peptide-4 (AIP-4), hich 
inhibits the bacteria SS and increases sural of a mouse model infected ith S. aureus by 
passie immunisation (24).  P. aeruginosa and S. aureus can co-infect hosts, and 3OC12-HS 
and C12-tetramic acid has anti-microbial effects on S. aureus (96, 9).  Hoeer, the anti-S 
ccine targeting ram-negati bacteria may affect this defence mechanism of P. aeruginosa 
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thereby allowing otherwise suppressed bacterial species to benefit.  It would be of interest to 
combine an anti-QSS vaccine specific for Gram-negative bacteria with an anti-QSS vaccine 
specific for Gram-positive bacteria as invented by Park and colleagues (248).  It is possible, 
that both vaccines used in conjunction will be antagonistic, however, it is equally possible that 
this can lead to broad-spectrum anti-QSS vaccine.  
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10.2 CONCLUSION 
The aim of this study was to demonstrate that inhibition of the QSS should include the three 
systems, Las, Rhl and Pqs QSS, thus improving the efficacy of this approach, and should be 
done so by a multi-component QSS vaccine.  This was only possible by producing an AHL 
hapten that targeted 3OC12-HSL and C4-HSL, and a separate PQS hapten, which targeted PQS, 
a technology that to date has not been reported.   
 
The objectives of this study have been met, and the study has contributed to the development 
of a multi-component anti-QSS vaccine.  These data suggest that the complete inhibition of the 
QSS is possible and that anti-QSS vaccine is a viable prophylaxis against P. aeruginosa in 
susceptible patients.  There is potential for a broad-spectrum anti-QSS vaccine, which could 
target Gram-negative bacteria and Gram-positive bacteria (10.1.4, p 134).   
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11 EXPERIMENTAL PROCEDURES 
GENERAL 
All reagents and solvents were purchased from Sigma Aldrich and Alfa Aesar (unless 
specified) and were used as received from manufacturers.  
1
H NMR spectra were recorded as 
CDCl3 (unless otherwise stated) sample solutions on Bruker Avance-400 instrument operating 
at 400 MHz.  
13
C NMR spectra were recorded as CDCl3 (unless otherwise stated) sample 
solutions on Bruker Avance-400 instrument operating at 100 MHz.  FT-IR spectra were 
recorded on Nicolet IR-200 using the range 400 Ð 4000 cm
-1
 with samples either in the form of 
KBr discs or as thin film.  ES-MS spectra were recorded using Mass (TOF ES ±) Water 2795 
Separation module/Micromass LCT platform.  TLC was performed using Merck silica gel 60 
GF254 pre-coated (0.2 mm).    
 
5-(TERT-BUTOXYCARBONYL)PENTANOIC ACID (13) 
DIC (1.6 mL, 1.27 g, 10 mmol) and catalytic DMAP (126 mg, 
1 mmol) were added to a stirred solution of adipic acid (1.47 g, 
10 mmol in anhydrous CH2Cl2 (50 mL) at 0 ¡C under an 
atmosphere of N2.  After the addition of tert-butanol (10 mL), 
the reaction mixture was left to stir until TLC analysis (EtOAc/PE (40-60¡C), 1:1) indicated no 
further reaction progression (72 h).  The reaction mixture was extracted consecutively with 2 
M aq. HCl, and brine, and dried over MgSO4.  The solvent was rotary evaporated and the 
residue was further purified by flash column chromatography (eluent EtOAc/PE (40-60¡C), 
5:95, then 10:90, then 100:0) or Kugelrohr vacuum distillation to afford the title compound as 
a yellow viscous oil (1.71 g, 84%).  
1
H NMR: ! 1.43 (s, 9H, (C(CH3)3), 1.62-1.65 (m, 4H, 
CH2CH2), 2.23 (t, J = 7.0 Hz, 2H, COCH2), 2.36 (t, J = 7.1 Hz, 2H, COCH2), 7.39 (br. s, 1H, 
OH).  
13
C NMR: ! 23.23 (CH2), 24.49 (CH2), 28.04 (C(CH3)3), 33.86 (CH2), 35.17 (CH2), 
80.32 (C(CH3)3), 173.02 (COOC(CH3)3), 178.26 (COOH).  Rf = 0.24 (EtOAc:hexane 2:8).  
HR-ESI-MS: m/z 225.1809 [M + Na]
+
. C10H18NaO4 requires 225.1103.   
 
(S)-3-AMINO-PYRROLIDIN-2-ONE (35) 
METHOD A 
L-2,4-diamino butyric acid dihydrochloride (2.1 g, 11.2 mmol) and 
hexamethyldisilazane (54 mL) were added to MeCN, (100 mL) which had 
been dried with molecular sieves (4A).  The reaction was heated under 
reflux for 48 h under N2.  The pale yellow solution was cooled and added to excess ice-cold 
MeOH and stirred for 30 min.  The solvent was rotary evaporated and the residue was 
dissolved in CHCl3.  A precipitate formed, which was removed by filtration and the filtrate was 
concentrated by rotary evaporation.  This procedure was repeated until all solid matter had 
been removed and the isolated pale yellow solid was dried under vacuum.  The title compound 
NH
O
H2N
O
O
OH
O
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was obtained as an yellow amorphous solid (0.97 g, 88%) and stored in a dessicator.  (The title 
compound discoloured over time.  It was stored in a dessicator and as a precaution, the product 
was dissolved in CHCl3 and any precipitate was removed before use). 
 
METHOD B 
The above protocol was modified by adding 3 drops of chlorotrimethylisilane and the 
subsequent procedure was followed as described above to afford the title compound as an 
yellow amorphous solid (1.0 g, 91%). 
1
H NMR: ! 1.59 (br. s, 2H, NH2), 1.80-1.9 (m, 1H, 
CH(H)CH2), 2.46-2.53 (m, 1H, CH(H)NH), 3.27-3.38 (m, 2H, CH2), 3.47-3.52 (m, 1H, 
CHNH2).  
13
C NMR: ! 30.87 (CH2CHNH2), 43.55 (CH2NH), 52.21 (CH), 179.69 (C(O)NH).  
IR ! (cm
-1
) 786, 893, 1069, 1292, 1690, 2994, 3185, 3342.  HR-ESI-MS: m/z 101.0545 [M + 
H], 124.0785 [M+Na]
+
, C4H8N2O requires 100.0636 and C4H8N2ONa
+
 requires 124.0613.   
 
GENERAL PROCEDURES FOR TERT-BUTYL 6-(2,2-
DIMETHYL-4,6-DIOXO-1,3-DIOXAN-5-YL)-6-
OXOHEXANOATE (18)  
METHOD A 
Oxalyl chloride (2 mL) and catalytic amount of anhydrous 
DMF (1 drop) were added to the stirred 5-(tert-
butoxycarbonyl)pentanoic acid (13, 7.8 mmol) in anhydrous CH2Cl2 (8 mL) under N2.  After 
completion (TLC, EtOAc), the solvent was rotary evaporated and kept under N2 to be used 
without further purification.   
  MeldrumÕs acid (17, 1.1 g, 7.8 mmol) was added to the stirred acyl chloride in anhydrous 
CH2Cl2 (60 mL) under N2 followed by the addition of anhydrous pyridine (1.26 mL, 15.6 
mmol).  The reaction was left to stir at rt for 16 h until complete (TLC, CH2Cl2).  The crude 
mixture was extracted consecutively with 2 M aq. HCl and brine..  After drying over MgSO4, 
the solvent was rotary evaporated and dried under vacuum.  The product was used without 
further purification.  
 
METHOD B  
EDC (401.3 mg, 2.1 mmol, Fluorochem Ltd) was added to a stirred mixture of the 5-(tert-
butoxycarbonyl)pentanoic acid (13, 346mg, 1.7 mmol), DMAP (253 mg. 2.1 mmol) in CH2Cl2 
(10 mL) at 0 ¡C followed by MeldrumÕs acid (247 mg, 1.7 mmol) after 5 min.  The solution 
was left to warm to rt and stirred under N2 for 16 h until complete (TLC, CH2Cl2).  The crude 
mixture was extracted consecutively with 2 M aq. HCl and brine, then dried over MgSO4.  The 
solvent was rotary evaporated and the residue was triturated with EtOAc/hexane.  After the 
solvent was rotary evaporated, the product was dried under vacuum to afford the tile compound 
as a yellow oil (0.54 g, 97%) and was used without further purification.  (Stored at 2-8¡C under 
N2 until use).  HR-ESI-MS: m/z 327.1492 [M-H]
-
, [C16H23O7]
-
 requires 327.1444.   
 
O
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8-TERT-BUTYL-1-BENZYL 3-OXOOCTANEDIOATE 
(23) 
BnOH (615 µL, 5.9 mmol) was added to a stirred 
solution of tert-butyl-6-hydroxy-6-(2,2-dimethyl-
4,6-dioxo-1,3-dioxan-5-ylidene)hexanoate (18, 628 mg, 1.9 mmol) in anhydrous toluene (20 
mL) and heated under reflux for 1-2 h until completion (TLC, CH2Cl2).  The solvent was rotary 
evaporated and the residue was dissolved in EtOAC.  The mixture was extracted consecutively 
with saturated NaHCO3, 2 M aq. HCl, and brine.  Once dried over MgSO4, the solvent was 
rotary evaporated.  BnOH was removed by Kugelrohr distillation (75 ¡C) and/or column 
chromatography (eluent EtOAc/PE (40-60¡C) 5:95, then 10:90, then 100:0) to afford the title 
compound as a yellow oil (442.6 mg, 67%) after three further washings with PE (40-60¡C).  
1
H 
NMR: ! 1.43 (s, 9H, C(CH3)3), 1.52-1.63 (m, 4H, CH2CH2), 2.18 (t, J = 7.0 Hz, 2H, 
CH2COO), 2.52 (t, J = 7.0 Hz, 2H, CH2COO), 3.47 (s, 2H, C(O)CH2), 5.16 (s, 2H, CH2C6H6), 
7.30-7.36 (m, 6H, C6H6).  
13
C NMR: ! 22.90 (CH2), 24.52 (CH2), 28.18 (C(CH3)), 34.82 
(CH2COO), 42.69 (CH2CO), 49.30 (C(O)CH2), 67.18 (COOCH2), 80.25 (C(CH3)3), 127.12, 
127.80, 128.77 (CH), 135.42 (CCH2(O)), 167.08 (COOCH2), 172.76 (COOC(CH3)3), 202.25 
(C(O)CH2).  HR-ESI-MS: m/z 357.1685 [M + Na]
+
, C19H26O5Na
+
 requires 357.1678.   
 
7-(TERT-BUTOXYCARBONYL)-3-OXOHEPTANOIC ACID 
(29) 
Pd-C 10% (50 mg) was added to anhydrous THF in an 
oven-dried RBF under N2.  The solution was sonicated 
and evacuated three times with N2.  8-tert-Butyl-1-benzyl 3-oxooctanedioate (23, 442.6 mg, 
1.3 mmol) was dissolved in minimum anhydrous THF and added via a syringe with rinsings at 
0 ¡C.  This was sonicated and evacuated once with N2.  H2 was introduced to the system via a 
three-way tap and the reaction was evacuated three times with H2.  The solution was stirred 
under H2 at 0 ¡C until completion (TLC, EtOAc).  The solution was passed through a celite pad 
and the solvent was rotary evaporated to afford the title compound as a pink oil (311.8 mg, 
96%).  
1
H NMR: ! 1.41 (C(CH3)3), 1.54-1.60 (m, 4H, CH2CH2), 2.20 (t, J = 6.8 Hz, 2H, 
CH2CO), 2.57 (t, J = 6.8 Hz, 2H, CH2CO), 3.47 (s, 2H, C(O)CH2), 10.06 (br. s, 1H, OH).  
13
C 
NMR: ! 22.75 (CH2), 24.36 (CH2), 24.58 (CH2), 28.13 (C(CH3)3), 35.21 (CH2CO), 42.77 
(CH2CO), 48.39 (CH2C(O)), 80.38 (C(CH3)3), 171.32 (COOH), 173.23 (COOC(CH3)3), 203.38 
(C(O)CH2).  HR-ESI-MS: m/z 242.5499, 243.5589 [M-H]
-
, 264.1600, 267.1235 [M + H + 
Na]
+
, C12H20O5 requires 244.1311, C12H19O5
-
 requires 243.1232 and C12H20O5Na
+
 requires 
267.1201.   
O
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TERT-BUTYL-7-((S)-2-OXOPYRROLIDIN-3-YLCARBAMOYL)-6-OXOHEPTANOATE (36)  
METHOD A 
DIC (206 µL, 167.9 mg, 1.3 mmol) was added to 
a stirred solution of 7-(tert-butoxycarbonyl)-3-
oxoheptanoic acid (29, 247.1 mg, 1 mmol) in 
anhydrous CH2Cl2 (20mL) with DMAP (148.7 mg, 1.2 mmol) at 0 ¡C under N2.  After 5 min, 
(S)-3-amino-pyrrolidin-2-one (35, 101.8 mg, 1 mmol) was added and the mixture was allowed 
to warm to room temperature and stirred overnight under N2.  The solvent was rotary 
evaporated and the residue was dissolved in EtOAc and was extracted consecutively with 1 M 
aq. KHSO4, saturated NaHCO3, and brine, then dried over MgSO4.  The solvent was rotary 
evaporated and the crude mixture was further purified by column chromatography (eluent 
DCM/MeOH 9.7:0.3) to afford the title compound as a yellow residue (35.9 mg, 10%). 
 
METHOD B 
(S)-3-Amino-pyrrolidin-2-one (35, 150 mg, 1.5 mmol) was stirred in anhydrous MeCN (10 
mL) with tert-butyl-6-hydroxy-6-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)hexanoate (18, 
544.4 mg, 1.7 mmol) at 40¡C overnight under N2.  The mixture was warmed to 50-60 ¡C until 
completion (TLC, CH2Cl2).  The solvent was rotary evaporated and the residue was dissolved 
in EtOAc and was extracted consecutively with 1 M aq. KHSO4, saturated NaHCO3, and brine, 
then dried over MgSO4.  The solvent was rotary evaporated and the crude mixture was further 
purified by column chromatography (eluent Et2O/MeOH 9:1) followed by preparative TLC 
(mobile phase EtOAc:PE (40-60¡C) 0.5:9.5).  The title compound was obtained as a yellow 
residue (91 mg, 19%).  
1
H NMR: ! 1.42 (s, 9H, C(CH3)3), 1.58 (m, 4H, CH2CH2), 1.91-2.02 
(m, 1H), 2.20 (t, J = 6.6 Hz, 2H, CH2COO), 2.56 (t, J = 6.7 Hz, 2H, CH2COO), 2.69 (m, 1H), 
3.27-3.46 (m, 4H, (Prominent singlet peak overlap with multiplet, ! 3.44 (CH2C(O) and CH2 
(ring)), 4.40-4.47 (m, 1H), 6.62 (undefined br. s, 1H, NH), 7.61 (s, 1H, NH).  
13
C NMR: 
(DMSO-d3) ! 22.81 (CH2), 24.43 (CH2), 28.21 (C(CH3)3), 29.66 (CH2CHNH2), 35.29 (CH2), 
39.38 (CH2NH), 43.26 (CH2CO), 49.31 (C(O)CH2), 50.83 (CH), 80.36 (C(CH3)3), 166.62 
(C(O)NH), 172.87 (COOC(CH3)3), 175.69 (HNC(O)NH), 205.82 (C(O)CH2).   HR-ESI-MS: 
m/z 325.1667 [M Ð H]
-
 and 327.1991 [M + H].   C16H26N2O5 requires 326.1842, [C16H25N2O5]
-
 
requires 325.1763 and [C16H27N2O5]
-
 requires 327.1920.   
 
7-((S)-2-OXOPYRROLIDIN-3-YLCARBAMOYL)-6-OXOHEPTANOIC ACID (37) 
 tert-Butyl-7-((S)-2-oxopyrrolidin-3-ylcarbamoyl)-6-
oxoheptanoate (36. 35.9 mg, 0.1 mmol) was stirred 
in TFA:CH2Cl2 (1:1) with 1 drop of dH2O at rt until 
the reaction was complete (TLC, EtOAc.).  The solvent was rotary evaporated, dissolved in 
CH2Cl2, and washed with dH2O twice.  After drying over MgSO4, the solvent was rotary 
evaporated and dried under vacuum to furnish the title compound as a pink solid (29.4 mg, 
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 ¡).  
1
H NMR¢ (Me£D) ! 1.59-1.¤¥ (m, 4H, CH2CH2), 1.9¤-2.15 (m, 1H, CHH), 2.30 (t, 2H, 
CH2), 2.48-2.55 (m, 1H, CHH), 2¦¤2 (t, 2H, J = 6.4 Hz, CH2), 3.32-3.42 (m, 4H, CH2 and 
CH2(CO)), 4.46-4.55 (m, 1H, CH). 
1
H NMR: (DMSO-d6) ! 7.77 (s, 1H, NH), 8.02-8.04 (d, 1H, 
J = 8.0 Hz, NH), 11.98, (br. s, 1H, OH).  
13
C NMR: (DMSO-d6) ! 22.38 (CH2), 23.90 (CH2), 
28.48 (CH2CHNH2), 33.44 (CH2), 38.05 (CH2NH), 41.58 (CH2CO), 49.77 (C(O)CH2), 50.35 
(CH), 166.22 (C(O)NH), 174.18 (COOH), 174.37 (HNC(O)NH), 204.61 (C(O)CH2).  IR ! 
(cm
-1
) 1555, 1648, 1715, 2543, 2950, 3077. 3279.  HR-ESI-MS: m/z 271.1318 [M + H]
+
, 
293.1140 [M + Na]
+
, C12H18N2O5 requires 270.1216 and [C12H18N2O5Na]
+
 requires 293.1113.    
 
L-HOMOSERINE LACTONE HYDROCHLORIDE 
L-homoserine (1 g, 8.4 mmol) was heated under reflux in 3 M HCl (50 mL) 
overnight.  The mixture was concentrated under reduced pressure and then 
stirred in (CH3)2CO for 4 h until a white precipitate formed.  The 
precipitate was collected by vacuum filtration, washed with cold (CH3)2CO and then air-dried 
to furnish the title compound as white crystals (1.0826 g, 94%).  
1
H NMR: ! 2.23-2.34 (m, 1H, 
CH), 2.52-2.59 (m, 1H, CH), 4.24-4.32 (m, 2H, CH2), 4.42-4.47 (dt, J = 1.0 Hz, 9.0 Hz, 1H, 
CH,), 8.67 (s, 2H, NH2).  
13
C NMR: ! 28.43 (CH2), 59.07 (CH), 67.38 (OCH2), 174.04 (CO).  
IR ! (cm
-1
) 940, 1013, 1073, 1157, 1216, 1505, 1591, 1780, 2524, 2633, 2983.  HR-ESI-MS: 
m/z 85.0824, 126.0976 [M + H + Na], C4H8ClNO2 requires 137.0244 and C4H9NO2Na
+
 
requires 126.0531.  Mp: 236-238 ¡C.   
 
N-((S)-TETRAHYDRO-2-OXOFURAN-3-YL)-BUTANAMIDE 
L-Homoserine lactone hydrochloride (138.5 mg, 1 mmol) was added to 
stirred butyryl chloride (103 µL, 0.9 mmol) in anhydrous CH2Cl2 (2 
mL) under N2.  Et3N (279 µL, 3.7 mmol) was added in one addition 
and the reaction was left to stir at rt for 16 h until reaction was complete (TLC, EtOAc).   The 
solvent was rotary evaporated.  (The product was dissolved in EtOAc and was extracted 
consecutively with 1 M KHSO4, saturated NaHCO3, and brine, then dried over MgSO4.  This 
resulted in loss of product due to water solubility).  The residue was purified by crystallisation 
in PE (40-60¡C) and EtOAc.  The title compound was obtained as white crystals (97.80 mg, 
57%) that were dried under vacuum.  
1
H NMR: ! 0.94-0.98 (t, J = 7.4 Hz, 3H, CH3), 1.60-1.73 
(sextet, J  = 7.4 Hz, 2H, CH2), 2.21-2.25 (t d, J =1.6, 7.6 Hz, 2H, CH2,), 2.81-2.88 (m, 1H, 
CH), 4.25-4.31 (m, 1H, CH), 4.40-4.49 (t d, J = 1.2, 9.2 Hz, 1H, CH,), 4.53-4.60 (m, 1H, CH), 
6.10 (br. s,1H, NH).  
13
C NMR: ! 13.81 (CH3), 19.01 (CH2), 30.75 (CH2), 38.17 (CH2), 49.36 
(CH), 66.25 (CH2), 173.75 (CO), 175.73 (CO)
 
.  Mp 124.5 - 126 ¡C.  Lit Mp: 120-123 ¡C 
(249).    
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METHYL 8-OXONONANOATE (41) 
Oxalyl chloride (1.1 mL, 13 mmol) was added to a stirred 
solution of suberic acid mono methyl ester (40, 1.1 mL, 6.3 
mmol) in anhydrous CH2Cl2 (10 mL) under N2 followed by 
the addition of catalytic anhydrous DMF (1 drop) and left to stir until completion (TLC, 
CH2Cl2).  The solvent was rotary evaporated and left under N2 and used without further 
purification.   
  In an oven-dried 2-necked RBF, MeLi (1.6 M in hexane, 7 mL, 246.4 mg, 11.2 mmol) was 
added to a stirred solution of CuI (1.1 g, 5.6 mmol) in anhydrous Et2O (40 mL) under N2 at -78 
¡C.  The solution was stirred until colourless for 30 min.  (Yellow residue indicated CuMeLi 
had formed, which is inert and the reaction did not proceed).  The acyl chloride was dissolved 
in minimum anhydrous THF under N2 and transferred with washings to the reaction over 5 min 
via a cannula (final reaction volume 50 mL).  The reaction was left to stir for a further 10 min 
(TLC, CH2Cl2) and then quenched with MeOH.  After the reaction was allowed to reach 10 ¡C, 
saturated NH4Cl was added and extracted with EtOAc three times.  The organic washings were 
combined, washed twice with brine, and dried over MgSO4.  Once filtered, the filtrate was 
concentrated by rotary evaporated and the crude product was further purified by Kugelrohr 
distillation (112.5-125 ¡C).  The title compound was isolated as a clear oil (1.14 g, 75%).  (It is 
recommended to use 2 equivalents of GilmanÕs reagent).  
1
H NMR: ! 1.26-1.34 (m, 4H, 
CH2CH2 ), 1.54-1.63 (m, 4H, CH2CO), 2.12 (s, 3H, CH3), 2.29 (t, J = 7.5 Hz, 2H, CH2), 2.41 
(t, J = 7.4 Hz, 2H, CH2), 3.65 (s, 3H, CH3).  
13
C NMR: !  23.70 (CH2), 24.86 (CH2), 28.89 
(CH2), 29.00 (CH2), 34.10 (CH2CO), 43.75 (CH2COO), 51.59 (COOCH3), 174.30 (COOCH3), 
209.26 (CO).  IR ! (cm
-1
) 756, 1215, 1729, 2858, 2935, 3019.  Rf (EtOAc): 0.81.   
 
GENERAL PROCEDURE FOR !-BROMOKETONE 
Bromine (256 µL, 4.6 mmol) was added drop-wise to a stirred solution of the appropriate 
ketone (851.6 mg, 4.6 mmol) in MeOH (8 mL) at -10 ¡C.  The mixture was warmed to 0 ¡C 
and stirred for 1 hr and allowed to warm to rt and stirred for 1 hr.  The mixture was cooled to 0 
¡C and dH2O (1.4 mL) followed by conc. H2SO4 (2.5 mL) were added.  The mixture was 
stirred for 16 h at rt until the reaction was complete (TLC, EtOAc).  The solvent was rotary 
evaporated, dissolved in EtOAc and washed twice with dH2O, brine and dried over MgSO4.  
The solvent was rotary evaporated and dried under vacuum.  The product was used without 
further purification.   
 
Methyl-9-bromo-8-oxononanoate (42) 
Methyl-8-oxononanoate (41) was used to produce the 
title compound as a yellow-orange oil (1.20 g, 60%).  
1
H 
NMR: !  1.28-1.33 (m, 4H, (CH2)2), 1.54-1.61 (m, 4H, 
CH2), 2.26 (t, J = 7.5 Hz, 2H, CH2), 2.60 (t, J = 7.3 Hz, 2H, CH2), 3.61 (s, 3H, CH3), 3.84 (s, 
O
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2H, CH2).   
 
1-bromononan-2-one (60) 
Nonan-2-one (854 µL, 5 mmol) was used to produce the title 
product as a yellow oil (671 mg, 61%).  
1
H NMR: ! 0.78-0.81 (m, 3H, CH3), 1.20-1.26 (m, 8H, 
(CH2)4), 1.49-1.56 (m, 2H, CH2), 2.56 (t, J = 7.4 Hz, CH2), 3.83 (s, 2H, CH2Br). 
 
Rf (EtOAc) = 
0.97.   
 
N-FORMYL ANTHRANILIC ACID (44) 
Anthranilic acid, (43, 219.5 mg, 1.6 mmol) was stirred in formic acid 98% 
(5ml) at rt for 3 days until precipitation formed, which was collected by 
vacuum filtration.  The solid was washed with minimum formic acid 98% and 
crystallised from EtOAc/PE (40Ð60 ¡C) (7:3).  The crude product was further 
purified by re-crystallisation from EtOAc/PE (40Ð60 ¡C) (7:3) to afford the title compound as a 
white solid (154 mg, 52%).  
1
H NMR ((CD3)2CO): ! 7.19 (t, J = 7.7 Hz, 1H, CH), 7.59-7.37 (t 
d, J = 1.6 Hz, 8.7 Hz, 1.6 Hz, 1H, CH), 8.10-8.13 (dd, J = 1.6 Hz, 8.0 Hz, 1H, CH), 8.59 (s, 
1H, NHCHO), 8.72 (d, J = 8.4 Hz, 1H, CH), 11.08 (br. s, 1H, OH).  
13
C NMR (MeOD): ! 
117.79 (CCOOH), 122.12 (CH), 124.44 (CH), 132.56 (CH), 135.14 (CH), 141.33 (CN), 162.08 
(CCOOH), 170.85 (NHCHO). IR ! (cm
-1
) 751, 1273, 1696, 2557, 2923, 3174.  HR-ESI-MS: 
m/z 164.0271 [M-H], C8H7NO3 requires 165.0426 and C8H6NO3
-
 requires 164.0348.  Rf 
(EtOAc/PE (40-60¡C), 7:3) = 0.41 (streak, ninhydrin negative).  Mp 167-170 ¡C (lit mp 167 
¡C) .   
 
GENERAL PROCEDURE FOR 2-OXO-ALKYL-2-FORMYL-AMINOBENZOATES  
N-formyl anthranilic acid (44, 628 mg, 3.8 mmol) was stirred with Et3N (556 µL, 403.7 mg, 4 
mmol) and the appropriate !-bromoketone (631.4 mg, 2.4 mmol) in (CH3)2CO (8 mL) at rt for 
16 h until the reaction was complete (TLC, EtOAc).  The solvent was rotary evaporated and 
the crude compound was washed with water.  Crystallisation attempts were not successful 
therefore, the product was used without further purification.   
 
8-(methoxycarbonyl)-2-oxooctyl-2-formyl-
aminobenzoate (45) 
Methyl 9-bromo-8-oxononanoate (42) was 
used to produce the title compound as a brown 
oil.  
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2-oxononyl 2-formyl-aminobenzoate (62) 
1-bromononan-2-one (60) was used to produce the 
title compound as a coloured oil.  
 
GENERAL PROCEDURE FOR 2-ALKYL-3-
HYDROXY-4(1H)-QUINOLONE 
The appropriate 2-oxo-alkyl-2-formyl-aminobenzoate (553.1 mg), ammonium formate (1 g, 
15.9 mmol) was dissolved in excess formic acid 98% (23 mL, 0.61 M) and transferred to 
microwave vials.  In batches, the mixture was subjected to microwave irradiation (300w, 150 
psi) at 120 ¡C for 50 min until the starting material was consumed (TLC, EtOAc).  To each 
vial, dH2O was added and the mixtures were combined and extracted three times with EtOAc.  
The organic phase was washed with brine and dried over MgSO4.  The solvent was rotary 
evaporated and further purified by crystallization in EtOAc.  (This reaction produces CO2 (g) 
and NH3 (g) which will produce equivalent pressure.  The reaction is conducted in closed vials 
therefore batch preparation minimises pressure.  It was noted that 10 equivalents of ammonium 
formate and 100 equivalents of formic acid were suitable to furnish the 2-alkyl-3-hydroxy-
4(1H)-quinolone).   
 
Methyl-7-(1,4-dihydro-3-hydroxy-4-oxoquinolin-2-
yl)heptanoate (46) 
8-(methoxycarbonyl)-2-oxooctyl-2-formyl-
aminobenzoate was used to furnish the title compound 
and 7-(1,4-dihydro-3-hydroxy-4-oxoquinolin-2-yl)heptanoic acid (47) in a mixture (286.4 mg, 
60%).  HR-ESI-MS: m/z 290.1085 [C16H9NO4 + H], 304.1353 [M + H], C17H21NO4 requires 
303.1471, and [C17H22NO4]
+
 requires 304.1549.   
2-heptyl-3-hydroxy-4(1H)-quinolone (4) 
2-oxononyl 2-formyl-aminobenzoate (62) was used to 
produce the title compound as a brown crystalline solid 
(85.8 mg, 46%).  
1
H NMR: ! 0.85 (t, J = 6.5 Hz, 3H, 
CH3), 1.04-1.32 (m, 8H, (CH2)4), 1.67 (t, 2H, CH2), 2.73 
(t, 2H, CH2), 7.21 (t, J = 6.8 Hz, 1H, CH), 7.54 (s, 2H, (CH)2), 8.08-8.10 (d, J = 8.0 Hz, 1H, 
CH), 11.45 (br. s, 1H, OH).  HR-ESI-MS: m/z 260.0898 [M + H], 261.1211; 257.6011 [M - H], 
258.6046, C16H21NO2 requires 259.1572 and [C16H20NO2]
-
 requires 258.1494.   
 
7-(1,4-DIHYDRO-3-HYDROXY-4-OXOQUINOLIN-2-
YL)HEPTANOIC ACID (47) 
The crude mixture of methyl-7-(1,4-dihydro-3-
hydroxy-4-oxoquinolin-2-yl)heptanoate (46) was 
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stirred in 12 M HCl in THF for 18 h and monitored by MS until the reaction was complete.  
The mixture was further purified by crystallisation from EtOAc to afford the title compound 
(47) as a purple solid film (71.6 mg, 73%).  
1
H NMR (500 MHz, DMSO-d6): ! 1.23-1.34 (m, 
4H, CH2CH2), 1.47-1.55 (m, 2H, CH2), 1.66 (m, 2H, CH2), 2.19 (t, J = 5.6 Hz, 2H, CH2), 2.73 
(t, J = 5.6 Hz, 2H, CH2), 7.21-7.23 (m 1H, CH), 7.53 (s 2H, CH), 8.08-8.09 (d, J = 6.4 Hz, 1H, 
CH), 11.44 (br. s, 1H, OH).  
13
C NMR (500 MHz, DMSO-d6): ! 28.82 (CH2), 28.66 (CH2), 
28.76 (CH2), 28.92 (CH2), 29.02 (CH2), 34.09 (CH2), 118.23 (CH), 121.97 (CH), 122.64 (C:C), 
124.94 (CH), 130.42 (CH), 135.95 (C:C), 137.81 C:C), 173.81 (COOH), 174.95 (CO).  HR-
ESI-MS: m/z = 288.1093 [M - H], C16H19NO4 requires 289.1314 and [C16H18NO4]
-
 requires 
288.1236.   
 
2-HEPTYL-QUINOLIN-4(1H)-ONE (3) 
The crude mixture of (E)-ethyl 3-(phenylamino)dec-2-
enoate  (701.8 mg) and Ph2O (15 mL) were stirred and 
divided into 5 mL batches.  The mixture was microwave 
irradiated at 250 ¡C for 10 min.  The batches were 
combined and the solvent was removed using Genevac instrument.  The crude product was 
washed PE (60-80 ¡C) and purified by silica column chromatography (eluent: EtOAc 100%).  
The residue was further purified by crystallization form EtOH to afford the title compound 
(103.30 mg, 21%) as beige solid.  
1
H NMR: ! 0.80 (t, J = 7.0 Hz, 3H, CH3), 1.16-1.26 (m, 8H, 
CH2), 1.71 (t, J = 6.6 Hz, 2H, CH2), 2.70 (t, J = 6.8 Hz, 2H, CH2), 6.45 (s, 1H, CH), 7.32 (t, J = 
7.4 Hz, 1H, CH), 7.58 (t, J = 7.4 Hz, 1H, CH), 7.82 (d, J = 6.8 Hz, 1H, CH), 8.35, (d, J = 8.0 
Hz, 1H. CH), 12.71 (br. s, 1H, NH).  
13
C NMR: ! 14.15 (CH3), 22.69 (CH2), 29.10 (CH2), 
29.30 (CH2), 29.32 (CH2), 31.77 (CH2), 34.48 (CH2), 108.15 (CH), 118.87 (CH), 123.66 (CH), 
125.07 (CH), 125.24 (CC), 131.85 (CH), 140.91 (C:C), 155.74 (C:C), 179.02 (CO).  HR-ESI-
MS: m/z 244.1476[M + H]; 241.8555 [M - H], 242.8600, C16H21NO requires 243.1623, 
[C16H21NO]
-
 requires 242.1545 and [C16H22NO]
+
 requires 244.1701.   
 
1-(2-AMINOPHENYL)-PROPAN-1-ONE (72) 
Magnesium turnings (365 mg, 15 mmol) were added under N2 to an oven-
dried RBF with I2 (solid ball, 10 mg), this was stirred dry for 5 min.  
Anhydrous Et2O (25 mL) followed by EtBr (15 mmol) was added and 
vigorously stirred and heated with a condenser under N2 at 50 ¡C for 10 min.  The solution was 
cooled and 2-aminobenzonitrile (71, 602.5 mg, 5 mmol) was added under N2 at -78 ¡C.  This 
was stirred, warming to rt, for 24 h (TLC, EtOAc).  The reaction was quenched by 10% HCl 
and stirred for 30 min at rt to form a pale yellow solution.  This was basified to pH 8 using 2 M 
NaOH and extracted with EtOAc three times.  The combined organic layers were combined 
and washed with brine and dried over MgSO4.  The solvent was rotary evaporated to leave the 
crude residue, which was further purified by silica gel column chromatography (EtOAc: PE, 
N
H
O
O
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(40-60¡C) 1:9) to afford the title compound as a green solid (108.7 mg, 14%).  
1
H NMR: ! 1.22 
(t, J = 7.2 Hz, 3H, CH3), 2.96-3.01 (q, J = 7.2 Hz, 2H, CH2), 6.29 (br. s, 2H, NH2), 6.63-6.67 
(m, 1H, CH), 7.24-7.28 (m, 1H, CH), 7.45-7.77 (dd, J = 1.4, 8.6 Hz).  
13
C NMR: ! 8.84 (CH3), 
32.40 (CH2), 115.82 (CH), 117.44 (CH), 117.96 (C:C), 131.15 (CH), 134.18 (CH), 150.37 
(CN), 203.46 (CO).   
 
N-(2-PROPIONYLPHENYL)-FOR§¨§©DE (73) 
1-(2-Aminophenyl)-propan-1-one (72, 100 mg, 0.7 mmol) was heated in 
98% formic acid at 50 ¡C until reaction was complete (TLC, EtOAc, 
ninhydrin negative).  The mixture was cooled and dH2O and extracted with 
EtOAc three times.  The organic layers were combined, washed with dH2O, followed by brine, 
and dried over MgSO4.  The solvent was rotary evaporated and dried under high vacuum to 
afford the title compound (98.2 mg, 83%).  The compound was used without further 
purification.  
1
H NMR: ! 1.21 (t, J = 7.2 Hz, 3H, CH3), 3.04-3.09 (q, J = 7.2 Hz, 2H, CH2), 
7.15 (t, J =  7.6 Hz, 1H, CH), 7.54 (t, J = 7.8 Hz, 1H, CH), 7.93-7.95 (d, J = 8.0 Hz, 1H, CH), 
8.48 (s, 1H, CH), 8.72-8.74 (d, J = 8.0 Hz, 1H, CH).  
13
C NMR: !  8.85 (CH3), 33.28 (CH2), 
121.82 (CH), 121.89 (CH), 123.17 (CCO), 130.74 (CH), 134.95 (CH), 139.85 (CN), 161.76 
(NCO), 205.46 (CO).  
 
3-ªETHYLQUINOLIN-4(1H)-ONE (74) 
N-(2-propionylphenyl)-formamide (73, 98.2 mg, 0.6 mmol) was dissolved in 
anhydrous 1,4 dioxane (1 mL) followed by NaOH (33 mg, 0.8 mmol).  The 
solution was stirred and subjected to microwave irradiation at 120 ¡C for 50 
min until reaction was complete (MS).  Work-up was followed as suggested 
by the authors , however, the title compound is water soluble.  The aq. phase was neutralised 
and dried by freeze-drying.  The product was extracted from the residue with MeOH, the 
solvent was rotary evaporated and crystallized from EtOAC.  The title compound was obtained 
as dark green solid (31.8 mg, 36%).  
1
H NMR: !  2.70 (s, 3H, CH3), 7.50 (t, J = 6.8 Hz, 1H, 
CH), 7.70-7.90 (m, 2H, CH), 8.23 (s, 1H, C(CH3):CH), 8.31 (d, J = 8.0 Hz, 1H, CH).  
13
C 
NMR (DMSO-d6): ! 13.52 (CH3), 116.47 (CCH3) 118.01 (CH), 122.50 (CH), 124.10 (C:C), 
124.94 (CH), 131.03 (CH), 136.72 (CH), 139.80 (C:C), 176.75 (CO)  HR-ESI-MS: m/z  
160.0567 [M + H], C10H9NO requires 159.0684, and [C10H10NO]
+
 requires 160.0762.  
 
4-«ªETHOXYCAR¬­NYL)-2-¨§INO¬E®¯OIC ACID «°7) 
4-Aminobenzene-1,3-dicarboxylic acid (°±, 1.1 g, 6.1 mmol), 
anhydrous MeOH (20 mL) and catalytic H2SO4 (1.1 mL) were 
heated under reflux under N2 for 8 h.  The solvent was rotary 
evaporated to half the volume and diluted with ice and dH2O.  The pH was adjusted to pH 9 by 
the addition of  solid NaHCO3 and extracted with CHCl3.  The aq. phase was acidified to pH 3-
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4 using concentrated HCl and the precipitate was collected by vacuum filtration.  Traces of 
HCl were removed by repeated washing with cold dH2O to afford the title compound as a 
yellow solid (592 mg, 49%).  
1
H NMR ! 3.88 (s, 3H, CH3), 7.01-7.03 (dd, J = 1.3, 8.3 Hz, 1H, 
CH), 7.40 (s, 1H, CH), 7.75-7.80 (d, J = 8.3 Hz, 1H, CH).  
13
C NMR: !  52.24 (CH3), 114.31 
(CH), 117.39 (CH), 131.66 (CH), 133.89 (CC(O)), 151.23 (CN), 166.03 (CCOOCH3), 169.09 
(CCOOH).  Rf (EtOAc: MeOH, 8.8:1.2) = 0.35.   
 
4-METHYL-1-(2-OXONONYL)-2-
AMINOBENZENE-1,4-DIOATE (88) 
1-Bromononan-2-one (60, 544 mg, 2.5 mmol) 
and 4-(methoxycarbonyl)-2-aminobenzoic 
acid (87, 483 mg, 2.5 mmol) were stirred with Et3N (352 µL, 255.6 mg, 2.5 mmol) in 
(CH3)2CO (30 mL) at rt for 16 h until the reaction was complete (TLC, EtOAc:MeOH, 
9.8:0.2).  The solvent was rotary evaporated and the crude compound was washed with water.  
Crystallisation attempts were not successful therefore, the title compound, a yellow solid 
(447.8 mg, 54%), was used without further purification.  
 
2-HEPTYL-1,4-DIHYDRO-3-HYDROXY-4-OXOQUINOLINE-7-CARBOXYLIC ACID (90) 
4-Methyl-1-(2-oxononyl)-2-aminobenzene-1,4-
dioate (88, 31 mg,  0.1 mmol) were dissolved in 
NMP (1 mL) and subjected to microwave 
irradiation at 250¡C for 10 min  (300W, 250 psi).  
The solvent was removed using the Genevac 
instrument until dryness.  The crude residue was purified crystallisation in EtOAc, the crystals 
were washed with cold (CH3)2CO to afford the title compound as a brown solid (12.4 mg, 
44%).  
1
H NMR: ! 0.83 (t, J = 6.6 Hz, CH3), 1.15-1.40 (m, 8H, CH2), 1.68 (m, 2H, CH2), 2.76 
(m, 2H, CH2), 7.68-7.71 (d, J = 8.4 Hz, 1H, CH), 8.16-8.18 (d, J = 8.4 Hz, 1H, CH), 8.23 (s, 
1H, CH), 11.72 (br. s, 1H, OH).  IR ! (cm
-1
) 1266, 1377, 1493, 1561, 1684, 2854, 2926, 2954, 
3129, 3213, 3255, 3398.  HR-ESI-MS: m/z 302.0946 [M - H]
-
, 303.0991, C17H21NO4 requires 
303.1471, and C17H20NO4 requires 302.1392.  Rf (EtOAc) = 0.22.   
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12 APPENDIX 1 
12.1.1 CROSS-REACTIVITY OF ANTI-AP1 ANTIBODIES 
O
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Figure 12-1: 3OC6-HSL and anti-AP1 serum.   
Competitive indirect ELISA using mouse anti-AP1 serum (-) and 3OC6-HSL as the competitive ligand.  (Data is represented as mean ± SD, n = 3).  
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Figure 12-2: 3OC8-HSL and anti-AP1 serum. 
Competitive indirect ELISA using mouse anti-AP1 serum (-) and 3OC8-HSL used as the competitive ligand.  (Data is represented as mean ± SD, n = 3).   
 
Figure 12-3: 3OC12-HSL and anti-AP1 serum. 
Competitive indirect ELISA using mouse anti-AP1 serum (-) and 3OC12-HSL as the competitive ligand.  (Data is represented as mean ± SD, n = 3).  
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Figure 12-4: C4-HSL and anti-AP1 serum. 
Competitive indirect ELISA using mouse anti-AP1 serum (-) and C4-HSL as the competitive ligand.  (Data is represented as mean ± SD, n = 3).   
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Figure 12-5: C6-HSL and anti-AP1 serum. 
Competitive indirect ELISA using mouse anti-AP1 serum (-) and C6-HSL as the competitive ligand.  (Data is represented as mean ± SD, n = 3).  
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Figure 12-6: C8-HSL and anti-AP1 serum. 
 Competitive indirect ELISA using mouse anti-AP1 serum (-) and C8-HSL as the competitive ligand.  (Data is represented as mean ± SD, n = 3).   
 
 
Figure 12-1 shows significant inhibition of pAb binding to AP1-BSA at 100 µM and 1 mM [3OC6-HSL] only.  Although the same conditions were used, one assay failed to 
show a concentration-dependent inhibition.  These data tentatively suggest that the anti-AP1 pAbs can cross-react with 3OC6-HSL.  Natural QSSM, 3OC8-HSL, the cognate 
of AP1, at 1 mM, significantly reduced the pAb binding to AP1-BSA, although there is an indication of a concentration-dependent reduction in pAb binding, it is only 
significant in one assay.  This assay (Figure 12-2) was repeated three times, however, the third assay (not shown) showed significant inhibition of pAb binding to AP1-BSA 
by 2.5% [DMSO] v/v.  The experiment could not be repeated due to time restrictions.  The results tentatively suggest that mouse anti-AP1 serum can cross-react with 3OC8-
HSL but an additional repeat is still required.  Results shown in Figure 12-3 indicate that mouse anti-AP1 serum cross-reacts with 3OC12-HSL, with significant reduction in 
absorbance (450 nm) seen at 100 µM and 1 mM [3OC12-HSL].  Following the significant (p = <0.001, ***) inhibition of pAb binding with AP1-BSA at 0.1 µM [3OC12-HSL] 
the absorbance increases to near control levels with 1 µM [3OC12-HSL].  The data shows a clear trend but does not show a typical concentration-dependent inhibition.  The 
data in Figure 12-4, suggests that mouse anti-AP1 serum shows some degree of cross-reactivity with C4-HSL as significant inhibition of pAb binding to AP1-BSA occurred at 
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1 mM [C4-HSL].  Collectively, the data suggests a decrease, although conservative, in mouse anti-AP1 serum binding as concentration of [C4-HSL] increases.  In comparison, 
data shown in Figure 12-5, showed significant inhibition of pAb at 100 µM and 1 mM [C6-HSL].  The trend is similar to that seen with 3OC6-HSL (Figure 12-1).  Figure 12-6 
shows a concentration-dependent inhibition of pAb by [C8-HSL], which is significant at concentrations 100 µM and 1 mM.   
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12.1.2 CROSS-REACTIVITY OF ANTI-AP2 ANTIBODIES 
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Figure 12-7: PQS and anti-AP2 sera.  
(a) Competitive indirect ELISA using mouse anti-AP2 serum (-) and PQS as the competitive ligand.  (Data is represented as mean ± SD, n = 3); (b) Competitive indirect ELISA using rabbit anti-
AP2 serum (-) and PQS as the competitive ligand.  (Data is represented as mean ± SD, n = 3). 
(b) 
(a) 
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Figure 12-8: HHQ and anti-AP2 sera. 
(a) Competitive indirect ELISA using mouse anti-AP2 serum (-) and HHQ as the competitive ligand.  (Data is represented as mean ± SD, n = 3); (b) Competitive indirect ELISA using rabbit 
anti-AP2 serum (-) HHQ as the competitive ligand.  (Data is represented as mean ± SD, n = 3).  
N
H
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Figure 12-9: 3-Methyl-quinolin-4(1H)-one and anti-AP2 sera.   
(a) Competitive indirect ELISA using mouse anti-AP2 serum (-) and 3-methylquinolin-4(1H)-one 74 as the competitive ligand (Data is represented as mean ± SD, n = 3); (b) Competitive 
indirect ELISA using rabbit anti-AP2 serum (-) and 74 as the competitive ligand (Data is represented as mean ± SD, n = 3).  
N
H
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Figure 12-7 shows a general concentration-dependent inhibition of mouse pAb binding by PQS 
however, only two experiments show significant inhibition at higher concentrations, 100 µ²
and 1m² ³P´S].  In contrast, data set b has a defined concentration-dependent inhibition of 
rabbit pAb by P
´
S with significant inhibition seen even by dilute concentrations of P
´
S.  The 
anomalous increase in OD (450 nm), suggesting decreased inhibition at 1 µ² (Figure µ¶-·, 
(data set a) and 10 µ² (data set b), is reflective of the data seen with ¸O¹
º»
-HSL (Figure 
µ¶-¸).  P´S is the cognate of AP2, the data shows that anti-AP2 pAb shows avidity for P´S.  
Figure 
µ¶
-¼ indicates a dependent-dependent inhibition of mouse½rabbit pAb by HH
´
.  Data 
strongly suggests that anti-AP2 pAb cross-reacts with HH
´
.  Figure 
µ¶
-¾ shows that anti-AP2 
pAb shows cross-reactivity to ¸-methyl-¿ÀÁnolin-4(1H)-one (74ÂÃ reduction in pAb binding to 
AP2-BSA, albeit only significant at high concentrations, 1 m² ³74].   
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